{
  "esketamine": {
    "ingredient": "esketamine",
    "is_drug": true,
    "canonical_name": "esketamine",
    "fda_search_term": "esketamine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Spravato"
    ],
    "generic_names": [
      "ESKETAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Janssen Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Central Nervous System Depressants Concomitant use with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation [see Warnings and Precautions (5.1) ] ",
      "Closely monitor for sedation with concomitant use of SPRAVATO with CNS depressants",
      "7.2 Psychostimulants Concomitant use with psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil) may increase blood pressure [see Warnings and Precautions (5.7) ] ",
      "Closely monitor blood pressure with concomitant use of SPRAVATO with psychostimulants",
      "7.3 Monoamine Oxidase Inhibitors (MAOIs) Concomitant use with monoamine oxidase inhibitors (MAOIs) may increase blood pressure [see Warnings and Precautions (5.7) ] ",
      "Closely monitor blood pressure with concomitant use of SPRAVATO with MAOIs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Sedation [see Warnings and Precautions (5.1) ] Dissociation [see Warnings and Precautions (5.2) ] Respiratory Depression [see Warnings and Precautions (5.3) ] Increase in Blood Pressur",
      "( 6 ) Treatment of depressive symptoms in adults with MDD with acute suicidal ideation or behavior: dissociation, dizziness, sedation, blood pressure increased, hypoesthesia, vomiting, euphoric mood, and vertigo",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc",
      "at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "Treatment-Resistant Depression In Conjunction with an Oral Antidepressant SPRAVATO was evaluated for safety in 1709 adults diagnosed with treatment-resistant depression (TRD) [see Clinical Studies (14.1) ] from five Phase 3 studies (3 short-term and 2 long-term studies) and one Phase 2 dose-ranging ",
      "Of all SPRAVATO-treated patients in the completed Phase 3 studies, 479 (30%) received at least 6 months of treatment, and 178 (11%) rece"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction w",
      "( 1 ) Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant",
      "( 1 ) Limitations of Use: The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated",
      "Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO",
      "( 1 ) SPRAVATO is not approved as an anesthetic agent"
    ]
  },
  "eslicarbazepine": {
    "ingredient": "eslicarbazepine",
    "is_drug": true,
    "canonical_name": "eslicarbazepine",
    "fda_search_term": "eslicarbazepine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Eslicarbazepine Acetate"
    ],
    "generic_names": [
      "ESLICARBAZEPINE ACETATE"
    ],
    "manufacturers": [
      "Apotex Corp.",
      "Ascend Laboratories, LLC",
      "Dr.Reddys Laboratories Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Carbamazepine: May need dose adjustment for eslicarbazepine acetate or carbamazepine",
      "( 2.3 , 5.6 , 7.1 )",
      "Phenytoin: Higher dosage of eslicarbazepine acetate may be necessary and dose adjustment may be needed for phenytoin",
      "( 2.3 , 7.1 , 7.2 )",
      "Phenobarbital or Primidone: Higher dosage of eslicarbazepine acetate may be necessary",
      "Hormonal Contraceptives: Eslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives",
      "( 7.4 , 8.3 ) 7.1 Other Antiepileptic Drugs Several AEDs (e.g., carbamazepine, phenobarbital, phenytoin, and primidone) can induce enzymes that metabolize eslicarbazepine acetate and can cause decreased plasma concentrations of eslicarbazepine [see Clinical Pharmacology ( 12.3 )] ",
      "Higher doses of eslicarbazepine acetate may be needed [see Dosage and Administration ( 2.4 )] ",
      "7.2 CYP2C19 Substrates Eslicarbazepine acetate can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are described in more detail in the Warnings and Precautions section of the label:",
      "Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.1 )]",
      "Serious Dermatologic Reactions [see Warnings and Precautions ( 5.2 )]",
      "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions ( 5.3 )]",
      "Anaphylactic Reactions and Angioedema [see Warnings and Precautions ( 5.4 )]",
      "Hyponatremia [see Warnings and Precautions ( 5.5 )]",
      "Neurological Adverse Reactions [see Warnings and Precautions ( 5.6 )]",
      "Drug Induced Liver Injury [see Warnings and Precautions ( 5.8 )]",
      "Abnormal Thyroid Function Tests [see Warnings and Precautions ( 5.9 )]",
      "Pancytopenia, Agranulocytosis, and Leukopenia [see Warnings and Precautions ( 5.10 )]",
      "Most common adverse reactions in adult patients receiving eslicarbazepine acetate (≥4% and ≥2% greater than placebo): dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor",
      "Adverse reactions in pediatric patients are similar to those seen in adult patients",
      "To report SUSPECTED ADVERSE REACTIONS, contact Dr",
      "Reddy’s Laboratories, Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older",
      "Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older"
    ]
  },
  "esmolol": {
    "ingredient": "esmolol",
    "is_drug": true,
    "canonical_name": "esmolol",
    "fda_search_term": "esmolol",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Esmolol Hydrochloride",
      "esmolol hydrochloride in sodium chloride"
    ],
    "generic_names": [
      "ESMOLOL HYDROCHLORIDE",
      "ESMOLOL HYDROCHLORIDE IN SODIUM CHLORIDE"
    ],
    "manufacturers": [
      "Gland Pharma Limited",
      "Mylan Institutional LLC",
      "REMEDYREPACK INC."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride injection’s effects o",
      "Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest",
      "In addition, with some drugs, beta blockade may precipitate increased withdrawal effects",
      "(See clonidine, guanfacine, and moxonidine below.) Esmolol hydrochloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to",
      "Digoxin does not affect esmolol hydrochloride injection pharmacokinetics",
      "Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate",
      "Concomitant use increases the risk of bradycardia",
      "Anticholinesterases: Esmolol hydrochloride injection prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium",
      "Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension",
      "If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Most common adverse reactions (incidence >10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma at 864-879-9994 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "The following adverse reaction rates are based on use of esmolol hydrochloride injection in clinical trials involving 369 patients with supraventricular tachycardia and over 600 intraoperative and postoperative patients enrolled in clinical trials",
      "Most adverse effects observed in controlled clinical trial settings have been mild and transient",
      "The most important and common adverse effect has been hypotension [see Warnings and Precautions ( 5.1 )]",
      "Deaths have been reported in post-marketing experience occurring during complex clinical states where esmolol hydrochloride injection was presumably being used simply to control ventricular rate [see Warnings and Precautions ( 5.5 )] ",
      "Table 3 Clinical Trial Adverse Reactions (Frequency ≥3%) System Organ Class (SOC) Preferred MedDRA Term Frequency VASCULAR DISORDERS Hypotension* Asymptomatic hypotension Symptomatic hypotension (hyperhidrosis, dizziness) 25% 12% GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Infusion site rea",
      "In 80% of the remaining patients, hypotension resolved within 30 minutes following discontinuation of infusion",
      "Clinical Trial Adverse Reactions (Frequency <3%) Psychiatric Disorders Confusional state and agitation"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Esmolol hydrochloride injection is a beta adrenergic blocker indicated for the short-term treatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ",
      "Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention",
      "Esmolol hydrochloride injection is intended for short-term use",
      "1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative pe",
      "Use of esmolol hydrochloride injection to prevent such events is not recommended"
    ]
  },
  "esmoprazole": {
    "ingredient": "esmoprazole",
    "is_drug": true,
    "canonical_name": "esomeprazole",
    "fda_search_term": "esomeprazole",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Acid Reducer",
      "Esomeprazole Magnesium"
    ],
    "generic_names": [
      "ESOMEPRAZOLE MAGNESIUM"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack",
      "CVS Pharmacy"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert : Do not use if you are allergic to esomeprazole",
      "Esomeprazole may cause severe skin reactions",
      "Symptoms may include: skin reddening blisters rash If an allergic reaction occurs, stop use and seek medical help right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with esomeprazole and instructions for preventing or managing them",
      "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs",
      "Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Esomeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable",
      "The clinical importance and the mechanisms behind these interactions are not always known",
      "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]",
      "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with esomeprazole may increase toxicity [see Clinical Pharmacology (12.3) ]",
      "There are other antiretroviral drugs which do not result in clinically relevant interactions with esomeprazole",
      "Intervention: Rilpivirine-containing products: Concomitant use with esomeprazole magnesium delayed-release capsules are contraindicated [see Contraindications (4) ] ",
      "Atazanavir: See prescribing information for atazanavir for dosing information",
      "Nelfinavir: Avoid concomitant use with esomeprazole magnesium delayed-release capsules"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] Bone Fracture [see Warnings and Precaut",
      "Pediatrics (1 to 17 years) (≥2%) are: headache, diarrhea, abdominal pain, nausea, and somnolence",
      "To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc",
      "at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults The safety of esomeprazole magnesium delayed-release capsules was evaluated in over 15,000 patients (aged 18 to 84 years) in clinical trials worldwide including over 8,500 patients in the United States and over 6,500 patients in Europe and Canada",
      "Over 2,900 patients were treated in long-term studies for up to 6 to 12 months",
      "The safety in the treatment of healing of EE in adults was assessed in four randomized comparative clinical trials, which included 1,240 patients who received esomeprazole magnesium delayed-release capsules 20 mg once daily, 2,434 patients on esomeprazole magnesium delayed-release capsules 40"
    ],
    "indications": [
      "Uses treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect"
    ]
  },
  "esomeprazol": {
    "ingredient": "esomeprazol",
    "is_drug": true,
    "canonical_name": "esomeprazole",
    "fda_search_term": "esomeprazole",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Acid Reducer",
      "Esomeprazole Magnesium"
    ],
    "generic_names": [
      "ESOMEPRAZOLE MAGNESIUM"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack",
      "CVS Pharmacy"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert : Do not use if you are allergic to esomeprazole",
      "Esomeprazole may cause severe skin reactions",
      "Symptoms may include: skin reddening blisters rash If an allergic reaction occurs, stop use and seek medical help right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with esomeprazole and instructions for preventing or managing them",
      "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs",
      "Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Esomeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable",
      "The clinical importance and the mechanisms behind these interactions are not always known",
      "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]",
      "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with esomeprazole may increase toxicity [see Clinical Pharmacology (12.3) ]",
      "There are other antiretroviral drugs which do not result in clinically relevant interactions with esomeprazole",
      "Intervention: Rilpivirine-containing products: Concomitant use with esomeprazole magnesium delayed-release capsules are contraindicated [see Contraindications (4) ] ",
      "Atazanavir: See prescribing information for atazanavir for dosing information",
      "Nelfinavir: Avoid concomitant use with esomeprazole magnesium delayed-release capsules"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] Bone Fracture [see Warnings and Precaut",
      "Pediatrics (1 to 17 years) (≥2%) are: headache, diarrhea, abdominal pain, nausea, and somnolence",
      "To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc",
      "at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults The safety of esomeprazole magnesium delayed-release capsules was evaluated in over 15,000 patients (aged 18 to 84 years) in clinical trials worldwide including over 8,500 patients in the United States and over 6,500 patients in Europe and Canada",
      "Over 2,900 patients were treated in long-term studies for up to 6 to 12 months",
      "The safety in the treatment of healing of EE in adults was assessed in four randomized comparative clinical trials, which included 1,240 patients who received esomeprazole magnesium delayed-release capsules 20 mg once daily, 2,434 patients on esomeprazole magnesium delayed-release capsules 40"
    ],
    "indications": [
      "Uses treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect"
    ]
  },
  "esomeprazole": {
    "ingredient": "esomeprazole",
    "is_drug": true,
    "canonical_name": "esomeprazole",
    "fda_search_term": "esomeprazole",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Acid Reducer",
      "Esomeprazole Magnesium"
    ],
    "generic_names": [
      "ESOMEPRAZOLE MAGNESIUM"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack",
      "CVS Pharmacy"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert : Do not use if you are allergic to esomeprazole",
      "Esomeprazole may cause severe skin reactions",
      "Symptoms may include: skin reddening blisters rash If an allergic reaction occurs, stop use and seek medical help right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with esomeprazole and instructions for preventing or managing them",
      "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs",
      "Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Esomeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable",
      "The clinical importance and the mechanisms behind these interactions are not always known",
      "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]",
      "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with esomeprazole may increase toxicity [see Clinical Pharmacology (12.3) ]",
      "There are other antiretroviral drugs which do not result in clinically relevant interactions with esomeprazole",
      "Intervention: Rilpivirine-containing products: Concomitant use with esomeprazole magnesium delayed-release capsules are contraindicated [see Contraindications (4) ] ",
      "Atazanavir: See prescribing information for atazanavir for dosing information",
      "Nelfinavir: Avoid concomitant use with esomeprazole magnesium delayed-release capsules"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] Bone Fracture [see Warnings and Precaut",
      "Pediatrics (1 to 17 years) (≥2%) are: headache, diarrhea, abdominal pain, nausea, and somnolence",
      "To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc",
      "at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults The safety of esomeprazole magnesium delayed-release capsules was evaluated in over 15,000 patients (aged 18 to 84 years) in clinical trials worldwide including over 8,500 patients in the United States and over 6,500 patients in Europe and Canada",
      "Over 2,900 patients were treated in long-term studies for up to 6 to 12 months",
      "The safety in the treatment of healing of EE in adults was assessed in four randomized comparative clinical trials, which included 1,240 patients who received esomeprazole magnesium delayed-release capsules 20 mg once daily, 2,434 patients on esomeprazole magnesium delayed-release capsules 40"
    ],
    "indications": [
      "Uses treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect"
    ]
  },
  "estradiol": {
    "ingredient": "estradiol",
    "is_drug": true,
    "canonical_name": "estradiol",
    "fda_search_term": "estradiol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Estradiol",
      "Estradiol Vaginal"
    ],
    "generic_names": [
      "ESTRADIOL"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Alvogen Inc.",
      "Direct_Rx"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See BOXED WARNINGS ",
      "Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%",
      "The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account",
      "Cardiovascular Disorders An increased risk of stroke and DVT has been reported with estrogen-alone therapy",
      "An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy",
      "Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately",
      "Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately",
      "Stroke In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years)",
      "The increase in risk was demonstrated in year one and persisted [see CLINICAL STUDIES ]",
      "Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately"
    ],
    "drug_interactions": [
      "Drug-Laboratory Test Interactions 1",
      "Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and ",
      "Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay",
      "T 3 resin uptake is decreased, reflecting the elevated TBG",
      "Free T 4 and free T 3 concentrations are unaltered",
      "Women on thyroid replacement therapy may require higher dose of thyroid hormone",
      "Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively",
      "Free hormone concentrations, such as testosterone and estradiol, may be decreased",
      "Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin)",
      "Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See BOXED WARNINGS, WARNINGS and PRECAUTIONS ",
      "Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%",
      "The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account",
      "The following adverse reactions have been reported with estrogen and/or progestin therapy",
      "Genitourinary System Abnormal uterine bleeding or spotting; dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in cervical secretion; cystitis-like syndrome; application site reactions of vulvovaginal discomfort including burning an",
      "Breasts Tenderness, enlargement, pain, nipple discharge, fibrocystic breast changes; breast cancer",
      "Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; myocardial infarction; stroke; increase in blood pressure",
      "Gastrointestinal Nausea, vomiting; abdominal cramps, bloating; increased incidence of gallbladder disease",
      "Skin Chloasma that may persist when drug is discontinued; loss of scalp hair; hirsutism; rash",
      "Eyes Retinal vascular thrombosis, intolerance to contact lenses",
      "Central Nervous System Headache; migraine; dizziness; mental depression; nervousness; mood disturbances; irritability; dementia",
      "Miscellaneous Increase or decrease in weight; glucose intolerance; edema; arthralgias; leg cramps; changes in libido; urticaria; exacerbation of asthma; increased triglycerides; hypersensitivity",
      "To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause"
    ]
  },
  "estradiol valerate": {
    "ingredient": "estradiol valerate",
    "is_drug": true,
    "canonical_name": "estradiol valerate",
    "fda_search_term": "estradiol valerate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ESTRADIOL VALERATE",
      "Estradiol Valerate",
      "Estradiol valerate"
    ],
    "generic_names": [
      "ESTRADIOL VALERATE"
    ],
    "manufacturers": [
      "American Regent, Inc.",
      "Hikma Pharmaceuticals USA Inc.",
      "Xiromed, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See BOXED WARNINGS",
      "The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer",
      "Cardiovascular disorders Estrogen and estrogen/progestin therapy has been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE)",
      "Should any of these occur or be suspected, estrogens should be discontinued immediately",
      "Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately",
      "Coronary heart disease and stroke In the Women's Health Initiative (WHI) study, an increase in the number of myocardial infarctions and strokes has been observed in women receiving CE compared to placebo",
      "These observations are preliminary [see CLINICAL PHARMACOLOGY, Clinical Studies ]",
      "In the CE/MPA substudy of WHI, an increased risk of coronary heart disease (CHD) events (defined as non-fatal myocardial infarction and CHD death) was observed in women receiving CE/MPA compared to women receiving placebo (37 vs",
      "30 per 10,000 women-years)",
      "The increase in risk was observed in year one and persisted"
    ],
    "drug_interactions": [
      "Drug Interactions In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4)",
      "Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism",
      "Inducers of CYP3A4 such as St",
      "John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile",
      "Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See BOXED WARNINGS, WARNINGS , and PRECAUTIONS ",
      "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates",
      "The following additional adverse reactions have been reported with estrogen and/or progestin therapy",
      "Genitourinary system Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ",
      "Breasts Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer",
      "Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction; stroke; increase in blood pressure",
      "Gastrointestinal Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gallbladder disease; pancreatitis, enlargement of hepatic hemangiomas",
      "Skin Chloasma or melasma, which may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus, rash",
      "Eyes Retinal vascular thrombosis; intolerance to contact lenses",
      "Central Nervous System Headache; migraine; dizziness; mental depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia",
      "Miscellaneous Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthalgias; leg cramps; changes"
    ],
    "indications": [
      "INDICATIONS AND USAGE Estradiol Valerate Injection is indicated in the: 1",
      "Treatment of moderate to severe vasomotor symptoms associated with the menopause",
      "Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause",
      "When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered",
      "Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure"
    ]
  },
  "estre c": {
    "ingredient": "estre c",
    "is_drug": true,
    "canonical_name": "estradiol",
    "fda_search_term": "estradiol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Estradiol",
      "Estradiol Vaginal"
    ],
    "generic_names": [
      "ESTRADIOL"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Alvogen Inc.",
      "Direct_Rx"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See BOXED WARNINGS ",
      "Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%",
      "The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account",
      "Cardiovascular Disorders An increased risk of stroke and DVT has been reported with estrogen-alone therapy",
      "An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy",
      "Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately",
      "Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately",
      "Stroke In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years)",
      "The increase in risk was demonstrated in year one and persisted [see CLINICAL STUDIES ]",
      "Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately"
    ],
    "drug_interactions": [
      "Drug-Laboratory Test Interactions 1",
      "Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and ",
      "Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay",
      "T 3 resin uptake is decreased, reflecting the elevated TBG",
      "Free T 4 and free T 3 concentrations are unaltered",
      "Women on thyroid replacement therapy may require higher dose of thyroid hormone",
      "Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively",
      "Free hormone concentrations, such as testosterone and estradiol, may be decreased",
      "Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin)",
      "Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See BOXED WARNINGS, WARNINGS and PRECAUTIONS ",
      "Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%",
      "The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account",
      "The following adverse reactions have been reported with estrogen and/or progestin therapy",
      "Genitourinary System Abnormal uterine bleeding or spotting; dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in cervical secretion; cystitis-like syndrome; application site reactions of vulvovaginal discomfort including burning an",
      "Breasts Tenderness, enlargement, pain, nipple discharge, fibrocystic breast changes; breast cancer",
      "Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; myocardial infarction; stroke; increase in blood pressure",
      "Gastrointestinal Nausea, vomiting; abdominal cramps, bloating; increased incidence of gallbladder disease",
      "Skin Chloasma that may persist when drug is discontinued; loss of scalp hair; hirsutism; rash",
      "Eyes Retinal vascular thrombosis, intolerance to contact lenses",
      "Central Nervous System Headache; migraine; dizziness; mental depression; nervousness; mood disturbances; irritability; dementia",
      "Miscellaneous Increase or decrease in weight; glucose intolerance; edema; arthralgias; leg cramps; changes in libido; urticaria; exacerbation of asthma; increased triglycerides; hypersensitivity",
      "To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause"
    ]
  },
  "estriol": {
    "ingredient": "estriol",
    "is_drug": true,
    "canonical_name": "estradiol",
    "fda_search_term": "estradiol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Estradiol",
      "Estradiol Vaginal"
    ],
    "generic_names": [
      "ESTRADIOL"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Alvogen Inc.",
      "Direct_Rx"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See BOXED WARNINGS ",
      "Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%",
      "The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account",
      "Cardiovascular Disorders An increased risk of stroke and DVT has been reported with estrogen-alone therapy",
      "An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy",
      "Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately",
      "Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately",
      "Stroke In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years)",
      "The increase in risk was demonstrated in year one and persisted [see CLINICAL STUDIES ]",
      "Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately"
    ],
    "drug_interactions": [
      "Drug-Laboratory Test Interactions 1",
      "Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and ",
      "Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T 4 levels (by column or by radioimmunoassay) or T 3 levels by radioimmunoassay",
      "T 3 resin uptake is decreased, reflecting the elevated TBG",
      "Free T 4 and free T 3 concentrations are unaltered",
      "Women on thyroid replacement therapy may require higher dose of thyroid hormone",
      "Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively",
      "Free hormone concentrations, such as testosterone and estradiol, may be decreased",
      "Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin)",
      "Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS See BOXED WARNINGS, WARNINGS and PRECAUTIONS ",
      "Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%",
      "The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account",
      "The following adverse reactions have been reported with estrogen and/or progestin therapy",
      "Genitourinary System Abnormal uterine bleeding or spotting; dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in cervical secretion; cystitis-like syndrome; application site reactions of vulvovaginal discomfort including burning an",
      "Breasts Tenderness, enlargement, pain, nipple discharge, fibrocystic breast changes; breast cancer",
      "Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; myocardial infarction; stroke; increase in blood pressure",
      "Gastrointestinal Nausea, vomiting; abdominal cramps, bloating; increased incidence of gallbladder disease",
      "Skin Chloasma that may persist when drug is discontinued; loss of scalp hair; hirsutism; rash",
      "Eyes Retinal vascular thrombosis, intolerance to contact lenses",
      "Central Nervous System Headache; migraine; dizziness; mental depression; nervousness; mood disturbances; irritability; dementia",
      "Miscellaneous Increase or decrease in weight; glucose intolerance; edema; arthralgias; leg cramps; changes in libido; urticaria; exacerbation of asthma; increased triglycerides; hypersensitivity",
      "To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause"
    ]
  },
  "estrogen": {
    "ingredient": "estrogen",
    "is_drug": true,
    "canonical_name": "estrogen",
    "fda_search_term": "estrogen",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "3.6oz BiEST 2.5 Estrogen Cream",
      "Arthcal ESTROGEN",
      "Estrogen 1517"
    ],
    "generic_names": [
      "ESTRIOL,ESTRADIOL,ESTROGEN CREAM",
      "ESTROGEN"
    ],
    "manufacturers": [
      "Beijing JUNGE Technology Co., Ltd.",
      "Professional Complementary Health Formulas",
      "SHYNE BRANDS/BIOLabs PRO"
    ],
    "dosage_forms": [],
    "warnings": [
      "For external use only",
      "Keep out of reach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Apply to clean skin (face, neck, or body) twice daily",
      "For optimal results, combine with a daily skincare routine",
      "Consult your healthcare provider before use if you have specific medical concerns"
    ]
  },
  "eszopiclone": {
    "ingredient": "eszopiclone",
    "is_drug": true,
    "canonical_name": "eszopiclone",
    "fda_search_term": "eszopiclone",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ESZOPICLONE",
      "Eszopiclone"
    ],
    "generic_names": [
      "ESZOPICLONE"
    ],
    "manufacturers": [
      "Camber Pharmaceuticals, Inc.",
      "Preferred Pharmaceuticals Inc.",
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "CNS Depressants Additive CNS-depressant effects with combination use",
      "Use with ethanol causes additive psychomotor impairment ( 7.1 )",
      "Rifampicin Combination use may decrease exposure and effects of eszopiclone tablets ( 7.2 )",
      "Ketoconazole Combination use increases exposure and effect of eszopiclone tablets",
      "Dose reduction of eszopiclone tablet is needed ( 7.2 ) 7.1 CNS Active Drugs Ethanol: An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol [see Warnings and Precautions (5.1 , 5.2) ]",
      "Olanzapine: Coadministration of eszopiclone and olanzapine produced a decrease in DSST scores",
      "The interaction was pharmacodynamic; there was no alteration in the pharmacokinetics of either drug",
      "7.2 Drugs that Inhibit or Induce CYP3A4 Drugs that Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone",
      "The exposure of eszopiclone was increased by coadministration of ketoconazole, a potent inhibitor of CYP3A4"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following are described in more detail in the Warnings and Precautions section of the label:",
      "Complex Sleep Behaviors [see Boxed Warning and Warnings and Precautions (5.1) ]",
      "CNS Depressant Effects and Next-Day Impairment [see Warnings and Precautions (5.2) ]",
      "Need to Evaluate for Comorbid Diagnoses [see Warnings and Precautions (5.3) ]",
      "Severe Anaphylactic and Anaphylactoid Reactions [see Warnings and Precautions (5.4) ]",
      "Abnormal Thinking and Behavioral Changes [see Warnings and Precautions (5.5) ]",
      "Withdrawal Effects [see Warnings and Precautions (5.6) ]",
      "Timing of Drug Administration [see Warnings and Precautions (5.7) ]",
      "Special Populations [see Warnings and Precautions (5.8) ] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates ",
      "The premarketing development program for eszopiclone tablets included eszopiclone exposures in patients and/or normal subjects from two different groups of studies: approximately 400 normal subjects in clinical pharmacology/pharmacokinetic studies, and approximately 1550 patients in placebo-controll",
      "The conditions and duration of treatment with eszopiclone tablets varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, and short-term and longer-term exposure",
      "Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs",
      "The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, adverse reaction of the type listed",
      "A reaction was considered treatment-emergent if it occurred for the f"
    ],
    "indications": [
      "1 INDICATIONS & USAGE Eszopiclone tablets are indicated for the treatment of insomnia",
      "In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance",
      "The clinical trials performed in support of efficacy were up to 6 months in duration",
      "The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only)",
      "Eszopiclone tablets are indicated for the treatment of insomnia"
    ]
  },
  "etanercept": {
    "ingredient": "etanercept",
    "is_drug": true,
    "canonical_name": "etanercept",
    "fda_search_term": "etanercept",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ENBREL"
    ],
    "generic_names": [
      "ETANERCEPT"
    ],
    "manufacturers": [
      "Immunex Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel",
      "Live vaccines – Avoid concurrent administration with Enbrel ( 5.8 , 7.1 ) Anakinra – Increased risk of serious infection ( 5.12 , 7.2 ) Abatacept – Increased risk of serious adverse events, including infections ( 5.12 , 7.2 ) Cyclophosphamide – Not recommended for use with Enbrel",
      "( 7.3 ) 7.1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel",
      "The clinical significance of this is unknown",
      "Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines",
      "No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel",
      "Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions (5.8 , 5.10) ] ",
      "7.2 Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions (5.1",
      "The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases)",
      "One patient with pulmonary fibrosis and pneumonia died due to respiratory failure"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Serious Infections [see Warnings and Precautions (5.1) ] Neurologic Reactions [see Warnings and Precautions (5.2) ] Malignancies [see Warnings and Precautions (5.3) ] Patien",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc",
      "at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions (5) ] ",
      "The most common adverse reactions with Enbrel were infections and injection site reactions",
      "Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice",
      "Adverse Reactions in Adult Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patien",
      "In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approxi"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular J",
      "Enbrel can be initiated in combination with methotrexate (MTX) or used alone",
      "1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older",
      "1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA)",
      "Enbrel can be used with or without methotrexate"
    ]
  },
  "ethambutol": {
    "ingredient": "ethambutol",
    "is_drug": true,
    "canonical_name": "ethambutol",
    "fda_search_term": "ethambutol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ETHAMBUTOL HYDROCHLORIDE",
      "Ethambutol Hydrochloride"
    ],
    "generic_names": [
      "ETHAMBUTOL HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Epic Pharma, LLC",
      "Marlex Pharmaceuticals, Inc.",
      "STI Pharma LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Ethambutol hydrochloride may produce decreases in visual acuity which appear to be due to optic neuritis",
      "This effect may be related to dose and duration of treatment",
      "This effect is generally reversible when administration of the drug is discontinued promptly",
      "However, irreversible blindness has been reported",
      "(See PRECAUTIONS and ADVERSE REACTIONS )",
      "Liver toxicities including fatalities have been reported (See ADVERSE REACTIONS )",
      "Baseline and periodic assessment of hepatic function should be performed"
    ],
    "drug_interactions": [
      "Drug Interactions The results of a study of coadministration of ethambutol hydrochloride (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13% respecti",
      "It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ethambutol hydrochloride may produce decreases in visual acuity, including irreversible blindness, which appear to be due to optic neuritis",
      "Optic neuropathy including optic neuritis or retrobulbar neuritis occurring in association with ethambutol therapy may be characterized by one or more of the following events: decreased visual acuity, scotoma, color blindness, and/or visual defect",
      "These events have also been reported in the absence of a diagnosis of optic or retrobulbar neuritis",
      "Patients should be advised to report promptly to their physician any change in visual acuity",
      "The change in visual acuity may be unilateral or bilateral and hence each eye must be tested separately and both eyes tested together",
      "Testing of visual acuity should be performed before beginning ethambutol hydrochloride therapy and periodically during drug administration, except that it should be done monthly when a patient is on a dosage of more than 15 mg/kg/day",
      "Snellen eye charts are recommended for testing of visual acuity",
      "Studies have shown that there are definite fluctuations of one or two lines of the Snellen chart in the visual acuity of many tuberculous patients not receiving ethambutol hydrochloride",
      "The following table may be useful in interpreting possible changes in visual acuity attributable to ethambutol hydrochloride",
      "Initial Snellen Reading Reading Indicating Significant Decrease Significant Number of Lines Decrease Number of Points 20/13 20/25 3 12 20/15 0/25 2 10 20/20 20/30 2 10 20/25 20/40 2 15 20/30 20/50 2 20 20/40 20/70 2 30 20/40 20/70 1 20 In general, changes in visual acuity less than those indicated u",
      "Conversely, changes in visual acuity equaling or exceeding those under “Significant Number of Lines” and “Decrease Number of Points” indicate the need for retesting and careful evaluatio"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ethambutol Hydrochloride Tablets, USP are indicated for the treatment of pulmonary tuberculosis",
      "It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug",
      "Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies",
      "In patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: Ethambutol hydrochloride, USP plus isoniazid Ethambutol hydrochloride, USP plus isoniazid plus streptomycin In patients who have received previous a",
      "Consequently, in such retreatment patients, ethambutol hydrochloride should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies"
    ]
  },
  "ethanol": {
    "ingredient": "ethanol",
    "is_drug": true,
    "canonical_name": "ethanol",
    "fda_search_term": "ethanol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "VOWST"
    ],
    "generic_names": [
      "FECAL MICROBIOTA SPORES, LIVE-BRPK"
    ],
    "manufacturers": [
      "Aimmune Therapeutics, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS VOWST contains bacterial spores; therefore, antibacterials should not be administered concurrently with VOWST",
      "Antibacterials should not be administered concurrently with VOWST"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%)",
      "Most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%) and diarrhea (10.0%)",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics, Inc",
      "at 1-833-246-2566 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of VOWST was evaluated in one Phase 3, randomized, double-blind clinical study (Study 1: NCT03183128) and one Phase 3, open-label clinical study (Study 2: NCT03183141) conducted in the United States and Canada",
      "Adults with confirmed rCDI were required to have symptoms controlled 48 to 96 hours post-antibacterial treatment to be eligible for enrollment and randomization (1:1) to receive either VOWST or placebo (capsules containing 92 ± 4% glycerol in saline) for 3 consecutive days",
      "Participants with neutropenia (absolute neutrophil count of <500 cells/mm 3 ), toxic megacolon, or small bowel ileus were excluded from these studies",
      "A total of 349 adults 18 years of age and older with rCDI were exposed to VOWST across both Study 1 (n=90) and Study 2 (n=259)",
      "Across both Study 1 and Study 2, 99.1% of adults (346/349) received all scheduled doses of VOWST",
      "Overall, across the 2 studies, the median age of VOWST recipients was 66 years (range, 21-100 years)",
      "The racial and ethnic distribution was as follows: 92.3% were white and 5.2% were black",
      "In Study 1, females comprised 68.9% of the VOWST arm compared to 51.1% in the placebo arm",
      "Rates of the following c"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)",
      "VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)",
      "( 1 ) Limitation of Use: VOWST is not indicated for treatment of CDI",
      "Limitation of Use: VOWST is not indicated for treatment of CDI"
    ]
  },
  "ethanolamine oleate": {
    "ingredient": "ethanolamine oleate",
    "is_drug": true,
    "canonical_name": "ethanolamine oleate",
    "fda_search_term": "ethanolamine oleate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ethamolin"
    ],
    "generic_names": [
      "ETHANOLAMINE OLEATE"
    ],
    "manufacturers": [
      "QOL Medical, LLC."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS ETHAMOLlN Injection should be used in pregnant women only when clearly needed (see PRECAUTIONS)",
      "The practice of injecting varicosities of the leg with ETHAMOLlN Injection is not supported by adequately controlled clinical trials",
      "Therefore, such use is not recommended"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The reported frequency of complications/adverse events per injection session was 13%",
      "The most common complications were pleural effusion/infiltration (2.1%), esophageal ulcer (2.1 %), pyrexia (1.8%), retrosternal pain (1.6%), esophageal stricture (1.3%), and pneumonia (1.2%)",
      "Other adverse local esophageal reactions have also been reported at rates of 0.1 to 0.4%, including esophagitis, tearing of the esophagus, sloughing of the mucosa overlying the injected varix, ulceration, stricture, necrosis, periesophageal abscess and perforation (see PRECAUTIONS)",
      "These complications appear to be dependent upon the dose and the patient's clinical state",
      "Bacteremia has been observed in patients following injection of esophageal varices with ETHAMOLlN",
      "Pyrexia and retrosternal pain are not infrequently observed during the post-injection period",
      "Fatal aspiration pneumonia has occurred in patients with esophageal varices who underwent ETHAMOLIN Injection Sclerotherapy (see PRECAUTIONS)",
      "Anaphylactic shock and acute renal failure with spontaneous recovery have occurred (see PRECAUTIONS)",
      "A case of disseminated intravascular coagulation has been reported",
      "Spinal cord paralysis due to occlusion of the anterior spinal artery has been reported in one child eight hours after ETHAMOLIN sclerotherapy"
    ],
    "indications": [
      "INDICATIONS AND USAGE ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding",
      "ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled",
      "There is no evidence that treatment of this population decreases the likelihood of bleeding",
      "Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection"
    ]
  },
  "ethosuximide": {
    "ingredient": "ethosuximide",
    "is_drug": true,
    "canonical_name": "ethosuximide",
    "fda_search_term": "ethosuximide",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ETHOSUXIMIDE",
      "Ethosuximide",
      "Zarontin"
    ],
    "generic_names": [
      "ETHOSUXIMIDE"
    ],
    "manufacturers": [
      "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.",
      "Mylan Pharmaceuticals Inc.",
      "Parke-Davis Div of Pfizer Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Blood Dyscrasias: Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of ethosuximide; therefore, periodic blood counts should be performed",
      "Should signs and/or symptoms of infection (e.g., sore throat, fever) develop, blood counts should be considered at that point",
      "Drug-Induced Immune Thrombocytopenia: Drug-induced immune thrombocytopenia (DITP) has been reported with ethosuximide",
      "In the reported cases, the onset of symptoms occurred 1 to 3 weeks after initiation of ethosuximide; one patient had recurrence of symptoms within 1 day of a subsequent re-challenge with the drug",
      "In those cases in which the platelet count was specified, the nadir was 2,000 and 3,000/mm 3 ",
      "When DITP is suspected, discontinue ethosuximide, monitor serial platelet counts, and treat as appropriate",
      "If possible, assess the presence of drug-dependent antiplatelet antibodies",
      "Avoid future use of ethosuximide in patients with history of ethosuximide-induced DITP",
      "Effects on Liver and Kidneys: Ethosuximide is capable of producing morphological and functional changes in the animal liver",
      "In humans, abnormal liver and renal function studies have been reported"
    ],
    "drug_interactions": [
      "Drug Interactions: Since ethosuximide may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (e.g., ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuxi"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Body As A Whole: Allergic reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
      "Gastrointestinal System: Gastrointestinal symptoms occur frequently and include anorexia, vague gastric upset, nausea and vomiting, cramps, epigastric and abdominal pain, weight loss, and diarrhea",
      "There have been reports of gum hypertrophy and swelling of the tongue",
      "Hemopoietic System: Hemopoietic complications associated with the administration of ethosuximide have included leukopenia, agranulocytosis, pancytopenia, with or without bone marrow suppression, eosinophilia, and thrombocytopenia (see WARNINGS )",
      "Nervous System: Neurologic and sensory reactions reported during therapy with ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia",
      "Psychiatric or psychological aberrations associated with ethosuximide administration have included disturbances of sleep, night terrors, inability to concentrate, and aggressiveness",
      "These effects may be noted particularly in patients who have previously exhibited psychological abnormalities",
      "There have been rare reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions",
      "Integumentary System: Dermatologic manifestations which have occurred with the administration of ethosuximide have included urticaria, pruritic erythematous rashes, Stevens-Johnson syndrome, and hirsutism",
      "Special Senses: Myopia",
      "Genitourinary System: Vaginal bleeding, microscopic hematuria",
      "To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc",
      "at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ethosuximide capsule is indicated for the control of absence (petit mal) epilepsy"
    ]
  },
  "ethosuxmide": {
    "ingredient": "ethosuxmide",
    "is_drug": true,
    "canonical_name": "ethosuximide",
    "fda_search_term": "ethosuximide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ETHOSUXIMIDE",
      "Ethosuximide",
      "Zarontin"
    ],
    "generic_names": [
      "ETHOSUXIMIDE"
    ],
    "manufacturers": [
      "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.",
      "Mylan Pharmaceuticals Inc.",
      "Parke-Davis Div of Pfizer Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Blood Dyscrasias: Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of ethosuximide; therefore, periodic blood counts should be performed",
      "Should signs and/or symptoms of infection (e.g., sore throat, fever) develop, blood counts should be considered at that point",
      "Drug-Induced Immune Thrombocytopenia: Drug-induced immune thrombocytopenia (DITP) has been reported with ethosuximide",
      "In the reported cases, the onset of symptoms occurred 1 to 3 weeks after initiation of ethosuximide; one patient had recurrence of symptoms within 1 day of a subsequent re-challenge with the drug",
      "In those cases in which the platelet count was specified, the nadir was 2,000 and 3,000/mm 3 ",
      "When DITP is suspected, discontinue ethosuximide, monitor serial platelet counts, and treat as appropriate",
      "If possible, assess the presence of drug-dependent antiplatelet antibodies",
      "Avoid future use of ethosuximide in patients with history of ethosuximide-induced DITP",
      "Effects on Liver and Kidneys: Ethosuximide is capable of producing morphological and functional changes in the animal liver",
      "In humans, abnormal liver and renal function studies have been reported"
    ],
    "drug_interactions": [
      "Drug Interactions: Since ethosuximide may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (e.g., ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuxi"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Body As A Whole: Allergic reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
      "Gastrointestinal System: Gastrointestinal symptoms occur frequently and include anorexia, vague gastric upset, nausea and vomiting, cramps, epigastric and abdominal pain, weight loss, and diarrhea",
      "There have been reports of gum hypertrophy and swelling of the tongue",
      "Hemopoietic System: Hemopoietic complications associated with the administration of ethosuximide have included leukopenia, agranulocytosis, pancytopenia, with or without bone marrow suppression, eosinophilia, and thrombocytopenia (see WARNINGS )",
      "Nervous System: Neurologic and sensory reactions reported during therapy with ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia",
      "Psychiatric or psychological aberrations associated with ethosuximide administration have included disturbances of sleep, night terrors, inability to concentrate, and aggressiveness",
      "These effects may be noted particularly in patients who have previously exhibited psychological abnormalities",
      "There have been rare reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions",
      "Integumentary System: Dermatologic manifestations which have occurred with the administration of ethosuximide have included urticaria, pruritic erythematous rashes, Stevens-Johnson syndrome, and hirsutism",
      "Special Senses: Myopia",
      "Genitourinary System: Vaginal bleeding, microscopic hematuria",
      "To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc",
      "at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ethosuximide capsule is indicated for the control of absence (petit mal) epilepsy"
    ]
  },
  "ethyl acetate": {
    "ingredient": "ethyl acetate",
    "is_drug": true,
    "canonical_name": "ethyl acetate",
    "fda_search_term": "ethyl acetate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Household Antigens"
    ],
    "generic_names": [
      "ACETONE, SODIUM TRIPOLYPHOSPHATE, PROPYLENE GLYCOL, BENZINUM, AMMONIUM MURIATICUM, SODIUM LAURYL SULFATE, TEREBINTHINA, BUTYL ACETATE, ETHYL ACETATE, TOLUENE, XYLENE, BISPHENOL A, PETROLEUM, ANACARDIUM ORIENTALE, GRAPHITES, NITRICUM ACIDUM, PULSATILLA (PRATENSIS), SULPHUR",
      "ACETONE, SODIUM TRIPOLYPHOSPHATE, PROPYLENE GLYCOL, BENZINUM, AMMONIUM MURIATICUM, SODIUM LAURYL SULFATE, TEREBINTHINA, BUTYL ACETATE, ETHYL ACETATE, TOLUENE, XYLENE, BISPHENOL A, PETROLEUM, FORMALINUM, GLYPHOSATE, METHYLPARABEN, NAPHTHALINUM, PROPYLPARABEN, ANACARDIUM ORIENTALE, GRAPHITES, NITRICUM ACIDUM, PULSATILLA (PRATENSIS), SULPHUR, PARAFFINUM"
    ],
    "manufacturers": [
      "Energique, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Do not use if tamper evident seal is broken or missing",
      "Store in a cool, dry place"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS: May temporariy relieve symptoms associated with household chemicals sensitivities, such as dizziness and headache.** **Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated"
    ]
  },
  "ethyl alcohol": {
    "ingredient": "ethyl alcohol",
    "is_drug": true,
    "canonical_name": "ethanol",
    "fda_search_term": "ethanol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "VOWST"
    ],
    "generic_names": [
      "FECAL MICROBIOTA SPORES, LIVE-BRPK"
    ],
    "manufacturers": [
      "Aimmune Therapeutics, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS VOWST contains bacterial spores; therefore, antibacterials should not be administered concurrently with VOWST",
      "Antibacterials should not be administered concurrently with VOWST"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%)",
      "Most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%) and diarrhea (10.0%)",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics, Inc",
      "at 1-833-246-2566 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of VOWST was evaluated in one Phase 3, randomized, double-blind clinical study (Study 1: NCT03183128) and one Phase 3, open-label clinical study (Study 2: NCT03183141) conducted in the United States and Canada",
      "Adults with confirmed rCDI were required to have symptoms controlled 48 to 96 hours post-antibacterial treatment to be eligible for enrollment and randomization (1:1) to receive either VOWST or placebo (capsules containing 92 ± 4% glycerol in saline) for 3 consecutive days",
      "Participants with neutropenia (absolute neutrophil count of <500 cells/mm 3 ), toxic megacolon, or small bowel ileus were excluded from these studies",
      "A total of 349 adults 18 years of age and older with rCDI were exposed to VOWST across both Study 1 (n=90) and Study 2 (n=259)",
      "Across both Study 1 and Study 2, 99.1% of adults (346/349) received all scheduled doses of VOWST",
      "Overall, across the 2 studies, the median age of VOWST recipients was 66 years (range, 21-100 years)",
      "The racial and ethnic distribution was as follows: 92.3% were white and 5.2% were black",
      "In Study 1, females comprised 68.9% of the VOWST arm compared to 51.1% in the placebo arm",
      "Rates of the following c"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)",
      "VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)",
      "( 1 ) Limitation of Use: VOWST is not indicated for treatment of CDI",
      "Limitation of Use: VOWST is not indicated for treatment of CDI"
    ]
  },
  "ethyl chloride": {
    "ingredient": "ethyl chloride",
    "is_drug": true,
    "canonical_name": "ethyl chloride",
    "fda_search_term": "ethyl chloride",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Glimepiride",
      "Moisturizing Antibacterial"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "GLIMEPIRIDE"
    ],
    "manufacturers": [
      "American Health Packaging",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "ethyl lactate": {
    "ingredient": "ethyl lactate",
    "is_drug": true,
    "canonical_name": "ethyl lactate",
    "fda_search_term": "ethyl lactate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "LACOSAMIDE",
      "Mekinist"
    ],
    "generic_names": [
      "LACOSAMIDE",
      "TRAMETINIB"
    ],
    "manufacturers": [
      "Novartis Pharmaceuticals Corporation",
      "Somerset Therapeutics, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See WARNING box",
      "Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis",
      "Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C",
      "difficile produces toxins A and B which contribute to the development of CDAD",
      "Hypertoxin producing strains of C",
      "difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
      "CDAD must be considered in all patients who present with diarrhea following antibiotic use",
      "Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents",
      "If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C",
      "difficile may need to be discontinued"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",
      "( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test",
      "( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options"
    ]
  },
  "ethyl salicylate": {
    "ingredient": "ethyl salicylate",
    "is_drug": true,
    "canonical_name": "ethyl salicylate",
    "fda_search_term": "ethyl salicylate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Glimepiride",
      "Naproxen"
    ],
    "generic_names": [
      "GLIMEPIRIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "American Health Packaging"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity",
      "In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction",
      "Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects",
      "The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective",
      "Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of:",
      "rheumatoid arthritis",
      "ankylosing spondylitis",
      "Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of:",
      "acute gout the management of:"
    ]
  },
  "ethyle alcohol": {
    "ingredient": "ethyle alcohol",
    "is_drug": true,
    "canonical_name": "ethanol",
    "fda_search_term": "ethanol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "VOWST"
    ],
    "generic_names": [
      "FECAL MICROBIOTA SPORES, LIVE-BRPK"
    ],
    "manufacturers": [
      "Aimmune Therapeutics, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS VOWST contains bacterial spores; therefore, antibacterials should not be administered concurrently with VOWST",
      "Antibacterials should not be administered concurrently with VOWST"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%)",
      "Most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%) and diarrhea (10.0%)",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics, Inc",
      "at 1-833-246-2566 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of VOWST was evaluated in one Phase 3, randomized, double-blind clinical study (Study 1: NCT03183128) and one Phase 3, open-label clinical study (Study 2: NCT03183141) conducted in the United States and Canada",
      "Adults with confirmed rCDI were required to have symptoms controlled 48 to 96 hours post-antibacterial treatment to be eligible for enrollment and randomization (1:1) to receive either VOWST or placebo (capsules containing 92 ± 4% glycerol in saline) for 3 consecutive days",
      "Participants with neutropenia (absolute neutrophil count of <500 cells/mm 3 ), toxic megacolon, or small bowel ileus were excluded from these studies",
      "A total of 349 adults 18 years of age and older with rCDI were exposed to VOWST across both Study 1 (n=90) and Study 2 (n=259)",
      "Across both Study 1 and Study 2, 99.1% of adults (346/349) received all scheduled doses of VOWST",
      "Overall, across the 2 studies, the median age of VOWST recipients was 66 years (range, 21-100 years)",
      "The racial and ethnic distribution was as follows: 92.3% were white and 5.2% were black",
      "In Study 1, females comprised 68.9% of the VOWST arm compared to 51.1% in the placebo arm",
      "Rates of the following c"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)",
      "VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI)",
      "( 1 ) Limitation of Use: VOWST is not indicated for treatment of CDI",
      "Limitation of Use: VOWST is not indicated for treatment of CDI"
    ]
  },
  "ethylene diamino tetra acetic acid": {
    "ingredient": "ethylene diamino tetra acetic acid",
    "is_drug": true,
    "canonical_name": "edetate",
    "fda_search_term": "edetate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Edetate Calcium Disodium",
      "Miracle FootCream Lavender",
      "Miracle FootCream Lemon"
    ],
    "generic_names": [
      "EDETATE CALCIUM DISODIUM",
      "UREA, GLYCERIN, ALOE, DISODIUM EDTA"
    ],
    "manufacturers": [
      "Aloe Vera Korea Co.,Ltd.",
      "Rising Pharma Holdings, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See Boxed Warning"
    ],
    "drug_interactions": [
      "Drug Interactions There is no known drug interference with standard clinical laboratory tests",
      "Steroids enhance the renal toxicity of edetate calcium disodium in animals",
      "7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following adverse effects have been associated with the use of edetate calcium disodium: Body as a Whole: pain at intramuscular injection site, fever, chills, malaise, fatigue, myalgia, arthralgia",
      "Cardiovascular: hypotension, cardiac rhythm irregularities",
      "Renal: acute necrosis of proximal tubules (which may result in fatal nephrosis), infrequent changes in distal tubules and glomeruli",
      "Urinary: glycosuria, proteinuria, microscopic hematuria and large epithelial cells in urinary sediment",
      "Nervous System: tremors, headache, numbness, tingling",
      "Gastrointestinal: cheilosis, nausea, vomiting, anorexia, excessive thirst",
      "Hepatic: mild increases in SGOT and SGPT are common, and return to normal within 48 hours after cessation of therapy",
      "Immunogenic: histamine-like reactions (sneezing, nasal congestion, lacrimation), rash",
      "Hematopoietic: transient bone marrow depression, anemia",
      "Metabolic: zinc deficiency, hypercalcemia",
      "To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc",
      "at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch "
    ],
    "indications": [
      "INDICATIONS AND USAGE Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults",
      "Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead"
    ]
  },
  "ethylhexy1 methoxycinnamate": {
    "ingredient": "ethylhexy1 methoxycinnamate",
    "is_drug": true,
    "canonical_name": "ethylhexyl methoxycinnamate",
    "fda_search_term": "ethylhexyl methoxycinnamate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "MENOW SUNSCREEN",
      "MURASAKI BEAUTY Silicence Scar Gel SPF 30",
      "ONE PERCENT Sunscreen"
    ],
    "generic_names": [
      "ETHYLHEXYL METHOXYCINNAMATE, BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, ZINC OXIDE, TITANIUM DIOXIDE",
      "ONE PERCENT SUNSCREEN",
      "ZINC OXIDE, ETHYLHEXYL METHOXYCINNAMATE"
    ],
    "manufacturers": [
      "Beijing Keyan Biotechnology Co., Ltd.",
      "Haikou Pucao Trading Co.,Ltd",
      "SHANTOU QIWEI INDUSTRY CO.,LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: 1.IF YOU HAVE SENSITIVE SKIN, PLEASE TRY IT LOCALLY FIRST ANDUSE IT AFTER NO DISCOMFORT; 2.DISCONTINUE USE IMMEDIATELY IF YOU FEELUNWELL AFTER USE; 3.KEEP OUT OF REACH OF YOUNG CHILDREN TO AVOID ACCI.DENTAL INGESTION, NOT BE USED FOR CHILDREN UNDER 3 YEARS OF AGE"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications & usage section:SUNSCREEN PRESSED POWDER,SETTING MAKEUP WHILE PROTECTING AGAINST UVA/UVB"
    ]
  },
  "ethylhexyl methoxy cinnamate": {
    "ingredient": "ethylhexyl methoxy cinnamate",
    "is_drug": true,
    "canonical_name": "ethylhexyl methoxycinnamate",
    "fda_search_term": "ethylhexyl methoxycinnamate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "MENOW SUNSCREEN",
      "MURASAKI BEAUTY Silicence Scar Gel SPF 30",
      "ONE PERCENT Sunscreen"
    ],
    "generic_names": [
      "ETHYLHEXYL METHOXYCINNAMATE, BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, ZINC OXIDE, TITANIUM DIOXIDE",
      "ONE PERCENT SUNSCREEN",
      "ZINC OXIDE, ETHYLHEXYL METHOXYCINNAMATE"
    ],
    "manufacturers": [
      "Beijing Keyan Biotechnology Co., Ltd.",
      "Haikou Pucao Trading Co.,Ltd",
      "SHANTOU QIWEI INDUSTRY CO.,LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: 1.IF YOU HAVE SENSITIVE SKIN, PLEASE TRY IT LOCALLY FIRST ANDUSE IT AFTER NO DISCOMFORT; 2.DISCONTINUE USE IMMEDIATELY IF YOU FEELUNWELL AFTER USE; 3.KEEP OUT OF REACH OF YOUNG CHILDREN TO AVOID ACCI.DENTAL INGESTION, NOT BE USED FOR CHILDREN UNDER 3 YEARS OF AGE"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications & usage section:SUNSCREEN PRESSED POWDER,SETTING MAKEUP WHILE PROTECTING AGAINST UVA/UVB"
    ]
  },
  "ethylhexyl methoxycinnamate": {
    "ingredient": "ethylhexyl methoxycinnamate",
    "is_drug": true,
    "canonical_name": "ethylhexyl methoxycinnamate",
    "fda_search_term": "ethylhexyl methoxycinnamate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "MENOW SUNSCREEN",
      "MURASAKI BEAUTY Silicence Scar Gel SPF 30",
      "ONE PERCENT Sunscreen"
    ],
    "generic_names": [
      "ETHYLHEXYL METHOXYCINNAMATE, BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, ZINC OXIDE, TITANIUM DIOXIDE",
      "ONE PERCENT SUNSCREEN",
      "ZINC OXIDE, ETHYLHEXYL METHOXYCINNAMATE"
    ],
    "manufacturers": [
      "Beijing Keyan Biotechnology Co., Ltd.",
      "Haikou Pucao Trading Co.,Ltd",
      "SHANTOU QIWEI INDUSTRY CO.,LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: 1.IF YOU HAVE SENSITIVE SKIN, PLEASE TRY IT LOCALLY FIRST ANDUSE IT AFTER NO DISCOMFORT; 2.DISCONTINUE USE IMMEDIATELY IF YOU FEELUNWELL AFTER USE; 3.KEEP OUT OF REACH OF YOUNG CHILDREN TO AVOID ACCI.DENTAL INGESTION, NOT BE USED FOR CHILDREN UNDER 3 YEARS OF AGE"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications & usage section:SUNSCREEN PRESSED POWDER,SETTING MAKEUP WHILE PROTECTING AGAINST UVA/UVB"
    ]
  },
  "ethylhexylmethoxy cinnamate": {
    "ingredient": "ethylhexylmethoxy cinnamate",
    "is_drug": true,
    "canonical_name": "ethylhexyl methoxycinnamate",
    "fda_search_term": "ethylhexyl methoxycinnamate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "MENOW SUNSCREEN",
      "MURASAKI BEAUTY Silicence Scar Gel SPF 30",
      "ONE PERCENT Sunscreen"
    ],
    "generic_names": [
      "ETHYLHEXYL METHOXYCINNAMATE, BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, ZINC OXIDE, TITANIUM DIOXIDE",
      "ONE PERCENT SUNSCREEN",
      "ZINC OXIDE, ETHYLHEXYL METHOXYCINNAMATE"
    ],
    "manufacturers": [
      "Beijing Keyan Biotechnology Co., Ltd.",
      "Haikou Pucao Trading Co.,Ltd",
      "SHANTOU QIWEI INDUSTRY CO.,LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: 1.IF YOU HAVE SENSITIVE SKIN, PLEASE TRY IT LOCALLY FIRST ANDUSE IT AFTER NO DISCOMFORT; 2.DISCONTINUE USE IMMEDIATELY IF YOU FEELUNWELL AFTER USE; 3.KEEP OUT OF REACH OF YOUNG CHILDREN TO AVOID ACCI.DENTAL INGESTION, NOT BE USED FOR CHILDREN UNDER 3 YEARS OF AGE"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications & usage section:SUNSCREEN PRESSED POWDER,SETTING MAKEUP WHILE PROTECTING AGAINST UVA/UVB"
    ]
  },
  "etodolac": {
    "ingredient": "etodolac",
    "is_drug": true,
    "canonical_name": "etodolac",
    "fda_search_term": "etodolac",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Etodolac"
    ],
    "generic_names": [
      "ETODOLAC"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack",
      "PD-Rx Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS CARDIOVASCULAR EFFECTS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can ",
      "Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs",
      "The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease",
      "However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate",
      "Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment",
      "The increase in CV thrombotic risk has been observed most consistently at higher doses",
      "To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible",
      "Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms",
      "Patients should be informed about the symptoms of serious CV events and the steps to take if they occur",
      "There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use"
    ],
    "drug_interactions": [
      "Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors",
      "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors (see WARNINGS )",
      "Antacids The concomitant administration of antacids has no apparent effect on the extent of absorption of etodolac",
      "However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak",
      "Aspirin When etodolac is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered",
      "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of etodolac and aspirin is not generally recommended because of the potential of increased adverse effects",
      "Cyclosporine, Digoxin, Methotrexate Etodolac, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity",
      "Nephrotoxicity associated with cyclosporine may also be enhanced",
      "Patients receiving these drugs who are given etodolac, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs",
      "NSAIDs, such as etodolac, should not be administered prior to or concomitantly with high doses of methotrexate"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS In patients taking etodolac or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1 to 10% of patients are: Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, hear",
      "Other events including: abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus",
      "Adverse-reaction information for etodolac was derived from 2,629 arthritic patients treated with etodolac in double-blind and open-label clinical trials of 4 to 320 weeks in duration and worldwide postmarketing surveillance studies",
      "In clinical trials, most adverse reactions were mild and transient",
      "The discontinuation rate in controlled clinical trials, because of adverse events, was up to 10% for patients treated with etodolac",
      "New patient complaints (with an incidence greater than or equal to 1%) are listed below by body system",
      "The incidences were determined from clinical trials involving 465 patients with osteoarthritis treated with 300 to 500 mg of etodolac b.i.d",
      "(i.e., 600 to 1000 mg/day)",
      "Incidence Greater Than Or Equal To 1%",
      "Probably Causally Related Body as a whole",
      "Chills and fever",
      "Digestive system",
      "Dyspepsia (10%), abdominal pain 1 , diarrhea 1 , flatulence 1 , nausea 1 , abdominal distension, epigastric pain, abnormal stools, constipation, gastritis, melena, vomiting",
      "Asthenia/malaise 1 , dizziness 1 , depression, nervousness, fatigue",
      "Skin and appendages"
    ],
    "indications": [
      "INDICATIONS AND USAGE Carefully consider the potential benefits and risks of etodolac tablets and other treatment options before deciding to use etodolac tablets",
      "Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS )",
      "Etodolac tablets are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain"
    ]
  },
  "etoline": {
    "ingredient": "etoline",
    "is_drug": true,
    "canonical_name": "etomidate",
    "fda_search_term": "etomidate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ETOMIDATE",
      "ETOMIDATE injection, solution",
      "Etomidate"
    ],
    "generic_names": [
      "ETOMIDATE",
      "ETOMIDATE INJECTION, SOLUTION"
    ],
    "manufacturers": [
      "Eugia US LLC",
      "HF Acquisition Co LLC, DBA HealthFirst",
      "Hikma Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS INTRAVENOUS ETOMIDATE SHOULD BE ADMINISTERED ONLY BY PERSONS TRAINED IN THE ADMINISTRATION OF GENERAL ANESTHETICS AND IN THE MANAGEMENT OF COMPLICATIONS ENCOUNTERED DURING THE CONDUCT OF GENERAL ANESTHESIA",
      "BECAUSE OF THE HAZARDS OF PROLONGED SUPPRESSION OF ENDOGENOUS CORTISOL AND ALDOSTERONE PRODUCTION, THIS FORMULATION IS NOT INTENDED FOR ADMINISTRATION BY PROLONGED INFUSION",
      "Pediatric Neurotoxicity: Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 ",
      "The clinical significance of these findings is not clear",
      "However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans (see PRECAUTIONS/PREGNANCY , PEDIA",
      "Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects",
      "These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness",
      "Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other",
      "Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions associated with use of intravenous etomidate are transient venous pain on injection and transient skeletal muscle movements, including myoclonus: 1",
      "Transient venous pain was observed immediately following intravenous injection of etomidate in about 20% of the patients, with considerable difference in the reported incidence (1.2% to 42%)",
      "This pain is usually described as mild to moderate in severity but it is occasionally judged disturbing",
      "The observation of venous pain is not associated with a more than usual incidence of thrombosis or thrombophlebitis at the injection site",
      "Pain also appears to be less frequently noted when larger, more proximal arm veins are employed and it appears to be more frequently noted when smaller, more distal, hand or wrist veins are employed",
      "Transient skeletal muscle movements were noted following use of intravenous etomidate in about 32% of the patients, with considerable difference in the reported incidence (22.7% to 63%)",
      "Most of these observations were judged mild to moderate in severity but some were judged disturbing",
      "The incidence of disturbing movements was less when 0.1 mg of fentanyl was given immediately before induction",
      "These movements have been classified as myoclonic in the majority of cases (74%), but averting movements (7%), tonic movements (10%), and eye movements (9%) have also been reported",
      "No exact classification is available, but these movements may also be placed into three groups by location: a",
      "Most movements are bilateral",
      "The arms, legs, shoulders, neck, chest wall, trunk and all four extremities have been described in some cases, with one or more of these muscle groups predominating in each individual case",
      "Results of electroencephalographic studies suggest that these muscle movements are a manifestation of disinhibition of cortical activity; cortical electroencephalograms, taken during periods when these muscle movements were observed, have failed"
    ],
    "indications": [
      "INDICATIONS & USAGE SECTION Etomidate Injection is indicated by intravenous injection for the induction of general anesthesia",
      "When considering use of Etomidate Injection, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY ) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS )",
      "Intravenous Etomidate Injection is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization"
    ]
  },
  "etonogestrel": {
    "ingredient": "etonogestrel",
    "is_drug": true,
    "canonical_name": "etonogestrel",
    "fda_search_term": "etonogestrel",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Etonogestrel and Ethinyl Estradiol Vaginal",
      "Etonogestrel and Ethinyl Estradiol Vaginal Ring",
      "NuvaRing"
    ],
    "generic_names": [
      "ETONOGESTREL AND ETHINYL ESTRADIOL",
      "ETONOGESTREL AND ETHINYL ESTRADIOL VAGINAL",
      "ETONOGESTREL AND ETHINYL ESTRADIOL VAGINAL RING"
    ],
    "manufacturers": [
      "Advanz Pharma (US) Corp.",
      "AvKARE",
      "Northstar Rx LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations",
      "Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the effectiveness of CHCs or increase breakthrough bleeding",
      "Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with CHCs",
      "( 7 ) 7.1 Effects of Other Drugs on CHCs Substances decreasing the plasma concentrations of CHCs and potentially diminishing the effectiveness of CHCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of CHCs and pote",
      "Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St",
      "Interactions between CHCs and other drugs may lead to breakthrough bleeding and/or contraceptive failure",
      "Counsel women to use an alternative non-hormonal method of contraception or a back-up method when enzyme inducers are used with Etonogestrel and ethinyl estradiol vaginal ring, and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer to ensure contracepti",
      "Note: Etonogestrel and ethinyl estradiol vaginal ring may interfere with the correct placement and position of certain female barrier methods such as a diaphragm or female condom",
      "These methods are not recommended as back-up methods with Etonogestrel and ethinyl estradiol vaginal ring use [see Dosage and Administration ( 2.5 )] ",
      "The serum concentrations of etonogestrel and ethinyl estradiol were not affected by concomitant administration of oral amoxicil"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of CHCs are discussed elsewhere in the labeling",
      "Serious cardiovascular events and stroke [ see Boxed Warning and Warnings and Precautions ( 5.1 ) ] Vascular events [ see Warnings and Precautions ( 5.1 ) ] Liver disease [ see Warnings and Precautions ( 5.3 ) ] Adverse reactions commonly reported by CHC users are: Irregular uterine bleeding Nausea ",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot",
      "Trials with a duration of 6 to 13 28-day cycles provided safety data",
      "In total, 2,501 women, aged 18 to 41 contributed 24,520 cycles of exposure",
      "Common Adverse Reactions (≥ 2%): vaginitis (13.8%), headache (including migraine) (11.2%), mood changes (e.g., depression, mood swings, mood altered, depressed mood, affect lability) (6.4%), device-related events (e.g., expulsion/discomfort/foreign body sensation) (6.3%), nausea/vomiting (5.9%), vag",
      "Adverse Reactions (≥ 1%) Leading to St"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE FOR VAGINAL USE ONLY Etonogestrel and ethinyl estradiol vaginal ring is indicated for use by females of reproductive age to prevent pregnancy",
      "Etonogestrel and ethinyl estradiol vaginal ring is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy"
    ]
  },
  "etoposide": {
    "ingredient": "etoposide",
    "is_drug": true,
    "canonical_name": "etoposide",
    "fda_search_term": "etoposide",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Etoposide"
    ],
    "generic_names": [
      "ETOPOSIDE"
    ],
    "manufacturers": [
      "Accord Healthcare Inc.",
      "BluePoint Laboratories"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Patients being treated with etoposide injection must be frequently observed for myelosuppression both during and after therapy",
      "Myelosuppression resulting in death has been reported",
      "Dose-limiting bone marrow suppression is the most significant toxicity associated with etoposide injection therapy",
      "Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of etoposide injection: platelet count, hemoglobin, white blood cell count, and differential",
      "The occurrence of a platelet count below 50,000/mm 3 or an absolute neutrophil count below 500/mm 3 is an indication to withhold further therapy until the blood counts have sufficiently recovered",
      "Physicians should be aware of the possible occurrence of an anaphylactic reaction manifested by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension",
      "Higher rates of anaphylactic-like reactions have been reported in children who received infusions at concentrations higher than those recommended",
      "The role that concentration of infusion (or rate of infusion) plays in the development of anaphylactic-like reactions is uncertain (see ADVERSE REACTIONS section)",
      "Treatment is symptomatic",
      "The infusion should be terminated immediately, followed by the administration of pressor agents, corticosteroids, antihistamines, or volume expanders at the discretion of the physician"
    ],
    "drug_interactions": [
      "Drug Interactions High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following data on adverse reactions are based on both oral and intravenous administration of etoposide injection as a single agent, using several different dose schedules for treatment of a wide variety of malignancies",
      "Hematologic Toxicity Myelosuppression is dose related and dose limiting, with granulocyte nadirs occurring 7 to 14 days after drug administration and platelet nadirs occurring 9 to 16 days after drug administration",
      "Bone marrow recovery is usually complete by day 20, and no cumulative toxicity has been reported",
      "Fever and infection have also been reported in patients with neutropenia",
      "Death associated with myelosuppression has been reported",
      "The occurrence of acute leukemia with or without a preleukemic phase has been reported rarely in patients treated with etoposide injection in association with other antineoplastic agents (see WARNINGS section)",
      "Gastrointestinal Toxicity Nausea and vomiting are the major gastrointestinal toxicities",
      "The severity of such nausea and vomiting is generally mild to moderate with treatment discontinuation required in 1% of patients",
      "Nausea and vomiting can usually be controlled with standard antiemetic therapy",
      "Mild to severe mucositis/esophagitis may occur",
      "Gastrointestinal toxicities are slightly more frequent after oral administration than after intravenous infusion",
      "Hypotension Transient hypotension following rapid intravenous administration has been reported in 1% to 2% of patients",
      "It has not been associated with cardiac toxicity or electrocardiographic changes",
      "No delayed hypotension has been noted",
      "To prevent this rare occurrence, it is recommended that etoposide injection be administered by slow intravenous infusion over a 30"
    ],
    "indications": [
      "INDICATIONS AND USAGE Etoposide Injection is indicated in the management of the following neoplasms: Refractory Testicular Tumors Etoposide Injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate",
      "Small Cell Lung Cancer Etoposide Injection and/or capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer"
    ]
  },
  "eucalyptol": {
    "ingredient": "eucalyptol",
    "is_drug": true,
    "canonical_name": "eucalyptol",
    "fda_search_term": "eucalyptol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Antispetic",
      "Eucalyptol, Menthol, Methyl Salicylate, Thymol"
    ],
    "generic_names": [
      "EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL"
    ],
    "manufacturers": [
      "AMERISOURCE BERGEN",
      "Cariba International",
      "Strategic Sourcing Services LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings for this product"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reaction SATISFACTION GUARANTEED Distributed By AmerisourceBergen 1 West First Avenue, Conshohocken, PA 19428 Questions or Concerns?",
      "1-888-593-0593 www.mygnp.com DSP-TN-21091 DSP-MO-20087"
    ],
    "indications": [
      "Use helps control plaque that leads to gingivitis"
    ]
  },
  "eucalyptus oil": {
    "ingredient": "eucalyptus oil",
    "is_drug": true,
    "canonical_name": "eucalyptus oil",
    "fda_search_term": "eucalyptus oil",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CVS Health Medicated Chest Rub",
      "Equate Rub",
      "Vicks childrens VapoRub"
    ],
    "generic_names": [
      "CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, MENTHOL",
      "CAMPHOR, EUCALYPTUS OIL, MENTHOL"
    ],
    "manufacturers": [
      "CVS Pharmacy",
      "Procter & Gamble Manufactura S de RL de CV",
      "Walmart Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only; avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses when applied to chest and throat, temporarily relieves cough due to minor throat and bronchial irritation associated with the common cold when applied to muscles and joints, temporarily relieves minor aches and pains of muscles and joints"
    ]
  },
  "eugenol": {
    "ingredient": "eugenol",
    "is_drug": true,
    "canonical_name": "eugenol",
    "fda_search_term": "eugenol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Chemstat",
      "Oligo Bio Iodine",
      "Teething Drops 2120"
    ],
    "generic_names": [
      "CHELIDONIUM MAJUS, IODIUM, LYCOPUS VIRGINICUS, GINKGO BILOBA, PINUS SYLVESTRIS, FUCUS VESICULOSUS, SPONGIA TOSTA, GERMANIUM SESQUIOXIDE, HYPOPHYSIS SUIS, THYROIDINUM (SUIS), CYSTEINUM, MANGANESE GLUCONATE, ALPHA-KETOGLUTARICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, FUMARICUM ACIDUM, KALI IODATUM, NATRUM OXALACETICUM, PULSATILLA (VULGARIS), ARGENTUM METALLICUM, AURUM METALLICUM, CUPRUM METALLICUM, EUGENOL, FORMALINUM, LIDOCAINE, MERCURIUS SOLUBILIS, MOLYBDENUM METALLICUM, NICCOLUM METALLICUM,",
      "GLYCERINUM, TARAXACUM OFFICINALE, PHYTOLACCA DECANDRA, ARSENICUM ALBUM, NITRICUM ACIDUM, NUX VOMICA, PETROLEUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, ACETYLSALICYLICUM ACIDUM, GLONOINUM, INSULINUM (HUMAN), LITHIUM CARBONICUM, THYROIDINUM (SUIS), ACETICUM ACIDUM, BENZOICUM ACIDUM, BENZYL ALCOHOL, BORICUM ACIDUM, CHLORINUM, CORTISONE ACETICUM, EUGENOL, FOLLICULINUM, ISOPROPYL PALMITATE, LACTICUM ACIDUM, PETROLEUM JELLY, PHENYL BUTAZONE, PLUMBUM METALLICUM, POTASSIUM SORBATE, RESORCINUM, SALICYLICUM ACIDUM,",
      "TEETHING DROPS"
    ],
    "manufacturers": [
      "BioActive Nutritional, Inc.",
      "Energique, Inc.",
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Do not use if tamper evident seal is broken or missing",
      "Store in a cool, dry place"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS: May temporarily relieve weakness and exhaustion, minor abdominal cramps, bloating, and vomiting.** **Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated"
    ]
  },
  "everolimus": {
    "ingredient": "everolimus",
    "is_drug": true,
    "canonical_name": "everolimus",
    "fda_search_term": "everolimus",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Afinitor",
      "Afinitor Disperz",
      "Everolimus"
    ],
    "generic_names": [
      "EVEROLIMUS"
    ],
    "manufacturers": [
      "Ascend Laboratories, LLC",
      "Breckenridge Pharmaceutical, Inc.",
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "DRUG INTERACTIONS P-gp and strong CYP3A4 inhibitors: Avoid concomitant use",
      "( 2.11 , 7.1 ) P-gp and moderate CYP3A4 inhibitors: Reduce the dose as recommended",
      "( 2.11 , 7.1 ) P-gp and strong CYP3A4 inducers: Increase the dose as recommended",
      "( 2.12 , 7.1 ) 7.1 Effect of Other Drugs on Everolimus Tablets/Everolimus Tablets for Oral Suspension Inhibitors Avoid the concomitant use of P-gp and strong CYP3A4 inhibitors [see Dosage and Administration (2.11) , Clinical Pharmacology (12.3) ] ",
      "Reduce the dose for patients taking everolimus tablets/everolimus tablets for oral suspension with a P-gp and moderate CYP3A4 inhibitor as recommended [see Dosage and Administration (2.11) , Clinical Pharmacology (12.3) ] ",
      "Inducers Increase the dose for patients taking everolimus tablets/everolimus tablets for oral suspension with a P-gp and strong CYP3A4 inducer as recommended [see Dosage and Administration (2.12) , Clinical Pharmacology (12.3) ] ",
      "7.2 Effects of Combination Use of Angiotensin Converting Enzyme (ACE) Inhibitors Patients taking concomitant ACE inhibitors with everolimus tablets/everolimus tablets for oral suspension may be at increased risk for angioedema",
      "Avoid the concomitant use of ACE inhibitors with everolimus tablets/everolimus tablets for oral suspension [see Warnings and Precautions (5.4) ]"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Non-Infectious Pneumonitis [see Warnings and Precautions (5.1) ] Infections [see Warnings and Precautions (5.2) ] Severe Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] Angioedema with",
      "( 6.1 ) TSC-Associated Renal Angiomyolipoma: Most common adverse reaction (incidence ≥ 30%) is stomatitis",
      "( 6.1 ) TSC-Associated SEGA: Most common adverse reactions (incidence ≥ 30%) are stomatitis and respiratory tract infection",
      "( 6.1 ) TSC-Associated Partial-Onset Seizures: Most common adverse reaction (incidence ≥ 30%) is stomatitis",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc",
      "at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice",
      "Hormone Receptor-Positive, HER2-Negative Breast Cancer The safety of everolimus tablets (10 mg orally once daily) in combination with exemestane (25 mg orally once daily) (n = 485) vs",
      "placebo in combination with exemestane (n = 239) was evaluated in a randomized, controlled trial (BOLERO-2) in"
    ],
    "indications": [
      "INDICATIONS AND USAGE Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole",
      "( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic",
      "Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors",
      "( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib",
      "( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery"
    ]
  },
  "evolocumab": {
    "ingredient": "evolocumab",
    "is_drug": true,
    "canonical_name": "evolocumab",
    "fda_search_term": "evolocumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "REPATHA"
    ],
    "generic_names": [
      "EVOLOCUMAB"
    ],
    "manufacturers": [
      "Amgen USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are also discussed in other sections of the label: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Common (> 5% of patients treated with REPATHA and more frequently than placebo) adverse reactions in adults with: Primary hyperchole",
      "( 6 ) Established CVD: diabetes mellitus, nasopharyngitis and upper respiratory tract infection",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "Adverse Reactions in Adults with Primary Hypercholesterolemia The data described below reflect exposure to REPATHA in 8 placebo-controlled trials that included 2651 patients treated with REPATHA, including 557 exposed for 6 months and 515 exposed for 1 year (median treatment duration of 12 weeks) ",
      "The mean age of the population was 57 years, 49% of the population were women, 85% White, 6% Black, 8% Asians, and 2% other races",
      "Adverse Reactions in a 52",
      "Week Controlled Trial In a 52-week, double-blind, randomized, placebo-controlled trial, 599 patients received 420 mg of REPATHA subcutaneously once monthly [see Clinical Studies (14) ] ",
      "The mean age was 56 years (range: 22 to 75 years), 23% were older than 65 years, 52% women, 80% White, 8% Black, 6% Asian; 6% identified as Hispanic ethnicity",
      "Adverse reactions reported in at least 3% of REPATHA-treated patients, and more frequently than in placebo-treated patients are shown in Table 1",
      "Adverse reactions led to discontinuation of treatment in 2.2% of R"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events",
      "As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia",
      "adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH)",
      "adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH)",
      "REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for t"
    ]
  },
  "exemestane": {
    "ingredient": "exemestane",
    "is_drug": true,
    "canonical_name": "exemestane",
    "fda_search_term": "exemestane",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EXEMESTANE",
      "Exemestane"
    ],
    "generic_names": [
      "EXEMESTANE"
    ],
    "manufacturers": [
      "Breckenridge Pharmaceutical, Inc.",
      "Bryant Ranch Prepack",
      "Mylan Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure",
      "Increase the exemestane tablets dose to 50 mg ( 2.2 , 7 )",
      "Drugs That Induce CYP 3A4 Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St",
      "John's Wort) may significantly decrease exposure to exemestane",
      "Dose modification is recommended for patients who are also receiving a strong CYP 3A4 inducer [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) ] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Reductions in Bone Mineral Density (BMD) [see Warnings and Precautions (5.1) ] Early breast cancer: Adverse reactions occurring in ≥10% of patients in any treatment group (exemestane t",
      "tamoxifen) were hot flushes (21% vs",
      "20%), fatigue (16% vs",
      "15%), arthralgia (15% vs",
      "9%), headache (13% vs",
      "11%), insomnia (12% vs",
      "9%), and increased sweating (12% vs",
      "Discontinuation rates due to AEs were similar between exemestane tablets and tamoxifen (6% vs",
      "Incidences of cardiac ischemic events (myocardial infarction, angina, and myocardial ischemia) were exemestane tablets 1.6%, tamoxifen 0.6%",
      "Incidence of cardiac failure: exemestane tablets 0.4%, tamoxifen 0.3% ( 6 , 6.1 )",
      "Advanced breast cancer: Most common adverse reactions were mild to moderate and included hot flushes (13% vs",
      "5%), nausea (9% vs",
      "5%), fatigue (8% vs",
      "10%), increased sweating (4% vs",
      "8%), and increased appetite (3% vs"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of fi",
      "treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 )",
      "1.1 Adjuvant Treatment of Postmenopausal Women Exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of fiv",
      "1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ]"
    ]
  },
  "exenatide": {
    "ingredient": "exenatide",
    "is_drug": true,
    "canonical_name": "exenatide",
    "fda_search_term": "exenatide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Byetta",
      "Exenatide"
    ],
    "generic_names": [
      "EXENATIDE"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals LLC",
      "AstraZeneca Pharmaceuticals LP"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "May impact absorption of orally administered medications",
      "Warfarin: Postmarketing reports of increased INR sometimes associated with bleeding",
      "Monitor INR frequently until stable upon initiation or alteration of BYETTA therapy",
      "( 7 ) Generic Section Table 6: Clinically Relevant Interactions with BYETTA Concomitant Use of Insulin Secretagogues or Insulin Clinical Impact Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations",
      "The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] ",
      "Intervention When initiating BYETTA, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia",
      "Warfarin Clinical Impact In a drug interaction study, BYETTA did not have a significant effect on INR [see Clinical Pharmacology (12.3) ] ",
      "There have been postmarketing reports for BYETTA of increased INR with concomitant use of warfarin, sometimes associated with bleeding [see Adverse Reactions (6.2) ] ",
      "Intervention In patients taking warfarin, the prothrombin time should be monitored more frequently after initiation or alteration of BYETTA therapy"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information:",
      "Acute Pancreatitis [see Warnings and Precautions (5.1) ]",
      "Never Share a BYETTA Pen Between Patients [see Warnings and Precautions (5.2) ]",
      "Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3) ]",
      "Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.4) ]",
      "Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.5) ]",
      "Immunogenicity [see Warnings and Precautions (5.6) ]",
      "Hypersensitivity [see Warnings and Precautions (5.7) ]",
      "Drug-Induced Thrombocytopenia [see Warnings and Precautions (5.8) ]",
      "Acute Gallbladder Disease [see Warnings and Precautions (5.9) ]",
      "Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.10) ]",
      "Most common (≥5%) and occurring more frequently than placebo in clinical trials: nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia",
      "Nausea usually decreases over time",
      "( 5.3 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus",
      "Limitations of Use",
      "BYETTA contains exenatide",
      "Coadministration with other exenatide-containing products is not recommended",
      "BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus"
    ]
  },
  "ezetimibe": {
    "ingredient": "ezetimibe",
    "is_drug": true,
    "canonical_name": "ezetimibe",
    "fda_search_term": "ezetimibe",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EZETIMIBE",
      "Ezetimibe and Simvastatin"
    ],
    "generic_names": [
      "EZETIMIBE",
      "EZETIMIBE AND SIMVASTATIN"
    ],
    "manufacturers": [
      "Actavis Pharma, Inc.",
      "Bryant Ranch Prepack",
      "Dr.Reddys Laboratories Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Ezetimibe and S imvastatin See full prescribing information for details regarding concomitant use of ezetimibe and simvastatin tablets with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis",
      "( 2.3 , 7.1 ) Cholestyramine : Combination decreases exposure of ezetimibe",
      "( 2.3 , 7.2 ) Coumarin Anticoagulants: Obtain INR before ezetimibe and simvastatin tablets initiation and monitor INR during ezetimibe and simvastatin tablets dosage initiation or adjustment",
      "( 7.3 ) Digoxin : During ezetimibe and simvastatin tablets initiation, monitor digoxin levels",
      "( 7.3 ) Fenofibrates : Combination increases exposure of ezetimibe",
      "If cholelithiasis is suspected in a patient receiving ezetimibe and a fenofibrate, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered",
      "( 7.3 , 12.3 ) 7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin is a substrate of CYP3A4 and of the transport protein OATP1B1",
      "Ezetimibe and Simvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and OATP1B1",
      "Table 2 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with Ezetimibe and Simvastatin and instructions for preventing or managing them [see Warnings and Precautions ( 5.1 ) and Clinical Pharmacology ( 12.3 )]",
      "Table 2: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Ezetimibe and Simvastatin Tablets Strong CYP3A4 inhibitors Clinical Impact: Simvastatin is a substrate of CYP3A4"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Myopathy and Rhabdomyolysis [see Warnings and Precautions ( 5.1 )] Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions ( 5.2 )] Hepatic Dysfunction [see Warnings",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Ezetimibe and Simvastatin In the ezetimibe and simvastatin placebo-controlled clinical trials database of 1420 patients (age range 20 to 83 years, 52% female, 87% White, 3% Black or African American, 3% Asians, 5% other races identified as Hispanic or Latino ethnicity) with a median treatment durati",
      "The most commonly reported adverse reactions (incidence ≥2% and greater than placebo) in controlled clinical trials were: headache (5.8%), increased ALT (3.7%), myalgia (3.6%), upper respiratory tract infection (3.6%), and diarrhea (2.8%)",
      "The most common adverse reactions in the group treated with ezetimibe and simvastatin that led to treatment discontinuation and occurred at a rate greater than placebo were: increased ALT (0.9%), myalgia (0.6%), increased AST (0.4%), and back pain (0.4%)",
      "Ezetimibe and simvastatin have been e"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ezetimibe and simvastatin tablets Ezetimibe and simvastatin tablets are a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia",
      "In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH)",
      "As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH)",
      "Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization proced",
      "Ezetimibe and simvastatin tablets are a combination of ezetimibe, a dietary cholesterol absorption inhibitor, and simvastatin, an HMG-CoA reductase inhibitor (statin) indicated: ( 1 ) As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperli"
    ]
  },
  "factor viii": {
    "ingredient": "factor viii",
    "is_drug": true,
    "canonical_name": "factor VIII",
    "fda_search_term": "factor VIII",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Estradiol Vaginal"
    ],
    "generic_names": [
      "ESTRADIOL"
    ],
    "manufacturers": [
      "A-S Medication Solutions"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use",
      "This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked",
      "For this reason, combination oral contraceptives, including ORTHO-NOVUM ® and MODICON ® , should not be used by women who are over 35 years of age and smoke",
      "The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying ",
      "The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and diabetes",
      "Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks",
      "The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today",
      "The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined",
      "Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies",
      "Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See also Contraindications (4), Clinical Pharmacology (12.3) ",
      "If LEXIVA is used in combination with ritonavir, see full prescribing information for ritonavir for additional information on drug interactions",
      "Coadministration of LEXIVA with drugs that induce CYP3A4 may decrease amprenavir (active metabolite) concentrations leading to potential loss of virologic activity",
      "(7, 12.3) Coadministration with drugs that inhibit CYP3A4 may increase amprenavir concentrations",
      "(7, 12.3) Coadministration of LEXIVA and ritonavir may result in clinically significant interactions with drugs metabolized by CYP2D6",
      "(7) 7.1 CYP Inhibitors and Inducers Amprenavir, the active metabolite of fosamprenavir, is an inhibitor of cytochrome P450 3A4 metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4",
      "Data also suggest that amprenavir induces CYP3A4",
      "Amprenavir is metabolized by CYP3A4",
      "Coadministration of LEXIVA and drugs that induce CYP3A4, such as rifampin, may decrease amprenavir concentrations and reduce its therapeutic effect",
      "Coadministration of LEXIVA and drugs that inhibit CYP3A4 may increase amprenavir concentrations and increase the incidence of adverse effects"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Severe or life-threatening skin reactions have been reported with the use of LEXIVA [see Warnings and Precautions (5.2)]",
      "The most common moderate to severe adverse reactions in clinical studies of LEXIVA were diarrhea, rash, nausea, vomiting, and headache",
      "Treatment discontinuation due to adverse events occurred in 6.4% of patients receiving LEXIVA and in 5.9% of patients receiving comparator treatments",
      "The most common adverse reactions leading to discontinuation of LEXIVA (incidence ≤1% of patients) included diarrhea, nausea, vomiting, AST increased, ALT increased, and rash",
      "In adults the most common adverse reactions (incidence ≥4%) are diarrhea, rash, nausea, vomiting, headache",
      "(6.1) Vomiting was more frequent in pediatrics than in adults",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Adults The data for the 3 active-controlled clinical trials described below reflect exposure of 700 HIV-1 infected patients to LEXIVA Tablets, i",
      "The population age ranged from 17 to 72 years",
      "Of these patients, 26% were female, 51% Caucasian, 31% black, 16% American Hispanic, and 70% were antiretroviral-naive",
      "Sixty-one percent received LEXIVA 1,400 mg once daily plus ritonavir 200 mg once daily, 24% received LEXIVA 1,400 mg twice daily, and 15% received LEXIVA 700 mg twice daily plus ritonavir 100 mg twice daily",
      "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice",
      "Selected adverse reactions reported during the clinical efficacy studies of LEXIVA are shown in Tables 2 and 3",
      "Each table presents adverse reactions of moderate or severe intensity"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE LEXIVA ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection",
      "The following points should be considered when initiating therapy with LEXIVA plus ritonavir in protease inhibitor-experienced patients: The protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA plus ritonavir and lopinavir plus ritonavir are ",
      "Once-daily administration of LEXIVA plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients",
      "LEXIVA is an HIV protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection"
    ]
  },
  "famciclovir": {
    "ingredient": "famciclovir",
    "is_drug": true,
    "canonical_name": "famciclovir",
    "fda_search_term": "famciclovir",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Famciclovir"
    ],
    "generic_names": [
      "FAMCICLOVIR"
    ],
    "manufacturers": [
      "Camber Pharmaceuticals, Inc.",
      "PD-Rx Pharmaceuticals, Inc.",
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Probenecid: May increase penciclovir levels",
      "Monitor for evidence of penciclovir toxicity",
      "(7.2) 7.1 Potential for Famciclovir to Affect Other Drugs The steady-state pharmacokinetics of digoxin were not altered by concomitant administration of multiple doses of famciclovir (500 mg three times daily)",
      "No clinically significant effect on the pharmacokinetics of zidovudine, its metabolite zidovudine glucuronide, or emtricitabine was observed following a single oral dose of 500 mg famciclovir coadministered with zidovudine or emtricitabine",
      "An in vitro study using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4enzymes",
      "7.2 Potential for Other Drugs to Affect Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine",
      "No clinically significant effect on penciclovir pharmacokinetics was observed following multiple-dose (three times daily) administration of famciclovir (500 mg) with multiple doses of digoxin",
      "Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir",
      "The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase",
      "Interactions with other drugs metabolized by this enzyme and/or inhibiting this enzyme could potentially occur"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Acute renal failure is discussed in greater detail in other sections of the label [see Warnings and Precautions ( 5 )]",
      "The most common adverse events reported in at least 1 indication by greater than 10% of adult patients treated with famciclovir are headache and nausea",
      "The most common adverse events reported in at least 1 indication by greater than 10% of adult patients are headache and nausea",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observe",
      "Immunocompetent patients: The safety of famciclovir has been evaluated in active",
      "and placebo-controlled clinical studies involving 816 famciclovir-treated patients with herpes zoster (famciclovir, 250 mg three times daily to 750 mg three times daily), 163 famciclovir-treated patients with recurrent genital herpes (Famciclovir, 1000 mg twice daily); 1,197 patients with recurrent ",
      "Table 2 lists selected adverse events",
      "Table 2: Selected Adverse Events (all grades and without regard to causality) Reported by Greater Than or Equal to 2% of Patients in Placebo-Controlled Famciclovir Trials* Incidence Events Herpes Zoster † Recurrent Genital Herpes ‡ Genital Herpes",
      "Suppression § Herpes Labialis ‡ Famciclovir (n=273) % Placebo (n=146) % Famciclovir (n=163) % Placebo (n=166) % Famciclovir"
    ],
    "indications": [
      "1 INDICATIONS & USAGE Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 )",
      "Herpes labialis (cold sores) o Treatment of recurrent episodes",
      "Genital herpes o Treatment of recurrent episodes o Suppressive therapy of recurrent episodes",
      "Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients ( 1.2 )",
      "Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for:"
    ]
  },
  "famotidine": {
    "ingredient": "famotidine",
    "is_drug": true,
    "canonical_name": "famotidine",
    "fda_search_term": "famotidine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Famotidine"
    ],
    "generic_names": [
      "FAMOTIDINE"
    ],
    "manufacturers": [
      "Northwind Health Company, LLC",
      "PD-Rx Pharmaceuticals, Inc.",
      "Wal-Mart Stores, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert: Do not use if you are allergic to famotidine or other acid reducers"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Drugs Dependent on Gastric pH for Absorption: Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy",
      "See full prescribing information for a list of interacting drugs",
      "Tizanidine (CYP1A2) Substrate: Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible",
      "( 7.2 ) 7.1 Drugs Dependent on Gastric pH for Absorption Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug",
      "Concomitant administration of famotidine with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir is not recommended",
      "See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine",
      "7.2 Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate",
      "Avoid concomitant use with famotidine",
      "If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions are: headache, dizziness, constipation, and diarrhea",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Annora Pharma Private Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Famotidine was studied in 7 US and international placebo",
      "and active-controlled trials in approximately 2500 patients [see Clinical Studies ( 14 )]",
      "A total of 1442 patients were treated with famotidine, including 302 treated with 40 mg twice daily, 456 treated with 20 mg twice daily, 461 treated with 40 mg once daily, and 396 treated with 20 mg once daily",
      "The population was 17 to 91 years old, fairly well distributed between gender and race; however, the predominant race treated was Caucasian",
      "The following adverse reactions occurred in greater than or equal to 1% of famotidine-treated patients: headache, dizziness and constipation",
      "The following other adverse reactions were reported in less than 1% of patients in clinical trials: Body as a Whole: fever, asthenia, fatigue Cardiovascular: palpitations Gastrointestinal: elevated liver enzymes, vomiting, nausea, abdominal discomfort, anorexia, dry mouth Hematologic: thrombocytopen",
      "Because these reactions are reported voluntar"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:",
      "active duodenal ulcer (DU)",
      "active gastric ulcer (GU)",
      "symptomatic nonerosive gastroesophageal reflux disease (GERD)",
      "erosive esophagitis due to GERD, diagnosed by biopsy"
    ]
  },
  "febuxostat": {
    "ingredient": "febuxostat",
    "is_drug": true,
    "canonical_name": "febuxostat",
    "fda_search_term": "febuxostat",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Febuxostat",
      "febuxostat"
    ],
    "generic_names": [
      "FEBUXOSTAT"
    ],
    "manufacturers": [
      "Aurobindo Pharma Limited",
      "MAJOR PHARMACEUTICALS",
      "Zydus Lifesciences Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Concomitant administration of febuxostat with XO substrate drugs, azathioprine or mercaptopurine could increase plasma concentrations of these drugs resulting in severe toxicity",
      "( 7 ) 7.1 Xanthine Oxidase Substrate Drugs Febuxostat is an XO inhibitor",
      "Based on a drug interaction study in healthy patients, febuxostat altered the metabolism of theophylline (a substrate of XO) in humans [see Clinical Pharmacology (12.3) ]",
      "Therefore, use with caution when coadministering febuxostat with theophylline",
      "A drug interaction study of febuxostat and azathioprine, also metabolized by XO, showed an increase in exposure of 6-mercaptopurine which may lead to toxicity [see Clinical Pharmacology (12.3) ] ",
      "Drug interaction studies of febuxostat with other drugs that are metabolized by XO (e.g., mercaptopurine) have not been conducted",
      "Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see Contraindications (4) ]",
      "7.2 Cytotoxic Chemotherapy Drugs Drug interaction studies of febuxostat with cytotoxic chemotherapy have not been conducted",
      "No data are available regarding the safety of febuxostat during cytotoxic chemotherapy",
      "7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, febuxostat does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the prescribing information: Cardiovascular Death [see Warnings and Precautions (5.1) ] Hepatic Effects [see Warnings and Precautions (5.3) ] Serious Skin Reactions [see Warnings and Precautions (5.4) ] Adverse re",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc",
      "at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "In Phase 2 and 3 clinical studies, a total of 2757 patients with hyperuricemia and gout were treated with febuxostat 40 mg or 80 mg daily",
      "For febuxostat 40 mg, 559 patients were treated for ≥6 months",
      "For febuxostat 80 mg, 1377 patients were treated for ≥6 months, 674 patients were treated for ≥1 year and 515 patients were treated for ≥2 years",
      "In the CARES study, a total of 3098 patients were treated with febuxostat 40 mg or 80 mg daily; of these, 2155 patients were treated for ≥1 year and 1539 were treated for ≥2 years [see Clinical Studies (14.2) ] ",
      "Most Common Adverse Reactions In three randomized, controlled clinical studies (Studies 1, 2 and 3), which were 6 to 12 months in duration, the following adverse reactions were reported by the treating physician as related to study drug",
      "Table 1 summarizes adverse reactions reported at a rate of at least 1% in febuxostat treatment groups and at least 0.5% greater than placebo",
      "* Of the patients who received allopurinol, 10 received 100 mg, 145 received 200 mg, and 1122 received 300 mg, based on level of renal impairment",
      "Table 1: Adverse Reactions Occurring in ≥1% of Pati"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Febuxostat is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopur",
      "Limitations of Use : Febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia",
      "Febuxostat is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable",
      "( 1 ) Limitations of Use : Febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia"
    ]
  },
  "felodipine": {
    "ingredient": "felodipine",
    "is_drug": true,
    "canonical_name": "felodipine",
    "fda_search_term": "felodipine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FELODIPINE",
      "Felodipine"
    ],
    "generic_names": [
      "FELODIPINE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "Drug Interactions CYP3A4 Inhibitors Felodipine is metabolized by CYP3A4",
      "Co-administration of CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several-fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism",
      "These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate)",
      "These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor)",
      "Caution should be used when CYP3A4 inhibitors are co-administered with felodipine",
      "A conservative approach to dosing felodipine should be taken",
      "The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6-fold increase in the C max , and 2-fold prolongation in the half-life of fe",
      "Erythromycin Co-administration of felodipine with erythromycin resulted in approximately 2.5-fold increase in the AUC and C max , and about 2-fold prolongation in the half-life of felodipine",
      "Grapefruit Juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and C max , but no prolongation in the half-life of felodipine",
      "Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the C max , of felodipine"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS In controlled studies in the United States and overseas, approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation",
      "The most common clinical adverse events reported with felodipine extended-release administered as monotherapy at the recommended dosage range of 2.5 mg to 10 mg once a day were peripheral edema and headache",
      "Peripheral edema was generally mild, but it was age and dose related and resulted in discontinuation of therapy in about 3% of the enrolled patients",
      "Discontinuation of therapy due to any clinical adverse event occurred in about 6% of the patients receiving felodipine extended-release, principally for peripheral edema, headache, or flushing",
      "Adverse events that occurred with an incidence of 1.5% or greater at any of the recommended doses of 2.5 mg to 10 mg once a day (felodipine extended-release, N = 861; Placebo, N = 334), without regard to causality, are compared to placebo and are listed by dose in the table below",
      "These events are reported from controlled clinical trials with patients who were randomized to a fixed dose of felodipine extended-release tablets, USP or titrated from an initial dose of 2.5 mg or 5 mg once a day",
      "A dose of 20 mg once a day has been evaluated in some clinical studies",
      "Although the antihypertensive effect of felodipine extended-release tablets, USP is increased at 20 mg once a day, there is a disproportionate increase in adverse events, especially those associated with vasodilatory effects (see DOSAGE AND ADMINISTRATION )",
      "Percent of Patients with Adverse Events in Controlled Trials* of Felodipine Extended-Release Tablets (N = 861) as Monotherapy without Regard to Causality (Incidence of discontinuations shown in parentheses) *Patients in titration studies may have been exposed to more than one dose level of felodipin",
      "Body System Adverse Events Placebo N = 334 2.5 mg N = 255 5 mg N = 581 10 mg N = 408 Body a"
    ],
    "indications": [
      "INDICATIONS AND USAGE Felodipine extended-release tablets, USP are indicated for the treatment of hypertension, to lower blood pressure",
      "Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions",
      "These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine",
      "Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake",
      "Many patients will require more than 1 drug to achieve blood pressure goals"
    ]
  },
  "fenofibrate": {
    "ingredient": "fenofibrate",
    "is_drug": true,
    "canonical_name": "fenofibrate",
    "fda_search_term": "fenofibrate",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fenofibrate"
    ],
    "generic_names": [
      "FENOFIBRATE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Aurobindo Pharma Limited",
      "Northwind Health Company, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Hepatotoxicity: Serious drug-induced liver injury (DILI), including liver transplantation and death, have been reported postmarketing with fenofibrate",
      "DILI has been reported within the first few weeks of treatment or after several months of therapy and in some cases has reversed with discontinuation of fenofibrate treatment",
      "Patients with DILI have experienced signs and symptoms including dark urine, abnormal stool, jaundice, malaise, abdominal pain, myalgia, weight loss, pruritus, and nausea",
      "Many patients had concurrent elevations of total bilirubin, serum alanine transaminase (ALT), and aspartate transaminase (AST)",
      "DILI has been characterized as hepatocellular, chronic active, and cholestatic hepatitis, and cirrhosis has occurred in association with chronic active hepatitis",
      "In clinical trials, fenofibrate at doses equivalent to 134 mg to 200 mg fenofibrate daily has been associated with increases in serum AST or ALT",
      "The incidence of increases in transaminases may be dose-related",
      "Fenofibrate is contraindicated in patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities (see CONTRAINDICATIONS)",
      "Monitor patient’s liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy with fenofibrate",
      "Discontinue fenofibrate if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST > 3 times the upper limit of normal, or if accompanied by elevation of bilirubin)"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coumarin anticoagulants: ( 7.1 )",
      "Immunosuppressants: ( 7.2 )",
      "Bile acid resins: ( 7.3 )",
      "7.1 Coumarin Anticoagulants Potentiation of coumarin-type anticoagulant effects has been observed with prolongation of the PT/INR",
      "Caution should be exercised when coumarin anticoagulants are given in conjunction with fenofibrate",
      "The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications",
      "Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized [see WARNINGS AND PRECAUTIONS (5.6)] ",
      "7.2 Immunosuppressants Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an ",
      "The benefits and risks of using fenofibrate tablet with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored",
      "7.3 Bile Acid Binding Resins Since bile acid binding resins may bind other drugs given concurrently, patients should take fenofibrate at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling:",
      "Mortality and coronary heart disease morbidity [see WARNINGS AND PRECAUTIONS ( 5.1 )]",
      "Hepatoxicity [see WARNINGS AND PRECAUTIONS ( 5.2 )]",
      "Pancreatitis [see WARNINGS AND PRECAUTIONS ( 5.7 )]",
      "Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS ( 5.9 )]",
      "Venothromboembolic disease [see WARNINGS AND PRECAUTIONS ( 5.10 )] Adverse reactions > 2% and at least 1% greater than placebo: Abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc",
      "at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of ",
      "Adverse events reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials, regardless of causality, are listed in Table 1 below",
      "Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo",
      "Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double",
      "Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials 1 Significantly different from Placebo",
      "BODY SYSTEM Fenofibrate Dosage equivalent to 160 mg fenofibrate",
      "Placebo Adverse Reaction ( N = 439 ) ( N = 365 ) BODY AS A WHOLE Abdominal Pain 4.6% 4.4% Back Pain 3.4% 2.5% Headache 3.2% 2.7% DIGESTIVE Nausea 2.3% 1.9% Constipation 2.1% 1.4% METABOLIC AND NUTRITIONAL DI"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fenofibrate tablet USP is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ",
      "For treatment of adult patients with severe hypertriglyceridemia ( 1.2 )",
      "Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 )",
      "1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablet USP is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein c",
      "1.2 Severe Hypertriglyceridemia Fenofibrate tablet USP is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia"
    ]
  },
  "fenofibric acid": {
    "ingredient": "fenofibric acid",
    "is_drug": true,
    "canonical_name": "fenofibric acid",
    "fda_search_term": "fenofibric acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FENOFIBRIC ACID DELAYED-RELEASE",
      "Fenofibric Acid"
    ],
    "generic_names": [
      "FENOFIBRIC ACID"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "Amneal Pharmaceuticals of New York LLC",
      "Laurus Labs Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coumarin Anticoagulants: ( 7.1 )",
      "Bile Acid Binding Resins: ( 7.2 )",
      "Immunosuppressants: ( 7.3 )",
      "7.1 Coumarin Anticoagulants Potentiation of coumarin-type anticoagulant effect has been observed with prolongation of the PT/INR",
      "Caution should be exercised when oral coumarin anticoagulants are given in conjunction with fenofibric acid",
      "The dosage of the anticoagulant should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications",
      "Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized [see Warnings and Precautions ( 5.6 )]",
      "7.2 Bile Acid Binding Resins Since bile acid binding resins may bind other drugs given concurrently, patients should take fenofibric acid at least 1 hour before or 4 to 6 hours after a bile acid resin to avoid impeding its absorption",
      "7.3 Immunosuppressants Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of drugs of the fibrate class including fenofibric acid, there i",
      "The benefits and risks of using fenofibric acid with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Mortality and coronary heart disease morbidity [see Warnings and Precautions ( 5.1 )] Hepatoxicity [see Warnings and Precautions ( 5.2 )] Pancreatitis [see Warnings and Precautions ( 5.7 )]",
      "To report SUSPECTED ADVERSE REACTIONS, contact Laurus Generics Inc",
      "at 1-833-3-LAURUS (1-833-352-8787) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "Fenofibric acid is the active metabolite of fenofibrate",
      "Adverse events reported by 2% or more of patients treated with fenofibrate and greater than placebo during double-blind, placebo-controlled trials are listed in Table 1",
      "Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo",
      "Increases in liver tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials",
      "Adverse Events Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials BODY SYSTEM Adverse Event Fenofibrate* (N = 439) Placebo (N = 365) BODY AS A WHOLE Abdominal Pain 4.6% 4.4% Back Pain 3.4% 2.5% Headache 3.2% 2.7% DI"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsules are peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 )",
      "Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )",
      "Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of fenofibric acid delayed-release capsules did not reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 )",
      "1.1 Treatment of Severe Hypertriglyceridemia Fenofibric acid delayed-release capsules are indicated as adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia",
      "Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacological intervention"
    ]
  },
  "fenoprofen": {
    "ingredient": "fenoprofen",
    "is_drug": true,
    "canonical_name": "fenoprofen",
    "fda_search_term": "fenoprofen",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FENOPROFEN CALCIUM",
      "FENOPRON TM",
      "NALFON"
    ],
    "generic_names": [
      "FENOPROFEN CALCIUM"
    ],
    "manufacturers": [
      "Galt Pharmaceuticals, LLC",
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cardiovascular Effects Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be f",
      "Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs",
      "The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease",
      "However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate",
      "Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment",
      "The increase in CV thrombotic risk has been observed most consistently at higher doses",
      "To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible",
      "Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms",
      "Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur",
      "There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use"
    ],
    "drug_interactions": [
      "Drug Interactions ACE Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors",
      "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors",
      "Aspirin The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine",
      "Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities",
      "As with other NSAIDs, concomitant administration of NALFON tablets and aspirin is not generally recommended because of the potential of increased adverse effects",
      "Diuretics Clinical studies, as well as post-marketing observations, have shown that NALFON tablets can reduce the natriuretic effect of furosemide and thiazides in some patients",
      "This response has been attributed to inhibition of renal prostaglandin synthesis",
      "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS: Renal Effects ), as well as to assure diuretic efficacy",
      "Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance",
      "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS During clinical studies for rheumatoid arthritis, osteoarthritis or mild to moderate pain and studies of pharmacokinetics, complaints were compiled from a checklist of potential adverse reactions, and the following data emerged",
      "These encompass observations in 6,786 patients, including 188 observed for at least 52 weeks",
      "For comparison, data are also presented from complaints received from the 266 patients who received placebo in these same trials",
      "During short-term studies for analgesia, the incidence of adverse reactions was markedly lower than that seen in longer-term studies",
      "Adverse Drug Reactions Reported in ≥ 1% of Patients During Clinical Trials Digestive System: During clinical trials with fenoprofen calcium, the most common adverse reactions were gastrointestinal in nature and occurred in 20.8% of patients receiving fenoprofen as compared to 16.9% of patients recei",
      "In descending order of frequency, these reactions included dyspepsia (10.3% fenoprofen vs",
      "2.3% placebo), nausea (7.7% vs",
      "7.1%), constipation (7% vs",
      "1.5%), vomiting (2.6% vs",
      "1.9%), abdominal pain (2% vs",
      "1.1%) and diarrhea (1.8% vs",
      "The drug was discontinued because of adverse gastrointestinal reactions in less than 2% of patients during premarketing studies",
      "Nervous System: The most frequent adverse neurologic reactions were headache (8.7% vs",
      "7.5%) and somnolence (8.5% vs",
      "Dizziness (6.5% vs"
    ],
    "indications": [
      "INDICATIONS AND USAGE Carefully consider the potential benefits and risks of NALFON tablets, USP and other treatment options before deciding to use NALFON tablets",
      "Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS )",
      "NALFON tablets are indicated:",
      "For relief of mild to moderate pain in adults",
      "For relief of the signs and symptoms of rheumatoid arthritis"
    ]
  },
  "fentanyl": {
    "ingredient": "fentanyl",
    "is_drug": true,
    "canonical_name": "fentanyl",
    "fda_search_term": "fentanyl",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FENTANYL",
      "Fentanyl Citrate"
    ],
    "generic_names": [
      "FENTANYL",
      "FENTANYL CITRATE"
    ],
    "manufacturers": [
      "Apotex Corp.",
      "Fresenius Kabi USA, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 2 includes clinically significant drug interactions with Fentanyl Citrate Injection",
      "Table 2: Clinically Significant Drug Interactions with Fentanyl Citrate Injection Inhibitors of CYP3A4 Clinical Impact: The concomitant use of Fentanyl Citrate Injection and CYP3A4 inhibitors can increase the plasma concentration of fentanyl, resulting in increased or prolonged opioid effects, parti",
      "After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the fentanyl plasma concentration will decrease [see Clinical Pharmacology ( 12.3 )] , resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to fentanyl",
      "Intervention: If concomitant use is necessary, consider dosage reduction of Fentanyl Citrate Injection until stable drug effects are achieved [see Dosage and Administration ( 2.1 )] ",
      "Monitor patients at frequent intervals for respiratory depression and sedation",
      "If a CYP3A4 inhibitor is discontinued, consider increasing the Fentanyl Citrate Injection dosage until stable drug effects are achieved",
      "Monitor for signs of opioid withdrawal",
      "Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g",
      "ketoconazole), protease inhibitors (e.g., ritonavir), grapefruit juice CYP3A4 Inducers Clinical Impact: The concomitant use of Fentanyl Citrate Injection and CYP3A4 inducers can decrease the plasma concentration of fentanyl [see Clinical Pharmacology ( 12.3 )] , resulting in decreased efficacy or on",
      "After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase [see Clinical Pharmacology ( 12.3 )] , which could increase or prolong both the the"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described, or described in greater detail, in other sections:",
      "Addiction, Abuse, and Misuse [see Warnings and Precautions ( 5.1 )]",
      "Life-Threatening Respiratory Depression [see Warnings and Precautions ( 5.2 )]",
      "Interactions with Benzodiazepines and Other CNS Depressants [see Warnings and Precautions ( 5.3 )]",
      "Severe Cardiovascular Depression [see Warnings and Precautions ( 5.6 )]",
      "Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions ( 5.7 )]",
      "Serotonin Syndrome [see Warnings and Precautions ( 5.8 )]",
      "Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.11 )]",
      "Seizures [see Warnings and Precautions ( 5.12 )] The following adverse reactions associated with the use of fentanyl were identified in clinical studies or postmarketing reports",
      "Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "As with other opioid agonists, the most common serious adverse reactions reported to occur with fentanyl are respiratory depression, apnea, rigidity and bradycardia; if these remain untreated, respiratory arrest, circulatory depression or cardiac arrest could occur",
      "Other adverse reactions that have been reported are hypertension, hypotension, dizziness, blurred vision, nausea, emesis, laryngospasm, diaphoresis, serotonin syndrome, adrenal insufficiency, and anaphylaxis",
      "It has been reported that secondary rebound respiratory depression may occasionally occur postoperatively",
      "When a tranquilizer is used with Fentanyl Citrate Injection, the following adverse reactions can occur: chills and/or shivering, restlessness and postoperative hallucinatory episodes (sometimes associated with transient periods of mental depression); extrapyramidal symptoms (dystonia, akathisia and "
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fentanyl Citrate Injection is indicated for:",
      "analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises",
      "use as a narcotic analgesic supplement in general or regional anesthesia",
      "administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia",
      "use as an anesthetic agent with oxygen in selected high-risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures"
    ]
  },
  "ferric cl": {
    "ingredient": "ferric cl",
    "is_drug": true,
    "canonical_name": "ferric chloride",
    "fda_search_term": "ferric chloride",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "MEB Gluco-Vitality Patch",
      "MEB PainGuard Patch",
      "MEB Puri-Mega",
      "N-13"
    ],
    "generic_names": [
      "CEANOTHUS AMERICANUS LEAF, URTICA URENS, SODIUM CHLORIDE, LACHESIS MUTA WHOLE, CINCHONA OFFICINALIS BARK, LYCOPODIUM CLAVATUM WHOLE, FERRIC CHLORIDE HEXAHYDRATE, AND SUS SCROFA SPLEEN",
      "MEB GLUCO-VITALITY PATCH",
      "MEB PAINGUARD PATCH",
      "MEB PURI-MEGA"
    ],
    "manufacturers": [
      "DNA Labs, Inc.",
      "Kadesh Incoporation Co,Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "Do not Use *If the needles inside the patch do not cause a tingling sensation, do not use it and replace it with a new patch",
      "*If headaches, dizziness, or any discomfort persist for more than 5 minutes, discontinue use",
      "Consult a physician if: *Symptoms persist for more than 7 days or worsen",
      "When using this product: *Due to its sensitivity to moisture, do not store the patch in the refrigerator, and it should be used immediately after opening",
      "Keep out of reach of Children"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "The MEB PainGuard Patch is designed to provide effective pain relief and treat various types of pain, providing fast-acting and long-lasting relief from pain, helping to alleviate discomfort caused by muscle pain, nerve pain, and other common types of pain",
      "This innovative patch targets and treats the underlying inflammation that causes pain to help eliminate the root cause of pain, leading to more effective and sustainable pain relief",
      "The Gluco Vitality Patch assists individuals with diabetes in stabilizing their blood sugar levels while promoting vascular health to provide a comprehensive approach to diabetes care",
      "By promoting vascular health, the GlucoVitaPatch aims to improve circulation and support the prevention and treatment of vascular diseases commonly associated with diabetes"
    ]
  },
  "ferric hydroxide polymaltose": {
    "ingredient": "ferric hydroxide polymaltose",
    "is_drug": true,
    "canonical_name": "ferric hydroxide polymaltose",
    "fda_search_term": "ferric hydroxide polymaltose",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine"
    ],
    "generic_names": [
      "POVIDONE-IODINE"
    ],
    "manufacturers": [
      "Atlantis Consumer Healthcare, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection",
      "Leaves the skin flawless and protected"
    ]
  },
  "ferric hydroxide saccharate complex": {
    "ingredient": "ferric hydroxide saccharate complex",
    "is_drug": true,
    "canonical_name": "ferric hydroxide saccharate",
    "fda_search_term": "ferric hydroxide saccharate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine"
    ],
    "generic_names": [
      "POVIDONE-IODINE"
    ],
    "manufacturers": [
      "Atlantis Consumer Healthcare, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection",
      "Leaves the skin flawless and protected"
    ]
  },
  "ferric oxide": {
    "ingredient": "ferric oxide",
    "is_drug": true,
    "canonical_name": "ferric oxide",
    "fda_search_term": "ferric oxide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aveeno Anti-Itch Concentrated",
      "Calamine Plus",
      "Powder"
    ],
    "generic_names": [
      "CALAMINE PLUS PRAMOXINE HCL",
      "TITANIUM DIOXIDE",
      "ZINC OXIDE, FERRIC OXIDE RED, AND PRAMOXINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Kenvue Brands LLC",
      "Meijer Distribution Inc.",
      "Oxygen Development LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Flammable: Do not use while smoking or near heat or flame",
      "Do not puncture or incinerate",
      "Contents under pressure",
      "Do not store at temperatures above 120°F",
      "Intentional misuse by deliberately concentrating and inhaling contents can be harmful or fatal",
      "When using this product do not get into eyes ask a doctor before using on children under 2 years of age Stop use and ask a doctor if condition worsens symptoms last more than 7 days or clear up and occur again in a few days Keep out of the reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses temporarily relieves pain and itching associated with: insect bites rashes minor skin irritations minor cuts dries the oozing and weeping of poison ivy, poison oak and poison sumac"
    ]
  },
  "ferric pyrophosphate": {
    "ingredient": "ferric pyrophosphate",
    "is_drug": true,
    "canonical_name": "ferric pyrophosphate",
    "fda_search_term": "ferric pyrophosphate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Bestmade Natural Products Bio1",
      "Bestmade Natural Products Bio3",
      "Bestmade Natural Products Ferr Phos"
    ],
    "generic_names": [
      "CALC PHOS, FERR PHOS, KALI PHOS, NAT MUR",
      "CALC PHOS, FERR PHOS, MAG PHOS, NAT SULPH",
      "FERR PHOS"
    ],
    "manufacturers": [
      "Bestmade Natural Products"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings and Storage: Ask a professional before use if pregnant or breastfeeding or if you have severe symptoms",
      "Keep away from children",
      "If you have a reaction to this product that is not positive, discontinue use",
      "Store in a cool and dry place",
      "*CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE",
      "NOT FDA EVALUATED",
      "This product is not intended to diagnose, treat, cure, or prevent any disease"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses Temporarily relieves occasional poor appetite, tiredness, vomiting, congestion, aches, elevated body temperature, and headaches.* *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE",
      "NOT FDA EVALUATED",
      "This product is not intended to diagnose, treat, cure, or prevent any disease"
    ]
  },
  "ferric pyrophsphate": {
    "ingredient": "ferric pyrophsphate",
    "is_drug": true,
    "canonical_name": "ferric pyrophosphate",
    "fda_search_term": "ferric pyrophosphate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Bestmade Natural Products Bio1",
      "Bestmade Natural Products Bio3",
      "Bestmade Natural Products Ferr Phos"
    ],
    "generic_names": [
      "CALC PHOS, FERR PHOS, KALI PHOS, NAT MUR",
      "CALC PHOS, FERR PHOS, MAG PHOS, NAT SULPH",
      "FERR PHOS"
    ],
    "manufacturers": [
      "Bestmade Natural Products"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings and Storage: Ask a professional before use if pregnant or breastfeeding or if you have severe symptoms",
      "Keep away from children",
      "If you have a reaction to this product that is not positive, discontinue use",
      "Store in a cool and dry place",
      "*CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE",
      "NOT FDA EVALUATED",
      "This product is not intended to diagnose, treat, cure, or prevent any disease"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses Temporarily relieves occasional poor appetite, tiredness, vomiting, congestion, aches, elevated body temperature, and headaches.* *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE",
      "NOT FDA EVALUATED",
      "This product is not intended to diagnose, treat, cure, or prevent any disease"
    ]
  },
  "ferric saccharate": {
    "ingredient": "ferric saccharate",
    "is_drug": true,
    "canonical_name": "ferric saccharate",
    "fda_search_term": "ferric saccharate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",
      "MEB Gluco-Vitality Patch",
      "MEB PainGuard Patch"
    ],
    "generic_names": [
      "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",
      "MEB GLUCO-VITALITY PATCH",
      "MEB PAINGUARD PATCH"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Kadesh Incoporation Co,Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Abuse, Misuse, and Addiction DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS has a high potential for abuse and misuse",
      "which can lead to the development of a substance use disorder, including addiction",
      "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS can be diverted for non-medical use into illicit channels or distribution [see DRUG ABUSE and DEPENDENCE: Abuse]",
      "Misuse and abuse of CNS stimulants, including DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS, can result in overdose and death [see OVERDOSAGE], and this risk is increased with higher doses or unapproved methods of administration, such ",
      "Before prescribing DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS, assess each patient’s risk for abuse, misuse, and addiction",
      "Educate patients and their families about these risks and proper disposal of any unused drug",
      "Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS to anyone else",
      "Throughout DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction",
      "Risks to Patients with Serious Cardiac Disease Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulant treatment at the recommended ADHD dosages",
      "Avoid DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS use in patients"
    ],
    "drug_interactions": [
      "Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis",
      "Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure",
      "Do not administer DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS concomitantly or within 14 days after discontinuing MAOI [see CONTRAINDICATIONS and WARNINGS ]",
      "Serotonergic Drugs The concomitant use of DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS and serotonergic drugs increases the risk of serotonin syndrome",
      "Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS initiation or dosage increase",
      "If serotonin syndrome occurs, discontinue DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS and the concomitant serotonergic drug(s) [see WARNINGS and PRECAUTIONS ]",
      "CYP2D6 Inhibitors The concomitant use of DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS and CYP2D6 inhibitors may increase the exposure of DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SU",
      "Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE TABLETS initiation and after a dosage increase",
      "If serotonin syndrome occurs, discontinue DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Cardiovascular Palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction",
      "There have been isolated reports of cardiomyopathy associated with chronic amphetamine use",
      "Central Nervous System Psychotic episodes at recommended doses, overstimulation, restlessness, irritability, euphoria, dyskinesia, dysphoria, depression, tremor, tics, aggression, anger, logorrhea, dermatillomania",
      "Eye Disorders Vision blurred, mydriasis",
      "Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances",
      "Anorexia and weight loss may occur as undesirable effects",
      "Allergic Urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis",
      "Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported",
      "Endocrine Impotence, changes in libido, frequent or prolonged erections",
      "Musculoskeletal Rhabdomyolysis"
    ],
    "indications": [
      "INDICATIONS AND USAGE Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Amphetamine Product) are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy",
      "Attention Deficit Hyperactivity Disorder (ADHD) A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV ® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years",
      "The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home",
      "The symptoms must not be better accounted for by another mental disorder",
      "For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effor"
    ]
  },
  "ferrous": {
    "ingredient": "ferrous",
    "is_drug": true,
    "canonical_name": "ferrous",
    "fda_search_term": "ferrous",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ferrum Quartz",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FERRUM QUARTZ"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "U.S. Pharmaceutical Corporation",
      "Uriel Pharmacy, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "ferrous bis": {
    "ingredient": "ferrous bis",
    "is_drug": true,
    "canonical_name": "ferrous bisglycinate",
    "fda_search_term": "ferrous bisglycinate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aflora",
      "Folixia",
      "Nutralyn"
    ],
    "generic_names": [
      "MULTIVITAMIN"
    ],
    "manufacturers": [
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Accidental overdose of iron-containing products is a leading cause of fatal poising in children under 6",
      "Keep this product out of the reach of children",
      "In the case of accidental overdose, call a doctor or poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Allergic sensitization has been reported following both oral and parenteral administration of folic acid",
      "You should call your doctor for medical advice about serious adverse events",
      "To reports adverse side effects or to obtain product information, contact Oncora Pharma at 888-321-2821"
    ],
    "indications": [
      "Nutralyn is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate, vitamin B supplementa­tion, and maintenance of good health is needed"
    ]
  },
  "ferrous bisglycenate": {
    "ingredient": "ferrous bisglycenate",
    "is_drug": true,
    "canonical_name": "ferrous bisglycinate",
    "fda_search_term": "ferrous bisglycinate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aflora",
      "Folixia",
      "Nutralyn"
    ],
    "generic_names": [
      "MULTIVITAMIN"
    ],
    "manufacturers": [
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Accidental overdose of iron-containing products is a leading cause of fatal poising in children under 6",
      "Keep this product out of the reach of children",
      "In the case of accidental overdose, call a doctor or poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Allergic sensitization has been reported following both oral and parenteral administration of folic acid",
      "You should call your doctor for medical advice about serious adverse events",
      "To reports adverse side effects or to obtain product information, contact Oncora Pharma at 888-321-2821"
    ],
    "indications": [
      "Nutralyn is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate, vitamin B supplementa­tion, and maintenance of good health is needed"
    ]
  },
  "ferrous bisglycinate": {
    "ingredient": "ferrous bisglycinate",
    "is_drug": true,
    "canonical_name": "ferrous bisglycinate",
    "fda_search_term": "ferrous bisglycinate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aflora",
      "Folixia",
      "Nutralyn"
    ],
    "generic_names": [
      "MULTIVITAMIN"
    ],
    "manufacturers": [
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Accidental overdose of iron-containing products is a leading cause of fatal poising in children under 6",
      "Keep this product out of the reach of children",
      "In the case of accidental overdose, call a doctor or poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Allergic sensitization has been reported following both oral and parenteral administration of folic acid",
      "You should call your doctor for medical advice about serious adverse events",
      "To reports adverse side effects or to obtain product information, contact Oncora Pharma at 888-321-2821"
    ],
    "indications": [
      "Nutralyn is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate, vitamin B supplementa­tion, and maintenance of good health is needed"
    ]
  },
  "ferrous bisglycinate chelate": {
    "ingredient": "ferrous bisglycinate chelate",
    "is_drug": true,
    "canonical_name": "ferrous bisglycinate",
    "fda_search_term": "ferrous bisglycinate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aflora",
      "Folixia",
      "Nutralyn"
    ],
    "generic_names": [
      "MULTIVITAMIN"
    ],
    "manufacturers": [
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Accidental overdose of iron-containing products is a leading cause of fatal poising in children under 6",
      "Keep this product out of the reach of children",
      "In the case of accidental overdose, call a doctor or poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Allergic sensitization has been reported following both oral and parenteral administration of folic acid",
      "You should call your doctor for medical advice about serious adverse events",
      "To reports adverse side effects or to obtain product information, contact Oncora Pharma at 888-321-2821"
    ],
    "indications": [
      "Nutralyn is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate, vitamin B supplementa­tion, and maintenance of good health is needed"
    ]
  },
  "ferrous bisglyicinate": {
    "ingredient": "ferrous bisglyicinate",
    "is_drug": true,
    "canonical_name": "ferrous bisglycinate",
    "fda_search_term": "ferrous bisglycinate",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aflora",
      "Folixia",
      "Nutralyn"
    ],
    "generic_names": [
      "MULTIVITAMIN"
    ],
    "manufacturers": [
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Accidental overdose of iron-containing products is a leading cause of fatal poising in children under 6",
      "Keep this product out of the reach of children",
      "In the case of accidental overdose, call a doctor or poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Allergic sensitization has been reported following both oral and parenteral administration of folic acid",
      "You should call your doctor for medical advice about serious adverse events",
      "To reports adverse side effects or to obtain product information, contact Oncora Pharma at 888-321-2821"
    ],
    "indications": [
      "Nutralyn is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate, vitamin B supplementa­tion, and maintenance of good health is needed"
    ]
  },
  "ferrous bisglysimate folic acid": {
    "ingredient": "ferrous bisglysimate folic acid",
    "is_drug": true,
    "canonical_name": "ferrous bisglycinate",
    "fda_search_term": "ferrous bisglycinate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aflora",
      "Folixia",
      "Nutralyn"
    ],
    "generic_names": [
      "MULTIVITAMIN"
    ],
    "manufacturers": [
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Accidental overdose of iron-containing products is a leading cause of fatal poising in children under 6",
      "Keep this product out of the reach of children",
      "In the case of accidental overdose, call a doctor or poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Allergic sensitization has been reported following both oral and parenteral administration of folic acid",
      "You should call your doctor for medical advice about serious adverse events",
      "To reports adverse side effects or to obtain product information, contact Oncora Pharma at 888-321-2821"
    ],
    "indications": [
      "Nutralyn is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate, vitamin B supplementa­tion, and maintenance of good health is needed"
    ]
  },
  "ferrous fumarate": {
    "ingredient": "ferrous fumarate",
    "is_drug": true,
    "canonical_name": "ferrous fumarate",
    "fda_search_term": "ferrous fumarate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Integra F",
      "PNV-DHA",
      "PRENATE Restore"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, FOLIC ACID, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN, BIOTIN, CALCIUM CARBONATE, FERROUS FUMARATE, MAGNESIUM OXIDE, LACTIC ACID AND DOCONEXENT",
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Avion Pharmaceuticals, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "ferrous fumerate": {
    "ingredient": "ferrous fumerate",
    "is_drug": true,
    "canonical_name": "ferric fumarate",
    "fda_search_term": "ferric fumarate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Acid Reducer",
      "Calcium Acetate"
    ],
    "generic_names": [
      "CALCIUM ACETATE",
      "ESOMEPRAZOLE MAGNESIUM"
    ],
    "manufacturers": [
      "CVS Pharmacy",
      "Cipla USA Inc.,"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert : Do not use if you are allergic to esomeprazole",
      "Esomeprazole may cause severe skin reactions",
      "Symptoms may include: skin reddening blisters rash If an allergic reaction occurs, stop use and seek medical help right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups)",
      "Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism",
      "There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs",
      "When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate",
      "Monitor blood levels of the concomitant drugs that have a narrow therapeutic range",
      "Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate",
      "Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones",
      "( 7 ) When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug",
      "( 7 ) 7.1 Ciprofloxacin In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Hypercalcemia is discussed elsewhere [see Warnings and Precautions (5.1) ]",
      "The most common (>10%) adverse reactions are hypercalcemia, nausea and vomiting",
      "( 6.1 ) In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd",
      "at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of anot",
      "In clinical studies, calcium acetate has been generally well tolerated",
      "Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients",
      "Adverse reactions (>2% on treatment) from these trials are presented in Table 1",
      "Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis Preferred Term Total adverse reactions reported for calcium acetate n=167 n (%) 3-month, open-label study of calcium acetate n=98 n (%) Double blind, placebo-controlled, cross-over study of liquid calcium ace",
      "More severe hypercalcemia is associated with confusion, delirium, stupor, and coma",
      "Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate",
      "induced hypercalcemia",
      "Isolated cases of pruritus have been reported, which ma"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD)",
      "Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease"
    ]
  },
  "ferrous gluconate": {
    "ingredient": "ferrous gluconate",
    "is_drug": true,
    "canonical_name": "ferrous gluconate",
    "fda_search_term": "ferrous gluconate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CitraNatal 90 DHA",
      "Embriva",
      "Gestyra"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, THIAMINE, PYRIDOXAL PHOSPHATE, FOLIC ACID, METHYLCOBALAMIN, CALCIUM CARBONATE, FERROUS GLUCONATE, POTASSIUM IODIDE",
      "VITAMIN C, CALCIUM, IRON, VITAMIN D3, VITAMIN E, THIAMIN, RIBOFLAVIN, NIACINAMIDE, VITAMIN B6, FOLIC ACID, IODINE, ZINC, COPPER, DOCUSATE SODIUM"
    ],
    "manufacturers": [
      "Mission Pharmacal Company",
      "Oncora Pharma LLC",
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under age 6",
      "Keep this product out of the reach of children",
      "In case of accidental overdose, call a doctor or Poison Control Center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS AND USAGE Prenatal and Postnatal prescriptive Folic Acid"
    ]
  },
  "ferrous gluonate": {
    "ingredient": "ferrous gluonate",
    "is_drug": true,
    "canonical_name": "ferrous gluconate",
    "fda_search_term": "ferrous gluconate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CitraNatal 90 DHA",
      "Embriva",
      "Gestyra"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, THIAMINE, PYRIDOXAL PHOSPHATE, FOLIC ACID, METHYLCOBALAMIN, CALCIUM CARBONATE, FERROUS GLUCONATE, POTASSIUM IODIDE",
      "VITAMIN C, CALCIUM, IRON, VITAMIN D3, VITAMIN E, THIAMIN, RIBOFLAVIN, NIACINAMIDE, VITAMIN B6, FOLIC ACID, IODINE, ZINC, COPPER, DOCUSATE SODIUM"
    ],
    "manufacturers": [
      "Mission Pharmacal Company",
      "Oncora Pharma LLC",
      "Oncora Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under age 6",
      "Keep this product out of the reach of children",
      "In case of accidental overdose, call a doctor or Poison Control Center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS AND USAGE Prenatal and Postnatal prescriptive Folic Acid"
    ]
  },
  "ferrous glycinate": {
    "ingredient": "ferrous glycinate",
    "is_drug": true,
    "canonical_name": "ferrous glycinate",
    "fda_search_term": "ferrous glycinate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "HealthWise Pain Relief Lidocaine Patch"
    ],
    "generic_names": [
      "LIDOCAINE 4%"
    ],
    "manufacturers": [
      "Veridian Healthcare"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS For External use only",
      "Use only as directed",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away",
      "■ More than one patch on your body at a time ■ On cut, irritated or swollen skin ■ On puncture wounds ■ For more than one week without consulting a doctor ■ If you are allergic to any active or inactive ingredients ■ If pouch is damaged or opened",
      "If pregnant or breast feeding Contact a physician prior to use",
      "WHEN USING: ■ Use only as directed ■ Read and follow all directions and warnings on this carton ■ Do not allow contact with the eyes ■ Do not use at the same time as other topical analgesics ■ Do not bandage tightly or apply local heat (such as heating pads) to the area of use ■ Do not microwave ■ D",
      "Used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch",
      "Stop use and consult a doctor if ■ Condition worsens ■ Redness is present ■ Irritation develops ■ Symptoms persist for more than 7 days or clear up and occur again within a few days ■ You experience signs of skin injury, such as pain, swelling or blistering where the product was applied"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS: FeRivaFA ™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency"
    ]
  },
  "ferrous glycine sulphate": {
    "ingredient": "ferrous glycine sulphate",
    "is_drug": true,
    "canonical_name": "ferrous glycinate",
    "fda_search_term": "ferrous glycinate",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "HealthWise Pain Relief Lidocaine Patch"
    ],
    "generic_names": [
      "LIDOCAINE 4%"
    ],
    "manufacturers": [
      "Veridian Healthcare"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS For External use only",
      "Use only as directed",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away",
      "■ More than one patch on your body at a time ■ On cut, irritated or swollen skin ■ On puncture wounds ■ For more than one week without consulting a doctor ■ If you are allergic to any active or inactive ingredients ■ If pouch is damaged or opened",
      "If pregnant or breast feeding Contact a physician prior to use",
      "WHEN USING: ■ Use only as directed ■ Read and follow all directions and warnings on this carton ■ Do not allow contact with the eyes ■ Do not use at the same time as other topical analgesics ■ Do not bandage tightly or apply local heat (such as heating pads) to the area of use ■ Do not microwave ■ D",
      "Used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch",
      "Stop use and consult a doctor if ■ Condition worsens ■ Redness is present ■ Irritation develops ■ Symptoms persist for more than 7 days or clear up and occur again within a few days ■ You experience signs of skin injury, such as pain, swelling or blistering where the product was applied"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS: FeRivaFA ™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency"
    ]
  },
  "ferrous glycine sulphate complex": {
    "ingredient": "ferrous glycine sulphate complex",
    "is_drug": true,
    "canonical_name": "ferrous glycinate",
    "fda_search_term": "ferrous glycinate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "HealthWise Pain Relief Lidocaine Patch"
    ],
    "generic_names": [
      "LIDOCAINE 4%"
    ],
    "manufacturers": [
      "Veridian Healthcare"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS For External use only",
      "Use only as directed",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away",
      "■ More than one patch on your body at a time ■ On cut, irritated or swollen skin ■ On puncture wounds ■ For more than one week without consulting a doctor ■ If you are allergic to any active or inactive ingredients ■ If pouch is damaged or opened",
      "If pregnant or breast feeding Contact a physician prior to use",
      "WHEN USING: ■ Use only as directed ■ Read and follow all directions and warnings on this carton ■ Do not allow contact with the eyes ■ Do not use at the same time as other topical analgesics ■ Do not bandage tightly or apply local heat (such as heating pads) to the area of use ■ Do not microwave ■ D",
      "Used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch",
      "Stop use and consult a doctor if ■ Condition worsens ■ Redness is present ■ Irritation develops ■ Symptoms persist for more than 7 days or clear up and occur again within a few days ■ You experience signs of skin injury, such as pain, swelling or blistering where the product was applied"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS: FeRivaFA ™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency"
    ]
  },
  "ferrous sulfate": {
    "ingredient": "ferrous sulfate",
    "is_drug": true,
    "canonical_name": "ferrous sulfate",
    "fda_search_term": "ferrous sulfate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FERRUM SULPHURICUM",
      "Ferrum Quartz",
      "Recovatone"
    ],
    "generic_names": [
      "FERROUS SULFATE",
      "FERRUM QUARTZ",
      "GLYCYRRHIZA GLABRA, KALI MURIATICUM, KALI PHOSPHORICUM, IODIUM, ZINCUM GLUCONICUM, PHOSPHORUS, ASCORBICUM ACIDUM, CALCIUM GLUCONATE, L-ARGININE, L-CARNITINE, L-ORNITHINE, MAGNESIA MURIATICA, MAGNESIUM GLUCONICUM DIHYDRICUM, MANGANESE GLUCONATE, NATRUM MURIATICUM, COBALT GLUCONATE, COPPER GLUCONATE, CREATINE, L-GLUTAMINE, L-LEUCINE, L-VALINE, POTASSIUM GLUCONATE, SELENIUM DIOXIDE, ADRENALINUM, BORON, CALCAREA PHOSPHORICA, FERRUM SULPHURICUM, MOLYBDENUM, NICCOLUM METALLICUM, SELENIUM METALLICUM,"
    ],
    "manufacturers": [
      "Boiron",
      "Energique, Inc.",
      "Uriel Pharmacy, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated",
      "Do not use if allergic to any ingredient",
      "Contains lactose",
      "Consult a doctor before use for serious conditions or if conditions worsen or persist",
      "If pregnant or nursing, consult a doctor before use",
      "Do not use if safety seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Directions: FOR ORAL USE ONLY"
    ]
  },
  "ferrous sulfate heptahydrate": {
    "ingredient": "ferrous sulfate heptahydrate",
    "is_drug": true,
    "canonical_name": "ferrous sulfate",
    "fda_search_term": "ferrous sulfate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FERRUM SULPHURICUM",
      "Ferrum Quartz",
      "Recovatone"
    ],
    "generic_names": [
      "FERROUS SULFATE",
      "FERRUM QUARTZ",
      "GLYCYRRHIZA GLABRA, KALI MURIATICUM, KALI PHOSPHORICUM, IODIUM, ZINCUM GLUCONICUM, PHOSPHORUS, ASCORBICUM ACIDUM, CALCIUM GLUCONATE, L-ARGININE, L-CARNITINE, L-ORNITHINE, MAGNESIA MURIATICA, MAGNESIUM GLUCONICUM DIHYDRICUM, MANGANESE GLUCONATE, NATRUM MURIATICUM, COBALT GLUCONATE, COPPER GLUCONATE, CREATINE, L-GLUTAMINE, L-LEUCINE, L-VALINE, POTASSIUM GLUCONATE, SELENIUM DIOXIDE, ADRENALINUM, BORON, CALCAREA PHOSPHORICA, FERRUM SULPHURICUM, MOLYBDENUM, NICCOLUM METALLICUM, SELENIUM METALLICUM,"
    ],
    "manufacturers": [
      "Boiron",
      "Energique, Inc.",
      "Uriel Pharmacy, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated",
      "Do not use if allergic to any ingredient",
      "Contains lactose",
      "Consult a doctor before use for serious conditions or if conditions worsen or persist",
      "If pregnant or nursing, consult a doctor before use",
      "Do not use if safety seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Directions: FOR ORAL USE ONLY"
    ]
  },
  "ferrous sulphate": {
    "ingredient": "ferrous sulphate",
    "is_drug": true,
    "canonical_name": "ferrous sulfate",
    "fda_search_term": "ferrous sulfate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FERRUM SULPHURICUM",
      "Ferrum Quartz",
      "Recovatone"
    ],
    "generic_names": [
      "FERROUS SULFATE",
      "FERRUM QUARTZ",
      "GLYCYRRHIZA GLABRA, KALI MURIATICUM, KALI PHOSPHORICUM, IODIUM, ZINCUM GLUCONICUM, PHOSPHORUS, ASCORBICUM ACIDUM, CALCIUM GLUCONATE, L-ARGININE, L-CARNITINE, L-ORNITHINE, MAGNESIA MURIATICA, MAGNESIUM GLUCONICUM DIHYDRICUM, MANGANESE GLUCONATE, NATRUM MURIATICUM, COBALT GLUCONATE, COPPER GLUCONATE, CREATINE, L-GLUTAMINE, L-LEUCINE, L-VALINE, POTASSIUM GLUCONATE, SELENIUM DIOXIDE, ADRENALINUM, BORON, CALCAREA PHOSPHORICA, FERRUM SULPHURICUM, MOLYBDENUM, NICCOLUM METALLICUM, SELENIUM METALLICUM,"
    ],
    "manufacturers": [
      "Boiron",
      "Energique, Inc.",
      "Uriel Pharmacy, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated",
      "Do not use if allergic to any ingredient",
      "Contains lactose",
      "Consult a doctor before use for serious conditions or if conditions worsen or persist",
      "If pregnant or nursing, consult a doctor before use",
      "Do not use if safety seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Directions: FOR ORAL USE ONLY"
    ]
  },
  "ferrus bisglycinat": {
    "ingredient": "ferrus bisglycinat",
    "is_drug": true,
    "canonical_name": "iron(II) bisglycinate",
    "fda_search_term": "iron(II) bisglycinate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ENTRESTO",
      "Glimepiride",
      "Mekinist"
    ],
    "generic_names": [
      "GLIMEPIRIDE",
      "SACUBITRIL AND VALSARTAN",
      "TRAMETINIB"
    ],
    "manufacturers": [
      "American Health Packaging",
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",
      "( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test",
      "( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options"
    ]
  },
  "ferrus fumerate": {
    "ingredient": "ferrus fumerate",
    "is_drug": true,
    "canonical_name": "ferric fumarate",
    "fda_search_term": "ferric fumarate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Acid Reducer",
      "Calcium Acetate"
    ],
    "generic_names": [
      "CALCIUM ACETATE",
      "ESOMEPRAZOLE MAGNESIUM"
    ],
    "manufacturers": [
      "CVS Pharmacy",
      "Cipla USA Inc.,"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert : Do not use if you are allergic to esomeprazole",
      "Esomeprazole may cause severe skin reactions",
      "Symptoms may include: skin reddening blisters rash If an allergic reaction occurs, stop use and seek medical help right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups)",
      "Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism",
      "There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs",
      "When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate",
      "Monitor blood levels of the concomitant drugs that have a narrow therapeutic range",
      "Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate",
      "Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones",
      "( 7 ) When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug",
      "( 7 ) 7.1 Ciprofloxacin In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Hypercalcemia is discussed elsewhere [see Warnings and Precautions (5.1) ]",
      "The most common (>10%) adverse reactions are hypercalcemia, nausea and vomiting",
      "( 6.1 ) In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd",
      "at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of anot",
      "In clinical studies, calcium acetate has been generally well tolerated",
      "Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients",
      "Adverse reactions (>2% on treatment) from these trials are presented in Table 1",
      "Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis Preferred Term Total adverse reactions reported for calcium acetate n=167 n (%) 3-month, open-label study of calcium acetate n=98 n (%) Double blind, placebo-controlled, cross-over study of liquid calcium ace",
      "More severe hypercalcemia is associated with confusion, delirium, stupor, and coma",
      "Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate",
      "induced hypercalcemia",
      "Isolated cases of pruritus have been reported, which ma"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD)",
      "Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease"
    ]
  },
  "ferulic acid": {
    "ingredient": "ferulic acid",
    "is_drug": true,
    "canonical_name": "ferulic acid",
    "fda_search_term": "ferulic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Anubis Barcelona"
    ],
    "generic_names": [
      "FERULIC ACID, VITAMIN C, DMAE"
    ],
    "manufacturers": [
      "ANUBIS COSMETICS SL"
    ],
    "dosage_forms": [],
    "warnings": [
      "Ferulic Concentrate warning"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Ferulic Concentrate indications"
    ]
  },
  "fesoterodine": {
    "ingredient": "fesoterodine",
    "is_drug": true,
    "canonical_name": "fesoterodine",
    "fda_search_term": "fesoterodine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fesoterodine Fumarate",
      "fesoterodine fumarate"
    ],
    "generic_names": [
      "FESOTERODINE FUMARATE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "Amneal Pharmaceuticals LLC",
      "Zydus Lifesciences Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Antimuscarinic Drugs Co-administration of fesoterodine fumarate with other antimuscarinic agents that produce dry mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects",
      "Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility",
      "7.2 CYP3A4 Inhibitors Doses of fesoterodine fumarate greater than 4 mg are not recommended in adult patients taking strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin [see Dosage and Administration (2.5) ] ",
      "In a study in adults, co-administration of the strong CYP3A4 inhibitor ketoconazole with fesoterodine led to approximately a doubling of the maximum concentration (C max ) and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesote",
      "Compared with CYP2D6 extensive metabolizers not taking ketoconazole, further increases in the exposure to 5-HMT were observed in subjects who were CYP2D6 poor metabolizers taking ketoconazole [see Clinical Pharmacology (12.3) ] ",
      "There is no clinically relevant effect of moderate CYP3A4 inhibitors on the pharmacokinetics of fesoterodine",
      "Following blockade of CYP3A4 by co-administration of the moderate CYP3A4 inhibitor fluconazole 200 mg twice a day for 2 days, the average (90% confidence interval) increase in C max and AUC of the active metabolite of fesoterodine was approximately 19% (11% to 28%) and 27% (18% to 36%) respectively",
      "No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, verapamil and grapefruit juice)",
      "The effect of weak CYP3A4 inhibitors (e.g",
      "cimetidine) was not examined; it is not expected to be in excess of the effect of moderate inhibitors [ see Clinical Pharmacology (12.3) ] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Angioedema [see Warnings and Precautions (5.1) ] Urinary Retention [see Warnings and Precautions (5.2) ] Decreased Gastrointestinal Motility [see Warnings and Precautions (5.3) ] Most freq",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "Pediatric use information is approved for Pfizer Inc.’s TOVIAZ ® (fesoterodine fumarate) extended-release tablets",
      "However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adult Overactive Bladder (OAB) The safety of fesoterodine fumarate was evaluated in Phase 2 and 3 controlled trials in a total of 2,859 patients with overactive bladder, of which 2,288 were treated with fesoterodine fumarate",
      "Of this total, 782 received fesoterodine fumarate 4 mg/day, and 785 received fesoterodine fumarate 8 mg/day with treatment periods of 8",
      "Approximately 80% of these patients had greater than 10-weeks of exposure to fesoterodine fumarate in these trials",
      "A total of 1,964 patients participated in two 12-week, Phase 3 efficacy and safety studies and subsequent open-label extension studies",
      "In these two studies combined, 554 patients received fesoterodine fumarate 4 mg/day and 566 patients received fesotero"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fesoterodine fumarate extended-release tablets are indicated for the treatment of: Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency",
      "( 1.1 ) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency",
      "Pediatric use information is approved for Pfizer Inc.’s TOVIAZ ® (fesoterodine fumarate) extended-release tablets",
      "However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information"
    ]
  },
  "fexofenadine": {
    "ingredient": "fexofenadine",
    "is_drug": true,
    "canonical_name": "fexofenadine",
    "fda_search_term": "fexofenadine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fexofenadine HCL",
      "Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride"
    ],
    "generic_names": [
      "FEXOFENADINE HCL",
      "FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "CVS",
      "CVS Pharmacy"
    ],
    "dosage_forms": [],
    "warnings": [
      "Severe Allergy Warning: Get emergency help immediately if you have hives along with any of the following symptoms:  trouble swallowing  dizziness or loss of consciousness  swelling of tongue  swelling in or around mouth  trouble speaking  wheezing or problems breathing  drooling These symptom",
      "This condition can be life threatening if not treated by a health professional immediately",
      "Symptoms of anaphylactic shock may occur when hives first appear or up to a few hours later"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses reduces hives and relieves itching due to hives (urticaria)",
      "This product will not prevent hives or an allergic skin reaction from occurring"
    ]
  },
  "filgrastim": {
    "ingredient": "filgrastim",
    "is_drug": true,
    "canonical_name": "filgrastim",
    "fda_search_term": "filgrastim",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "NYPOZI",
      "NYPOZI txid",
      "RELEUKO"
    ],
    "generic_names": [
      "FILGRASTIM",
      "FILGRASTIM-TXID"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals LLC",
      "Cipla USA Inc.",
      "Tanvex BioPharma USA, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Splenic Rupture [see Warnings and Precautions (5.1) ] Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2) ] Serious Allergic Reactions [see Warnings and ",
      "( 6.1 ) With AML (≥ 2% difference in incidence) are pain, epistaxis and rash",
      "( 6.1 ) With nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT (≥ 5% difference in incidence) is rash",
      "( 6.1 ) Undergoing peripheral blood progenitor cell mobilization and collection (≥ 5% incidence) are bone pain, pyrexia and headache",
      "( 6.1 ) With severe chronic neutropenia (SCN) (≥ 5% difference in incidence) are pain, anemia, epistaxis, diarrhea, hypoesthesia and alopecia",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Tanvex BioPharma USA at 1-833-826-8398 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug an"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia wit",
      "1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NYPOZI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinic",
      "1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NYPOZI is indicated to reduce the duratio"
    ]
  },
  "finasteride": {
    "ingredient": "finasteride",
    "is_drug": true,
    "canonical_name": "finasteride",
    "fda_search_term": "finasteride",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Finasteride"
    ],
    "generic_names": [
      "FINASTERIDE"
    ],
    "manufacturers": [
      "Camber Pharmaceuticals, Inc.",
      "Direct_Rx",
      "Rising Pharma Holdings, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Cytochrome P450-Linked Drug Metabolizing Enzyme System No drug interactions of clinical importance have been identified",
      "Finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system",
      "Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found",
      "7.2 Other Concomitant Therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, ben"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions, reported in ≥1% of patients treated with finasteride tablets USP and greater than in patients treated with placebo are: decreased libido, erectile dysfunction and ejaculation disorder ( 6.1 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "Clinical Studies for Finasteride Tablets USP 1 mg in the Treatment of Male Pattern Hair Loss In three controlled clinical trials for finasteride tablets USP of 12-month duration, 1.4% of patients taking finasteride tablets USP (n=945) were discontinued due to adverse experiences that were considered",
      "Clinical adverse experiences that were reported as possibly, probably or definitely drug-related in ≥1% of patients treated with finasteride tablets USP or placebo are presented in Table 1",
      "TABLE 1 Drug-Related Adverse Experiences for Finasteride Tablets USP, 1 mg in Year 1 (%) MALE PATTERN HAIR LOSS Finasteride tablets USP N=945 Placebo N=934 Decreased Libido 1.8 1.3 Erectile Dysfunction 1.3 0.7 Ejaculation Disorder (Decreased Volume of Ejaculate) 1.2 (0.8) 0.7 (0.4) Discontinuation d",
      "Resolution occurred in men who discontinued therapy with fina"
    ],
    "indications": [
      "1 INDICATIONS & USAGE Finasteride tablets USP are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY",
      "Efficacy in bitemporal recession has not been established",
      "Finasteride tablets USP are not indicated for use in women",
      "Finasteride tablets USP are 5α-reductase inhibitors indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY ( 1 )",
      "Finasteride tablets USP are not indicated for use in women ( 1 , 4 , 5.1 )"
    ]
  },
  "fingolimod": {
    "ingredient": "fingolimod",
    "is_drug": true,
    "canonical_name": "fingolimod",
    "fda_search_term": "fingolimod",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FINGOLIMOD",
      "Fingolimod"
    ],
    "generic_names": [
      "FINGOLIMOD",
      "FINGOLIMOD HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Ascend Laboratories, LLC",
      "AvKARE",
      "Quallent Pharmaceuticals Health LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Systemic Ketoconazole: Monitor during concomitant use",
      "Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping fingolimod treatment",
      "( 5.2 , 7.3 ) 7.1 QT Prolonging Drugs Fingolimod has not been studied in patients treated with drugs that prolong the QT interval",
      "Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia",
      "Since initiation of fingolimod treatment results in decreased heart rate and may prolong the QT interval, patients on QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous EC",
      "7.2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole",
      "Patients who use fingolimod and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater",
      "7.3 Vaccines Fingolimod reduces the immune response to vaccination",
      "Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with fingolimod [see Clinical Pharmacology ( 12.2 )] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in labeling: Bradyarrhythmia and Atrioventricular Blocks [see Warnings and Precautions ( 5.1 )] Infections [see Warnings and Precautions ( 5.2 )] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautio",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ascend Laboratories, LLC at 1-877-272-7901 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults In clinical trials (Studies 1, 2, and 3), a total of 1,212 patients with relapsing forms of multiple sclerosis received fingolimod capsule 0.5 mg",
      "This included 783 patients who received fingolimod capsule 0.5 mg in the 2-year placebo-controlled trials (Studies 1 and 3) and 429 pa"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older",
      "Fingolimod capsules are a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older"
    ]
  },
  "flavoxate": {
    "ingredient": "flavoxate",
    "is_drug": true,
    "canonical_name": "flavoxate",
    "fda_search_term": "flavoxate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLAVOXATE HYDROCHLORIDE",
      "Flavoxate Hydrochloride"
    ],
    "generic_names": [
      "FLAVOXATE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Epic Pharma, LLC",
      "Padagis US LLC",
      "PuraCap Laboratories LLC dba Blu Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Flavoxate HCl should be given cautiously in patients with suspected glaucoma"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency",
      "Gastrointestinal: Nausea, vomiting, dry mouth",
      "CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness",
      "Hematologic: Leukopenia (one case which was reversible upon discontinuation of the drug)",
      "Cardiovascular: Tachycardia and palpitation",
      "Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia",
      "Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation"
    ],
    "indications": [
      "INDICATIONS AND USAGE Flavoxate HCl tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis",
      "Flavoxate HCl tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections"
    ]
  },
  "flavoxate hydrochloride": {
    "ingredient": "flavoxate hydrochloride",
    "is_drug": true,
    "canonical_name": "flavoxate",
    "fda_search_term": "flavoxate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLAVOXATE HYDROCHLORIDE",
      "Flavoxate Hydrochloride"
    ],
    "generic_names": [
      "FLAVOXATE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Epic Pharma, LLC",
      "Padagis US LLC",
      "PuraCap Laboratories LLC dba Blu Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Flavoxate HCl should be given cautiously in patients with suspected glaucoma"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency",
      "Gastrointestinal: Nausea, vomiting, dry mouth",
      "CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness",
      "Hematologic: Leukopenia (one case which was reversible upon discontinuation of the drug)",
      "Cardiovascular: Tachycardia and palpitation",
      "Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia",
      "Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation"
    ],
    "indications": [
      "INDICATIONS AND USAGE Flavoxate HCl tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis",
      "Flavoxate HCl tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections"
    ]
  },
  "flecainide acetate": {
    "ingredient": "flecainide acetate",
    "is_drug": true,
    "canonical_name": "flecainide",
    "fda_search_term": "flecainide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Flecainide Acetate"
    ],
    "generic_names": [
      "FLECAINIDE ACETATE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Aurobindo Pharma Limited"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Mortality Flecainide was included in the National Heart Lung and Blood Institute’s Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarctio",
      "An excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with flecainide compared with that seen in a carefully matched placebo-treated group",
      "This rate was 16/315 (5.1%) for flecainide and 7/309 (2.3%) for the matched placebo",
      "The average duration of treatment with flecainide in this study was 10 months",
      "The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain, but at present it is prudent to consider the risks of Class 1C agents (including flecainide), coupled with the lack of any evidence of improved survival, generally unacceptable",
      "Ventricular Proarrhythmic Effects in Patients with Atrial Fibrillation/Flutter A review of the world literature revealed reports of 568 patients treated with oral flecainide for paroxysmal atrial fibrillation/flutter (PAF)",
      "Ventricular tachycardia was experienced in 0.4% (2/568) of these patients",
      "Of 19 patients in the literature with chronic atrial fibrillation (CAF), 10.5% (2) experienced VT or VF",
      "FLECAINIDE IS NOT RECOMMENDED FOR USE IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased PVCs, VT, ventricular fibrillation (VF) and death",
      "As with other Class 1 agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate"
    ],
    "drug_interactions": [
      "Drug Interactions Flecainide acetate has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects",
      "During administration of multiple oral doses of flecainide acetate to healthy subjects stabilized on a maintenance dose of digoxin , a 13% to 19% increase in plasma digoxin levels occurred at six hours postdose",
      "In a study involving healthy subjects receiving flecainide acetate and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values",
      "In this formal interaction study, flecainide acetate and propranolol were each found to have negative inotropic effects; when the drugs were administered together, the effects were additive",
      "The effects of concomitant administration of flecainide acetate and propranolol on the PR interval were less than additive",
      "In flecainide acetate clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects",
      "Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized",
      "Flecainide is not extensively bound to plasma proteins",
      "In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less",
      "Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS In post-myocardial infarction patients with asymptomatic PVCs and non-sustained ventricular tachycardia, flecainide acetate therapy was found to be associated with a 5.1% rate of death and non-fatal cardiac arrest, compared with a 2.3% rate in a matched placebo group",
      "(See WARNINGS .) Adverse effects reported for flecainide acetate, described in detail in the WARNINGS section, were new or worsened arrhythmias which occurred in 1% of 108 patients with PSVT and in 7% of 117 patients with PAF; and new or exacerbated ventricular arrhythmias which occurred in 7% of 13",
      "In patients treated with flecainide for sustained VT, 80% (51/64) of proarrhythmic events occurred within 14 days of the onset of therapy",
      "198 patients with sustained VT experienced a 13% incidence of new or exacerbated ventricular arrhythmias when dosage was initiated at 200 mg/day with slow upward titration, and did not exceed 300 mg/day in most patients",
      "In some patients, flecainide acetate treatment has been associated with episodes of unresuscitatable VT or ventricular fibrillation (cardiac arrest)",
      "(See WARNINGS .) New or worsened CHF occurred in 6.3% of 1046 patients with PVCs, non-sustained or sustained VT",
      "Of 297 patients with sustained VT, 9.1% experienced new or worsened CHF",
      "New or worsened CHF was reported in 0.4% of 225 patients with supraventricular arrhythmias",
      "There have also been instances of second",
      "(0.5%) or third-degree (0.4%) AV block",
      "Patients have developed sinus bradycardia, sinus pause, or sinus arrest, about 1.2% altogether (see WARNINGS )",
      "The frequency of most of these serious adverse events probably increases with higher trough plasma levels, especially when these trough levels exceed 1 mcg/mL",
      "There have been rare reports of isolated elevations of serum alkaline phosphatase and isolated elevations of serum transaminase levels",
      "These elevations have been asymptomatic and no cause and effect relationship with"
    ],
    "indications": [
      "INDICATIONS AND USAGE In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of — paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraven",
      "Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital",
      "The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic",
      "Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks",
      "Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction"
    ]
  },
  "flibanserin": {
    "ingredient": "flibanserin",
    "is_drug": true,
    "canonical_name": "flibanserin",
    "fda_search_term": "flibanserin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ADDYI"
    ],
    "generic_names": [
      "FLIBANSERIN"
    ],
    "manufacturers": [
      "Sprout Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 3 contains clinically significant drug interactions (DI) with ADDYI",
      "Table 3 Clinically Significant Drug Interactions with ADDYI Alcohol Clinical Implications The coadministration of ADDYI with alcohol increased the risk of hypotension, syncope, and CNS depression compared to the use of ADDYI alone or alcohol alone [see Warnings and Precautions (5.1) and Clinical Pha",
      "Preventing or Managing DI Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more alcoholic drinks that evening",
      "[see Boxed Warning , Warnings and Precautions (5.1) , and Adverse Reactions (6.1) ] ",
      "Other CNS Depressants Examples Diphenhydramine, opioids, hypnotics, benzodiazepines Clinical Implications The concomitant use of ADDYI with CNS depressants may increase the risk of CNS depression (e.g., somnolence) compared to the use of ADDYI alone",
      "Preventing or Managing DI Discuss the concomitant use of other CNS depressants with the patient when prescribing ADDYI",
      "Moderate or Strong CYP3A4 Inhibitors Examples of strong CYP3A4 inhibitors Ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan Examples of moderate CYP3A4 inhibitors Amprenavir, atazan",
      "The risk of hypotension and syncope is increased with concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors [see Warnings and Precautions (5.2) , Adverse Reactions (6.1) , and Clinical Pharmacology (12.3) ]",
      "Preventing or Managing DI The concomitant use of ADDYI with moderate or strong CYP3A4 inhibit"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Hypotension and syncope [see Warnings and Precautions (5.1, 5.2, 5.4, 5.5) ]",
      "CNS depression [see Warnings and Precautions (5.3) ] Most common adverse reactions (incidence ≥2%) are dizziness, somnolence, nausea, fatigue, insomnia, urinary tract infection, anxiety, sinusitis, constipation and dry mouth",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sprout Pharmaceuticals, Inc",
      "at 1-844-746-5745, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The approved 100 mg ADDYI dosage at bedtime was administered to 2,997 premenopausal women with acquired, generalized HSDD in clinical trials, of whom 1,672 received treatment for at least 6 months, 850 received treatment for at least 12 months, and 88 received treatment for at least 18 months [see C",
      "In clinical trials, ADDYI 100 mg once daily at bedtime was administered to 801 postmenopausal women less than 65 years of age with acquired, generalized HSDD, of whom 460 received ADDYI treatment for at least 6 months, and 23 received ADDYI treatment for longer than 6 months",
      "Premenopausal Women The data presented below in Table 1 and Table 2 (left columns) are derived from five 24-week randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD",
      "In these trials, the frequency and quantity of alcohol use was not recorded",
      "Three of these trials (Studies 1, 2, and 3) also provided efficacy data [see Clinical Studies (14.1) ]",
      "One trial (Study 5) did not evaluate the 100 mg bedtime dose",
      "In four trials in premenopausal women (Studies 1 through 4)"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to:",
      "A co-existing medical or psychiatric condition,",
      "Problems within the relationship, or",
      "The effects of a medication or other drug substance",
      "Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire"
    ]
  },
  "floc acid": {
    "ingredient": "floc acid",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "flouride": {
    "ingredient": "flouride",
    "is_drug": true,
    "canonical_name": "fluoride",
    "fda_search_term": "fluoride",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aluminium Fluoratum",
      "Anticavity Rinse",
      "Prime Tooth Care Hami Melon"
    ],
    "generic_names": [
      "ALUMINIUM FLUORATUM",
      "SODIUM FLUORIDE"
    ],
    "manufacturers": [
      "Hahnemann Laboratories, INC.",
      "Meijer, Inc.",
      "Prime Tooth Care LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings for this product"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse reactions Distributed By Meijer Distribution, Inc",
      "Grand Rapids, MI 49544 www.meijer.com Our Quality Guarantee www.meijer.com/satisfcation Discard Seal, Empty & Replace Cap PLASTIC BOTTLE how2recycle.info"
    ],
    "indications": [
      "Use aids in the prevention of dental cavities"
    ]
  },
  "flourine": {
    "ingredient": "flourine",
    "is_drug": true,
    "canonical_name": "fluorine",
    "fda_search_term": "fluorine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Amalgam 6003",
      "Toxagent Detox 6035"
    ],
    "generic_names": [
      "AMALGAM",
      "TOXAGENT DETOX"
    ],
    "manufacturers": [
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Consult a doctor if condition worsens or symptoms persist",
      "Not intended for use by individuals with retained amalgams",
      "Keep out of the reach of children",
      "In case of overdose, get medical help or contact a poison control center right away",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep out of the reach of children",
      "If pregnant or breastfeeding, ask a healthcare professional before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For the temporary relief of swollen, red, or tender gums, occasional bad breath, minor toothache, occasional headache, irritability, or fatigue due to sensitivity to or exposure to oral/dental materials.*"
    ]
  },
  "fluconazole": {
    "ingredient": "fluconazole",
    "is_drug": true,
    "canonical_name": "fluconazole",
    "fda_search_term": "fluconazole",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluconazole"
    ],
    "generic_names": [
      "FLUCONAZOLE"
    ],
    "manufacturers": [
      "NuCare Pharmaceuticals,Inc.",
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS (1) Hepatic injury: Fluconazole should be administered with caution to patients with liver dysfunction",
      "Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions",
      "In cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex, or age of the patient has been observed",
      "Fluconazole hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy",
      "Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more severe hepatic injury",
      "Fluconazole should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole",
      "(2) Anaphylaxis: In rare cases, anaphylaxis has been reported",
      "(3) Dermatologic: Exfoliative skin disorders during treatment with fluconazole have been reported",
      "Fatal outcomes have been reported in patients with serious underlying diseases",
      "Patients with deep seated fungal infections who develop rashes during treatment with fluconazole should be monitored closely and the drug discontinued if lesions progress"
    ],
    "drug_interactions": [
      "Drug Interaction Studies (See PRECAUTIONS, Drug Interactions) Oral contraceptives: Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women",
      "There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole",
      "The mean increase in ethinyl estradiol AUC was 6% (range: –47 to 108%) and levonorgestrel AUC increased 17% (range: –33 to 141%)",
      "In a second study, twenty-five normal females received daily doses of both 200 mg fluconazole tablets or placebo for two, ten-day periods",
      "The treatment cycles were one month apart with all subjects receiving fluconazole during one cycle and placebo during the other",
      "The order of study treatment was random",
      "Single doses of an oral contraceptive tablet containing levonorgestrel and ethinyl estradiol were administered on the final treatment day (Day 10) of both cycles",
      "Following administration of 200 mg of fluconazole, the mean percentage increase of AUC for levonorgestrel compared to placebo was 25% (range: –12 to 82%) and the mean percentage increase for ethinyl estradiol compared to placebo was 38% (range: –11 to 101%)",
      "Both of these increases were statistically significantly different from placebo",
      "A third study evaluated the potential interaction of once-weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Fluconazole is generally well tolerated",
      "In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationshi",
      "In Patients Receiving a Single Dose for Vaginal Candidiasis: During comparative clinical studies conducted in the United States, 448 patients with vaginal candidiasis were treated with fluconazole, 150 mg single dose",
      "The overall incidence of side effects possibly related to fluconazole was 26%",
      "In 422 patients receiving active comparative agents, the incidence was 16%",
      "The most common treatment-related adverse events reported in the patients who received 150 mg single dose fluconazole for vaginitis were headache (13%), nausea (7%), and abdominal pain (6%)",
      "Other side effects reported with an incidence equal to or greater than 1% included diarrhea (3%), dyspepsia (1%), dizziness (1%), and taste perversion (1%)",
      "Most of the reported side effects were mild to moderate in severity",
      "Rarely, angioedema and anaphylactic reaction have been reported in marketing experience",
      "In Patients Receiving Multiple Doses for Other Infections: Sixteen percent of over 4000 patients treated with fluconazole in clinical trials of 7 days or more experienced adverse events",
      "Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of patients due to laboratory test abnormalities",
      "Clinical adverse events were reported more frequently in HIV infected patients (21%) than in non-HIV infected patients (13%); however, the patterns in HIV infected and non-HIV infected patients were similar",
      "The proportions of patients discontinuing therapy due to clinical adverse events were similar in the two groups (1.5%)",
      "The following treatment-related clinical adverse events occurred at an inciden"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida )",
      "Oropharyngeal and esophageal candidiasis",
      "In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia",
      "Cryptococcal meningitis ",
      "Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis , please see CLINICAL STUDIES section"
    ]
  },
  "fludarabine": {
    "ingredient": "fludarabine",
    "is_drug": true,
    "canonical_name": "fludarabine",
    "fda_search_term": "fludarabine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fludarabine Phosphate",
      "Fludarabine phosphate"
    ],
    "generic_names": [
      "FLUDARABINE PHOSPHATE"
    ],
    "manufacturers": [
      "Actavis Pharma, Inc.",
      "Lannett Company, Inc.",
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS (See BOXED WARNINGS ) Dose Dependent Neurologic Toxicities There are clear dose-dependent toxic effects seen with Fludarabine Phosphate for Injection",
      "Dose levels approximately 4 times greater (96 mg/m 2 /day for 5 to 7 days) than that recommended for CLL (25 mg/m 2 /day for 5 days) were associated with a syndrome characterized by delayed blindness, coma and death",
      "Symptoms appeared from 21 to 60 days following the last dose",
      "Thirteen of 36 patients (36%) who received Fludarabine Phosphate for Injection at high doses (96 mg/m 2 /day for 5 to 7 days) developed this severe neurotoxicity",
      "Similar severe central nervous system toxicity, including coma, seizures, agitation and confusion, has been reported in patients treated at doses in the range of the dose recommended for chronic lymphocytic leukemia",
      "In post-marketing experience neurotoxicity has been reported to occur either earlier or later than in clinical trials (range 7 to 225 days)",
      "The effect of chronic administration of Fludarabine Phosphate for Injection on the central nervous system is unknown; however, patients have received the recommended dose for up to 15 courses of therapy",
      "Bone Marrow Suppression Severe bone marrow suppression, notably anemia, thrombocytopenia and neutropenia, has been reported in patients treated with Fludarabine Phosphate for Injection",
      "In a Phase I study in adult solid tumor patients, the median time to nadir counts was 13 days (range, 3 to 25 days) for granulocytes and 16 days (range, 2 to 32) for platelets",
      "Most patients had hematologic impairment at baseline either as a result of disease or as a result of prior myelosuppressive therapy"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Fludarabine phosphate injection in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity ( 5.5 and 7.1 )",
      "7.1 Pentostatin The use of Fludarabine Phosphate Injection in combination with pentostatin is not recommended due to the risk of fatal pulmonary toxicity [see Warnings and Precautions ( 5.5 )]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Very common adverse reactions include myelosuppression (neutropenia, thrombocytopenia and anemia), fever and chills, fatigue, weakness, infection, pneumonia, cough, nausea, vomiting and diarrhea",
      "Other commonly reported events include malaise, mucositis, and anorexia",
      "Serious opportunistic infections have occurred in CLL patients treated with fludarabine phosphate",
      "The most frequently reported adverse reactions and those reactions which are more clearly related to the drug are arranged below according to body system",
      "Most common adverse reactions (incidence > 30%) include myelosuppression (neutropenia, thrombocytopenia and anemia), fever, infection, nausea and vomiting, fatigue, anorexia, cough and weakness ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Areva at 1-855-853-4760 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Hematopoietic Systems Hematologic events (neutropenia, thrombocytopenia, and/or anemia) were reported in the majority of CLL patients treated with fludarabine phosphate",
      "During fludarabine phosphate treatment of 133 patients with CLL, the absolute neutrophil count decreased to less than 500/mm 3 in 59% of patients, hemoglobin decreased from pretreatment values by at least 2 grams percent in 60%, and platelet count decreased from pretreatment values by at least 50% i",
      "Myelosuppression may be severe, cumulative, and may affect multiple cell lines",
      "Bone marrow fibrosis occurred in one CLL patient treated with fludarabine phosphate",
      "Several instances of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported in post-marketing surveillance",
      "The duration of clinically significant cytopenia in"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fludarabine Phosphate Injection is a nucleotide metabolic inhibitor indicated for: The treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-a",
      "Benefit in treatment-naïve or non-refractory CLL patients is not established",
      "( 1.1 ) 1.1 Indication Fludarabine Phosphate Injection is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen",
      "The safety and effectiveness of Fludarabine Phosphate Injection in previously untreated or non-refractory patients with CLL have not been established"
    ]
  },
  "fludrocortisone": {
    "ingredient": "fludrocortisone",
    "is_drug": true,
    "canonical_name": "fludrocortisone",
    "fda_search_term": "fludrocortisone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLUDROCORTISONE ACETATE",
      "Fludrocortisone Acetate"
    ],
    "generic_names": [
      "FLUDROCORTISONE ACETATE"
    ],
    "manufacturers": [
      "American Health Packaging",
      "AvPAK",
      "NorthStar Rx LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS BECAUSE OF ITS MARKED EFFECT ON SODIUM RETENTION THE USE OF FLUDROCORTISONE ACETATE IN THE TREATMENT OF CONDITIONS OTHER THAN THOSE INDICATED HEREIN IS NOT ADVISED",
      "Corticosteroids may mask some signs of infection, and new infections may appear during their use",
      "There may be decreased resistance and inability to localize infection when corticosteroids are used",
      "If an infection occurs during fludrocortisone acetate therapy, it should be promptly controlled by suitable antimicrobial therapy",
      "Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses",
      "Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium",
      "These effects are less likely to occur with the synthetic derivatives except when used in large doses",
      "However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain",
      "Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary",
      "All corticosteroids increase calcium excretion"
    ],
    "drug_interactions": [
      "Drug Interactions When administered concurrently, the following drugs may interact with adrenal corticosteroids",
      "Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) – enhanced hypokalemia",
      "Check serum potassium levels at frequent intervals; use potassium supplements if necessary (see WARNINGS )",
      "Digitalis glycosides – enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia",
      "Monitor serum potassium levels; use potassium supplements if necessary",
      "Oral anticoagulants – decreased prothrombin time response",
      "Monitor prothrombin levels and adjust anticoagulant dosage accordingly",
      "Antidiabetic drugs (oral agents and insulin) – diminished antidiabetic effect",
      "Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary",
      "Aspirin – increased ulcerogenic effect; decreased pharmacologic effect of aspirin"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, congestive heart failure, potassium loss, and hypokalemic alkalosis",
      "When fludrocortisone is used in the small dosages recommended, the glucocorticoid side effects often seen with cortisone and its derivatives are not usually a problem; however the following untoward effects should be kept in mind, particularly when fludrocortisone is used over a prolonged period of ",
      "Musculoskeletal – muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, and spontaneous fractures",
      "Gastrointestinal – peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis",
      "Dermatologic – impaired wound healing, thin fragile skin, bruising, petechiae and ecchymoses, facial erythema, increased sweating, subcutaneous fat atrophy, purpura, striae, hyperpigmentation of the skin and nails, hirsutism, acneiform eruptions and hives; reactions to skin tests may be suppressed",
      "Neurological – convulsions, increased intracranial pressure with papilledema (psuedo-tumor cerebri) usually after treatment, vertigo, headache, and severe mental disturbances",
      "Endocrine – menstrual irregularities; development of the cushingoid state; suppression of growth in children; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress (e.g., trauma, surgery, or illness); decreased carbohydrate tolerance; manifestations of latent diabe",
      "Ophthalmic – posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and exophthalmos",
      "Metabolic – hyperglycemia, glycosuria, a"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fludrocortisone acetate tablets, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome"
    ]
  },
  "flumazenil": {
    "ingredient": "flumazenil",
    "is_drug": true,
    "canonical_name": "flumazenil",
    "fda_search_term": "flumazenil",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLUMAZENIL",
      "Flumazenil"
    ],
    "generic_names": [
      "FLUMAZENIL"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Henry Schein, Inc.",
      "Medical Purchasing Solutions, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Risk of Seizures The reversal of benzodiazepine effects may be associated with the onset of seizures in certain high-risk populations",
      "Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning",
      "Flumazenil is not recommended in cases of serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, focal seizure), dysrhythmia (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), and cardiovascul",
      "In such cases flumazenil should be withheld and the patient should be allowed to remain sedated (with ventilatory and circulatory support as needed) until the signs of antidepressant toxicity have subsided",
      "Treatment with flumazenil has no known benefit to the seriously ill mixed-overdose patient other than reversing sedation and should not be used in cases where seizures (from any cause) are likely",
      "Most convulsions associated with flumazenil administration require treatment and have been successfully managed with benzodiazepines, phenytoin or barbiturates",
      "Because of the presence of flumazenil, higher than usual doses of benzodiazepines may be required",
      "Hypoventilation Patients who have received flumazenil for the reversal of benzodiazepine effects (after conscious sedation or general anesthesia) should be monitored for resedation, respiratory depression, or other residual benzodiazepine effects for an appropriate period (up to 120 minutes) based o",
      "This is because flumazenil has not been established in patients as an effective treatment for hypoventilation due to benzodiazepine administration",
      "In healthy male volunteers, flumazenil is capabl"
    ],
    "drug_interactions": [
      "Drug Interactions Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied; however, no deleterious interactions were seen when flumazenil was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagoni",
      "Particular caution is necessary when using flumazenil in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil ",
      "The use of flumazenil is not recommended in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period",
      "Although flumazenil exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients",
      "Flumazenil blocks the central effects of benzodiazepines by competitive interaction at the receptor level",
      "The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by flumazenil",
      "The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa",
      "There is no pharmacokinetic interaction between ethanol and flumazenil"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Serious Adverse Reactions Deaths have occurred in patients who received flumazenil in a variety of clinical settings",
      "The majority of deaths occurred in patients with serious underlying disease or in patients who had ingested large amounts of non-benzodiazepine drugs (usually cyclic antidepressants), as part of an overdose",
      "Serious adverse events have occurred in all clinical settings, and convulsions are the most common serious adverse events reported",
      "Flumazenil administration has been associated with the onset of convulsions in patients with severe hepatic impairment and in patients who are relying on benzodiazepine effects to control seizures, are physically dependent on benzodiazepines, or who have ingested large doses of other drugs (mixed-dr",
      "Two of the 446 patients who received flumazenil in controlled clinical trials for the management of a benzodiazepine overdose had cardiac dysrhythmias (1 ventricular tachycardia,1 junctional tachycardia)",
      "Adverse Events in Clinical Studies The following adverse reactions were considered to be related to flumazenil administration (both alone and for the reversal of benzodiazepine effects) and were reported in studies involving 1875 individuals who received flumazenil in controlled trials",
      "Adverse events most frequently associated with flumazenil alone were limited to dizziness, injection site pain, increased sweating, headache, and abnormal or blurred vision (3% to 9%)",
      "Body as a Whole: fatigue (asthenia, malaise), headache, injection site pain*, injection site reaction (thrombophlebitis, skin abnormality, rash) Cardiovascular System: cutaneous vasodilation (sweating, flushing, hot flushes) Digestive System: nausea, vomiting (11%) Nervous System: agitation (anxiety"
    ],
    "indications": [
      "INDICATIONS AND USAGE Adult Patients Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines",
      "Pediatric Patients (aged 1 to 17) Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (see PRECAUTIONS: Pediatric Use )"
    ]
  },
  "fluocinolone": {
    "ingredient": "fluocinolone",
    "is_drug": true,
    "canonical_name": "fluocinolone",
    "fda_search_term": "fluocinolone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DERMA-SMOOTHE/FS",
      "Fluocinolone Acetonide",
      "Fluocinolone Acetonide Oil"
    ],
    "generic_names": [
      "FLUOCINOLONE ACETONIDE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Royal Pharmaceuticals",
      "Sun Pharmaceutical Industries, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings",
      "These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses"
    ]
  },
  "fluocinonide": {
    "ingredient": "fluocinonide",
    "is_drug": true,
    "canonical_name": "fluocinonide",
    "fda_search_term": "fluocinonide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLUOCINONIDE",
      "Fluocinonide"
    ],
    "generic_names": [
      "FLUOCINONIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Sun Pharmaceutical Industries, Inc.",
      "Zydus Lifesciences Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings",
      "These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fluocinonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses"
    ]
  },
  "fluorescein sodium": {
    "ingredient": "fluorescein sodium",
    "is_drug": true,
    "canonical_name": "fluorescein",
    "fda_search_term": "fluorescein",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dry Eye Test",
      "Fluorescein",
      "Fluorescein Sodium and Benoxinate Hydrochloride"
    ],
    "generic_names": [
      "FLUORESCEIN",
      "FLUORESCEIN SODIUM",
      "FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Bausch & Lomb Incorporated",
      "Nexus Pharmaceuticals LLC",
      "Nomax Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most common adverse reactions include skin discoloration, urine discoloration, nausea, vomiting, and gastrointestinal distress",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lambda Therapeutics Limited at 1-855-642-2594or email: safety.nexuspharma@lambda-cro.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ( 6 ) 6.1 Skin and urine discoloration The most common reaction is discoloration of the skin and urine",
      "Skin will attain a temporary ye lowish discoloration",
      "Urine attains a bright ye llow color",
      "Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours",
      "6.2 Gastrointestinal Reaction The next most common adverse reaction is nausea",
      "Vomiting, and gastrointestinal distress have also occurred",
      "A strong taste may develop after injection",
      "6.3 Hypersensitivity Reactions Symptoms and signs of hypersensitivity have occurred",
      "Generalized hives and itching, bronchospasm and anaphylaxis have been reported",
      "[see CONTRAINDICATIONS ( 4.1 ) and WARNINGS AND PRECAUTIONS ( 5.1 )] ",
      "6.4 Cardiopulmonary Reactions Syncope and hypotension may occur",
      "Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely [see WARNINGS AND PRECAUTIONS ( 5.1 )] ",
      "6.5 Neurologic Reactions Headache may occur",
      "Convulsions may rarely occur following injection"
    ],
    "indications": [
      "INDICATIONS For testing tear film stability by determining the fluorescein break-up time (FBUT)"
    ]
  },
  "fluoride": {
    "ingredient": "fluoride",
    "is_drug": true,
    "canonical_name": "fluoride",
    "fda_search_term": "fluoride",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aluminium Fluoratum",
      "Anticavity Rinse",
      "Prime Tooth Care Hami Melon"
    ],
    "generic_names": [
      "ALUMINIUM FLUORATUM",
      "SODIUM FLUORIDE"
    ],
    "manufacturers": [
      "Hahnemann Laboratories, INC.",
      "Meijer, Inc.",
      "Prime Tooth Care LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings for this product"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse reactions Distributed By Meijer Distribution, Inc",
      "Grand Rapids, MI 49544 www.meijer.com Our Quality Guarantee www.meijer.com/satisfcation Discard Seal, Empty & Replace Cap PLASTIC BOTTLE how2recycle.info"
    ],
    "indications": [
      "Use aids in the prevention of dental cavities"
    ]
  },
  "fluorometholone": {
    "ingredient": "fluorometholone",
    "is_drug": true,
    "canonical_name": "fluorometholone",
    "fda_search_term": "fluorometholone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLUOROMETHOLONE",
      "FML FORTE",
      "Flarex"
    ],
    "generic_names": [
      "FLUOROMETHOLONE",
      "FLUOROMETHOLONE ACETATE"
    ],
    "manufacturers": [
      "Allergan, Inc.",
      "Eyevance Pharmaceuticals",
      "Pacific Pharma, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS FOR TOPICAL OPHTHALMIC USE",
      "NOT FOR INJECTION",
      "Use in the treatment of herpes simplex infection requires great caution",
      "Prolonged use may result in glaucoma, damage to the optic nerve, defect in visual acuity and visual field, cataract formation and/or may aid in the establishment of secondary ocular infections from pathogens due to suppression of host response",
      "Acute purulent infections of the eye may be masked or exacerbated by presence of steroid medication",
      "Topical ophthalmic corticosteroids may slow corneal wound healing",
      "In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with chronic use of topical steroids",
      "If these products are used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur",
      "Postmarketing Experience The following reaction has been identified during post-marketing use of FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1% in clinical practice",
      "Because reactions are reported voluntarily from a population of unknown size, estimates of frequency cannot be made",
      "The reaction, which has been chosen for inclusion due to either its seriousness, frequency of reporting, possible causal connection to FLAREX, or a combination of these factors, includes: dysgeusia",
      "The following rare adverse reactions have been reported: Cushing's syndrome and adrenal suppression may occur after very frequent use of topical ophthalmic corticosteroids, particularly in very young children"
    ],
    "indications": [
      "INDICATIONS AND USAGE FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye"
    ]
  },
  "fluorouracil": {
    "ingredient": "fluorouracil",
    "is_drug": true,
    "canonical_name": "fluorouracil",
    "fda_search_term": "fluorouracil",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLUOROURACIL",
      "Fluorouracil"
    ],
    "generic_names": [
      "FLUOROURACIL"
    ],
    "manufacturers": [
      "Eugia US LLC",
      "Mayne Pharma Inc.",
      "Xiromed LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration",
      "Additionally, cases of miscarriage and a birth defect (ventricular septal defect) have been reported when Fluorouracil Cream was applied to mucous membrane areas during pregnancy",
      "Occlusion of the skin with resultant hydration has been shown to increase percutaneous penetration of several topical preparations",
      "If any occlusive dressing is used in treatment of basal cell carcinoma, there may be an increase in the severity of inflammatory reactions in the adjacent normal skin",
      "A porous gauze dressing may be applied for cosmetic reasons without increase in reaction",
      "Exposure to ultraviolet rays should be minimized during and immediately following treatment with Fluorouracil Cream because the intensity of the reaction may be increased",
      "Patients should discontinue therapy with Fluorouracil Cream if symptoms of DPD enzyme deficiency develop (see CONTRAINDICATIONS )",
      "Rarely, life-threatening toxicities such as stomatitis, diarrhea, neutropenia, and neurotoxicity have been reported with intravenous administration of fluorouracil in patients with DPD enzyme deficiency",
      "One case of life-threatening systemic toxicity has been reported with the topical use of Fluorouracil Cream in a patient with DPD enzyme deficiency",
      "Symptoms included severe abdominal pain, bloody diarrhea, vomiting, fever, and chills"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Anticoagulants and CYP 2C9 Substrates Elevated coagulation times have been reported in patients taking fluorouracil concomitantly with warfarin",
      "While pharmacokinetic data are not available to assess the effect of fluorouracil administration on warfarin pharmacokinetics, the elevation of coagulation times that occurs with the fluorouracil prodrug capecitabine is accompanied by an increase in warfarin concentrations",
      "Thus, the interaction may be due to inhibition of cytochrome P450 2C9 by fluorouracil or its metabolites"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions to Fluorouracil Cream occur locally and are often related to an extension of the pharmacological activity of the drug",
      "These include burning, crusting, allergic contact dermatitis, pruritus, scarring, rash, soreness, and ulceration",
      "Ulcerations, other local reactions, cases of miscarriage, and a birth defect (ventricular septal defect) have been reported when Fluorouracil Cream was applied to mucous membrane areas",
      "Leukocytosis is the most frequent hematological side effect",
      "Although a causal relationship is remote, other adverse reactions which have been reported infrequently are: Central Nervous System: Emotional upset, insomnia, irritability",
      "Gastrointestinal: Medicinal taste, stomatitis",
      "Hematological: Eosinophilia, thrombocytopenia, toxic granulation",
      "Integumentary: Alopecia, blistering, bullous pemphigoid, discomfort, ichthyosis, scaling, suppuration, swelling, telangiectasia, tenderness, urticaria, skin rash",
      "Special Senses: Conjunctival reaction, corneal reaction, lacrimation, nasal irritation",
      "Miscellaneous: Herpes simplex",
      "To report SUSPECTED ADVERSE REACTIONS contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fluorouracil Cream is recommended for the topical treatment of multiple actinic or solar keratoses",
      "In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites",
      "Safety and efficacy in other indications have not been established",
      "The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas",
      "With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%"
    ]
  },
  "fluoxetine": {
    "ingredient": "fluoxetine",
    "is_drug": true,
    "canonical_name": "fluoxetine",
    "fda_search_term": "fluoxetine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluoxetine",
      "Fluoxetine HCL"
    ],
    "generic_names": [
      "FLUOXETINE HCL",
      "FLUOXETINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Direct_Rx"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.) is a possibility",
      "Monoamine Oxidase Inhibitors (MAOIs): ( 2.9 , 2.10 , 4.1 , 5.2 ) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway ( 7.7 ) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinu",
      "further psychomotor performance decrement due to increased levels ( 7.7 ) Antipsychotics: Potential for elevation of haloperidol and clozapine levels ( 7.7 ) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity ( 7.7 ) Serotonergic Drugs: ( ",
      "NSAIDs, Aspirin, Warfarin): May potentiate the risk of bleeding ( 7.4 ) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations ( 7.6 , 7.7 ) Olanzapine: When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for Symbyax",
      "Use with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.11 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) [see Dosage and Administration (2.9, 2.10) , Contraindications (4.1) , and Warnings and Precautions (5.2) ]",
      "7.2 CNS Acting Drugs Caution is advised if the concomitant administration of fluoxetine and such drugs is required",
      "In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of c"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings and Precautions (5.1) ] Serotonin Syndrome [see Warnings and Precautions (5.2",
      "Most common adverse reactions (≥5% and at least twice that for placebo) associated with: Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia, and Panic Disorder: abnormal dreams, abnormal ejaculation, anorexia, anxiety, asthenia, diarrhea, dry mouth, dyspepsia, flu syndrome, impotence,",
      "at 1-800-385-1540 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fluoxetine is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] ",
      "Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] ",
      "Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] ",
      "Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] ",
      "Fluoxetine and Olanzapine in Combination is indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder"
    ]
  },
  "fluphenazine": {
    "ingredient": "fluphenazine",
    "is_drug": true,
    "canonical_name": "fluphenazine",
    "fda_search_term": "fluphenazine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluphenazine Decanoate",
      "Fluphenazine Hydrochloride"
    ],
    "generic_names": [
      "FLUPHENAZINE DECANOATE",
      "FLUPHENAZINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Hikma Pharmaceuticals USA Inc.",
      "PAI Holdings, LLC dba PAI Pharma",
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death",
      "Fluphenazine Hydrochloride Oral Solution USP (Concentrate) is not approved for the treatment of patients with dementia-related psychosis ( see BOXED WARNING )",
      "Tardive Dyskinesia Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with neuroleptic (antipsychotic) drugs",
      "Although the prevalence of the syndrome appears to be the highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of neuroleptic treatment, which patients are likely to develop the syndrome",
      "Whether neuroleptic drug products differ in their potential to cause tardive dyskinesia is unknown",
      "Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of neuroleptic drugs administered to the patient increase",
      "However, the syndrome can develop although much less commonly, after relatively brief treatment periods at low doses",
      "There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if neuroleptic treatment is withdrawn",
      "Neuroleptic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying disease process",
      "The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Central Nervous System The side effects most frequently reported with phenothiazine compounds are extrapyramidal symptoms including pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia",
      "Most often these extrapyramidal symptoms are reversible; however, they may be persistent (see below)",
      "With any given phenothiazine derivative, the incidence and severity of such reactions depend more on individual patient sensitivity than on other factors, but dosage level and patient age are also determinants",
      "Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment",
      "Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue",
      "While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs",
      "An elevated risk of acute dystonia is observed in males and younger age groups",
      "Extrapyramidal reactions may be alarming, and the patient should be forewarned and reassured",
      "These reactions can usually be controlled by administration of antiparkinsonian drugs such as Benztropine Mesylate or Intravenous Caffeine and Sodium Benzoate Injection, and by subsequent reduction in dosage",
      "Tardive Dyskinesia (See WARNINGS ) ",
      "The syndrome is characterized by involuntary choreoathetoid movements which variously involve the tongue, face, mouth, lips, or jaw (e.g., protrusion of the tongue, puffing of cheeks, puckering of the mouth, chewing movements), trunk and extremities",
      "The severity of the syndrome and the degree of impairment produced vary widely",
      "The syndrome may become clinically recognizable either during treatment, upon dosage reduction, or upon withdrawal of treatment",
      "Early detection of tardive dyskinesia is imp"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fluphenazine hydrochloride is indicated in the management of manifestations of psychotic disorders",
      "Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation"
    ]
  },
  "flurbiprofen": {
    "ingredient": "flurbiprofen",
    "is_drug": true,
    "canonical_name": "flurbiprofen",
    "fda_search_term": "flurbiprofen",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Flurbiprofen",
      "Flurbiprofen Sodium",
      "Rinol-STroche"
    ],
    "generic_names": [
      "FLUBIPROFEN",
      "FLURBIPROFEN",
      "FLURBIPROFEN SODIUM"
    ],
    "manufacturers": [
      "Bausch & Lomb Incorporated",
      "Genus Lifesciences",
      "Lydia Co., Ltd."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation",
      "There have been reports that flurbiprofen sodium ophthalmic solution may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery",
      "There is the potential for cross-sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs",
      "Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs"
    ],
    "drug_interactions": [
      "Drug Interactions Interaction of flurbiprofen sodium ophthalmic solution with other topical ophthalmic medications has not been fully investigated",
      "Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when use"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of flurbiprofen sodium ophthalmic solution",
      "Other adverse reactions reported with the use of flurbiprofen sodium ophthalmic solution include: fibrosis, hyphema, miosis, mydriasis, and ocular hyperemia",
      "Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported [see Warnings ]",
      "To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Flurbiprofen sodium ophthalmic solution is indicated for the inhibition of intraoperative miosis"
    ]
  },
  "fluride": {
    "ingredient": "fluride",
    "is_drug": true,
    "canonical_name": "fluoride",
    "fda_search_term": "fluoride",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aluminium Fluoratum",
      "Anticavity Rinse",
      "Prime Tooth Care Hami Melon"
    ],
    "generic_names": [
      "ALUMINIUM FLUORATUM",
      "SODIUM FLUORIDE"
    ],
    "manufacturers": [
      "Hahnemann Laboratories, INC.",
      "Meijer, Inc.",
      "Prime Tooth Care LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings for this product"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse reactions Distributed By Meijer Distribution, Inc",
      "Grand Rapids, MI 49544 www.meijer.com Our Quality Guarantee www.meijer.com/satisfcation Discard Seal, Empty & Replace Cap PLASTIC BOTTLE how2recycle.info"
    ],
    "indications": [
      "Use aids in the prevention of dental cavities"
    ]
  },
  "fluroide": {
    "ingredient": "fluroide",
    "is_drug": true,
    "canonical_name": "fluoride",
    "fda_search_term": "fluoride",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aluminium Fluoratum",
      "Anticavity Rinse",
      "Prime Tooth Care Hami Melon"
    ],
    "generic_names": [
      "ALUMINIUM FLUORATUM",
      "SODIUM FLUORIDE"
    ],
    "manufacturers": [
      "Hahnemann Laboratories, INC.",
      "Meijer, Inc.",
      "Prime Tooth Care LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings for this product"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse reactions Distributed By Meijer Distribution, Inc",
      "Grand Rapids, MI 49544 www.meijer.com Our Quality Guarantee www.meijer.com/satisfcation Discard Seal, Empty & Replace Cap PLASTIC BOTTLE how2recycle.info"
    ],
    "indications": [
      "Use aids in the prevention of dental cavities"
    ]
  },
  "flurouracil": {
    "ingredient": "flurouracil",
    "is_drug": true,
    "canonical_name": "fluorouracil",
    "fda_search_term": "fluorouracil",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FLUOROURACIL",
      "Fluorouracil"
    ],
    "generic_names": [
      "FLUOROURACIL"
    ],
    "manufacturers": [
      "Eugia US LLC",
      "Mayne Pharma Inc.",
      "Xiromed LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration",
      "Additionally, cases of miscarriage and a birth defect (ventricular septal defect) have been reported when Fluorouracil Cream was applied to mucous membrane areas during pregnancy",
      "Occlusion of the skin with resultant hydration has been shown to increase percutaneous penetration of several topical preparations",
      "If any occlusive dressing is used in treatment of basal cell carcinoma, there may be an increase in the severity of inflammatory reactions in the adjacent normal skin",
      "A porous gauze dressing may be applied for cosmetic reasons without increase in reaction",
      "Exposure to ultraviolet rays should be minimized during and immediately following treatment with Fluorouracil Cream because the intensity of the reaction may be increased",
      "Patients should discontinue therapy with Fluorouracil Cream if symptoms of DPD enzyme deficiency develop (see CONTRAINDICATIONS )",
      "Rarely, life-threatening toxicities such as stomatitis, diarrhea, neutropenia, and neurotoxicity have been reported with intravenous administration of fluorouracil in patients with DPD enzyme deficiency",
      "One case of life-threatening systemic toxicity has been reported with the topical use of Fluorouracil Cream in a patient with DPD enzyme deficiency",
      "Symptoms included severe abdominal pain, bloody diarrhea, vomiting, fever, and chills"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Anticoagulants and CYP 2C9 Substrates Elevated coagulation times have been reported in patients taking fluorouracil concomitantly with warfarin",
      "While pharmacokinetic data are not available to assess the effect of fluorouracil administration on warfarin pharmacokinetics, the elevation of coagulation times that occurs with the fluorouracil prodrug capecitabine is accompanied by an increase in warfarin concentrations",
      "Thus, the interaction may be due to inhibition of cytochrome P450 2C9 by fluorouracil or its metabolites"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions to Fluorouracil Cream occur locally and are often related to an extension of the pharmacological activity of the drug",
      "These include burning, crusting, allergic contact dermatitis, pruritus, scarring, rash, soreness, and ulceration",
      "Ulcerations, other local reactions, cases of miscarriage, and a birth defect (ventricular septal defect) have been reported when Fluorouracil Cream was applied to mucous membrane areas",
      "Leukocytosis is the most frequent hematological side effect",
      "Although a causal relationship is remote, other adverse reactions which have been reported infrequently are: Central Nervous System: Emotional upset, insomnia, irritability",
      "Gastrointestinal: Medicinal taste, stomatitis",
      "Hematological: Eosinophilia, thrombocytopenia, toxic granulation",
      "Integumentary: Alopecia, blistering, bullous pemphigoid, discomfort, ichthyosis, scaling, suppuration, swelling, telangiectasia, tenderness, urticaria, skin rash",
      "Special Senses: Conjunctival reaction, corneal reaction, lacrimation, nasal irritation",
      "Miscellaneous: Herpes simplex",
      "To report SUSPECTED ADVERSE REACTIONS contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fluorouracil Cream is recommended for the topical treatment of multiple actinic or solar keratoses",
      "In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites",
      "Safety and efficacy in other indications have not been established",
      "The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas",
      "With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%"
    ]
  },
  "flutamide": {
    "ingredient": "flutamide",
    "is_drug": true,
    "canonical_name": "flutamide",
    "fda_search_term": "flutamide",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Eulexin"
    ],
    "generic_names": [
      "FLUTAMIDE"
    ],
    "manufacturers": [
      "Waylis Therapeutics LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Hepatic Injury SEE BOXED WARNINGS Use in Women Eulexin ® capsules are for use only in men",
      "This product has no indication for women and should not be used in this population, particularly for nonserious or nonlife-threatening conditions",
      "Fetal toxicity Eulexin ® may cause fetal harm when administered to a pregnant woman (see Pregnancy )",
      "Aniline toxicity One metabolite of Eulexin ® is 4-nitro-3-fluoro-methylaniline",
      "Several toxicities consistent with aniline exposure, including methemoglobinemia, hemolytic anemia and cholestatic jaundice have been observed in both animals and humans after Eulexin ® administration",
      "In patients susceptible to aniline toxicity (e.g",
      "persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered"
    ],
    "drug_interactions": [
      "Drug Interactions Increases in prothrombin time have been noted in patients receiving long-term warfarin therapy after Eulexin ® was initiated",
      "Therefore close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when Eulexin ® capsules are administered concomitantly with warfarin"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant did not add substantially to the toxicity of radiation treatment alone",
      "The following adverse experiences were reported during a multicenter clinical trial comparing Eulexin ® + goserelin acetate implant + radiation versus radiation alone",
      "The most frequently reported (greater than 5%) adverse experiences are listed below: Adverse Events During Acute Radiation Therapy (within first 90 days of radiation therapy) (n=231) Goserelin Acetate Implant + Eulexin ® + Radiation (n=235) Radiation Only % All % All Rectum/Large Bowel 80 76 Bladder",
      "Adverse experiences occurring in more than 5% of patients in this group, over both parts of the study, were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%)",
      "Stage D 2 Metastatic Carcinoma The following adverse experiences were reported during a multicenter clinical trial comparing Eulexin ® + LHRH agonist versus placebo + LHRH agonist",
      "The most frequently reported (greater than 5%) adverse experiences during treatment with Eulexin ® capsules in combination with an LHRH agonist are listed in the table below",
      "For comparison, adverse experiences seen with an LHRH agonist and placebo are also listed in the following table",
      "(n=294) Eulexin ® + LHRH agonist (n=28) Placebo + LHRH agonist % All % All Hot Flashes 61 57 Loss of Libido 36 31 Impotence 33 29 Diarrhea 12 4 Nausea/Vomiting 11 10 Gynecomastia 9 11 Other 7 9 Other GI 6 4 As shown in the table, for bot"
    ],
    "indications": [
      "INDICATIONS AND USAGE Eulexin ® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate",
      "Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation therapy and continue during radiation therapy",
      "Stage D 2 Metastatic Carcinoma To achieve benefit from treatment, Eulexin ® capsules should be initiated with the LHRH-agonist and continued until progression"
    ]
  },
  "fluticasone": {
    "ingredient": "fluticasone",
    "is_drug": true,
    "canonical_name": "fluticasone",
    "fda_search_term": "fluticasone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluticasone Propionate"
    ],
    "generic_names": [
      "FLUTICASONE PROPIONATE",
      "FLUTICASONE PROPIONATE NASAL"
    ],
    "manufacturers": [
      "Advagen Pharma Ltd.",
      "Bryant Ranch Prepack",
      "Sam's West Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Only for use in the nose",
      "Do not spray into your eyes or mouth"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Clinical Trial Experience",
      "In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of fluticasone propionate cream, 0.05% was approximately 4%",
      "These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning",
      "These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively",
      "Two clinical studies compared once",
      "to twice-daily administration of fluticasone propionate cream, 0.05% for the treatment of moderate to severe eczema",
      "The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1",
      "In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years",
      "Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study",
      "Fluticasone propionate cream, 0.05% was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%)",
      "The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) show",
      "In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were ≤18 μg/dL, indicating adrenal suppression",
      "Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis",
      "Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky ery"
    ],
    "indications": [
      "Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing"
    ]
  },
  "fluticasone furoate": {
    "ingredient": "fluticasone furoate",
    "is_drug": true,
    "canonical_name": "fluticasone furoate",
    "fda_search_term": "fluticasone furoate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Arnuity Ellipta",
      "FLONASE SENSIMIST ALLERGY RELIEF",
      "Fluticasone Furoate and Vilanterol"
    ],
    "generic_names": [
      "FLUTICASONE FUROATE",
      "FLUTICASONE FUROATE AND VILANTEROL"
    ],
    "manufacturers": [
      "GlaxoSmithKline LLC",
      "Haleon US Holdings LLC",
      "Prasco Laboratories"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Only for use in the nose",
      "Do not spray into your eyes or mouth",
      "in children under 2 years of age",
      "if you have an injury or surgery to your nose that is not fully healed",
      "if you have ever had an allergic reaction to this product or any of the ingredients Ask a doctor before use if you have or had glaucoma or cataracts Ask a doctor or pharmacist before use if you are taking",
      "medicine for HIV infection (such as ritonavir)",
      "a steroid medicine for asthma, allergies or skin rash",
      "ketoconazole pills (medicine for fungal infection) When using this product",
      "the growth rate of some children may be slower",
      "stinging or sneezing may occur for a few seconds right after use"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution",
      "May cause systemic corticosteroid and cardiovascular effects",
      "Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution",
      "May potentiate effect of vilanterol on cardiovascular system",
      "Beta-blockers: Use with caution",
      "May block bronchodilatory effects of beta-agonists and produce severe bronchospasm",
      "Diuretics: Use with caution",
      "Electrocardiographic changes and/or hypokalemia associated with non–potassium-sparing diuretics may worsen with concomitant beta-agonists",
      "( 7.4 ) 7.1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are both substrates of CYP3A4"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling:",
      "Serious Asthma-Related Events – Hospitalizations, Intubations, Death [see Warnings and Precautions ( 5.1 )]",
      "Oropharyngeal Candidiasis [see Warnings and Precautions ( 5.4 )]",
      "Pneumonia [see Warnings and Precautions ( 5.5 )]",
      "Immunosuppression and Risk of Infections [see Warnings and Precautions ( 5.6 )]",
      "Hypercorticism and Adrenal Suppression [see Warnings and Precautions ( 5.8 )]",
      "Paradoxical Bronchospasm [see Warnings and Precautions ( 5.10 )]",
      "Cardiovascular Effects [see Warnings and Precautions ( 5.12 )]",
      "Reduction in Bone Mineral Density [see Warnings and Precautions ( 5.13 )]",
      "Growth Effects [see Warnings and Precautions ( 5.14 )]",
      "Glaucoma and Cataracts [see Warnings and Precautions ( 5.15 )] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the",
      "COPD: Most common adverse reactions (incidence ≥3%) are nasopharyngitis, upper respiratory tract infection, headache, oral candidiasis, back pain, pneumonia, bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, hypertension, influenza, pharyngitis, and pyrexia",
      "Asthma: Most common adverse reactions (incidence ≥2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough",
      "( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Prasco Laboratories at 1-866-525-0688 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease The safety data described below are based on two 6-month and two 12-month trials and one long-term mortality trial"
    ],
    "indications": [
      "Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies:",
      "nasal congestion",
      "itchy, watery eyes (for ages 12 and older)"
    ]
  },
  "fluticasone propionate": {
    "ingredient": "fluticasone propionate",
    "is_drug": true,
    "canonical_name": "fluticasone",
    "fda_search_term": "fluticasone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluticasone Propionate"
    ],
    "generic_names": [
      "FLUTICASONE PROPIONATE",
      "FLUTICASONE PROPIONATE NASAL"
    ],
    "manufacturers": [
      "Advagen Pharma Ltd.",
      "Bryant Ranch Prepack",
      "Sam's West Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Only for use in the nose",
      "Do not spray into your eyes or mouth"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Clinical Trial Experience",
      "In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of fluticasone propionate cream, 0.05% was approximately 4%",
      "These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning",
      "These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively",
      "Two clinical studies compared once",
      "to twice-daily administration of fluticasone propionate cream, 0.05% for the treatment of moderate to severe eczema",
      "The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1",
      "In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years",
      "Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study",
      "Fluticasone propionate cream, 0.05% was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%)",
      "The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) show",
      "In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were ≤18 μg/dL, indicating adrenal suppression",
      "Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis",
      "Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky ery"
    ],
    "indications": [
      "Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing"
    ]
  },
  "fluvastatin": {
    "ingredient": "fluvastatin",
    "is_drug": true,
    "canonical_name": "fluvastatin",
    "fda_search_term": "fluvastatin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluvastatin",
      "Fluvastatin Sodium"
    ],
    "generic_names": [
      "FLUVASTATIN",
      "FLUVASTATIN SODIUM"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Lannett Company, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Cyclosporine: Combination increases fluvastatin exposure",
      "Limit fluvastatin dose to 20 mg ( 2.4 , 7.1 ) Fluconazole: Combination increases fluvastatin exposure",
      "Limit fluvastatin dose to 20 mg ( 2.5 , 7.2 ) Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥ 1 g/day) of niacin increases the risk of adverse skeletal muscle effects",
      "Caution should be used when prescribing with fluvastatin ( 5.1 , 7.3 , 7.4 ) Glyburide: Monitor blood glucose levels when fluvastatin dose is changed ( 7 ) Phenytoin: Monitor plasma phenytoin levels when fluvastatin treatment is initiated or when the dosage is changed ( 7 ) Warfarin and coumarin der",
      "Therefore, in patients taking cyclosporine, therapy should be limited to fluvastatin 20 mg twice daily [see Warnings and Precautions ( 5.1 ) and Clinical Pharmacology ( 12.3 )]",
      "7.2 Fluconazole Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with fluconazole for 4 days results in an increase of fluvastatin exposure",
      "Therefore, in patients taking fluconazole, therapy should be limited to fluvastatin 20 mg twice daily [see Clinical Pharmacology ( 12.3 )]",
      "7.3 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of fluvastatin sodium with gemfibrozil should be avoided",
      "7.4 Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, fluvastatin sodium should be administered with caution when used concomitantly with other fibrates [see Warnings and Prec",
      "7.5 Niacin The risk of skeletal muscle effe"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [ see Warnings and Precautions ( 5.1 ) ]",
      "Liver Enzyme Abnormalities [ see Warnings and Precautions ( 5.3 ) ]",
      "Most frequent adverse reactions (rate ≥ 2% and > placebo) are: headache, dyspepsia, myalgia, abdominal pain and nausea ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Studies Experience in Adult Patients Because clinical studies on fluvastatin capsules are conducted in varying study populations and study designs, the frequency of adverse reactions observed in the clinical studies of fluvastatin capsules cannot be directly compared with that in the cl",
      "In the fluvastatin capsules placebo-controlled clinical trials database of 2326 patients treated with fluvastatin capsules 1 (age range 18 to 75 years, 44% women, 94% Caucasians, 4% Blacks, 2% other ethnicities) with a median treatment duration of 24 weeks, 3.4% of patients on fluvastatin capsules a",
      "The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: transaminase increased (0.8%), upper abdominal pain (0.3%), dyspepsia (0.3%), fatigue (0.2%) and diarrhea (0.2%)",
      "Clinically relevant adverse experiences occurring in the fluvastatin capsules controlled studies with a frequency ≥ 2%, regardless of causality, included the following: Table 1: Clinical Adverse Events Reported in > 2% in Patients Treated With Fluvastatin Capsules and at an Incidence Greater Than Pl"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia",
      "Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate",
      "Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( 1.1 ) Reduce elevated TC, LDL-C, and Apo B leve",
      "( 1.3 ) 1.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia Fluvastatin capsules are indicated as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein B (Apo B) levels,",
      "as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: LDL-C remains ≥ 1"
    ]
  },
  "fluvoxamine maleate": {
    "ingredient": "fluvoxamine maleate",
    "is_drug": true,
    "canonical_name": "fluvoxamine",
    "fda_search_term": "fluvoxamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluvoxamine Maleate",
      "Fluvoxamine maleate"
    ],
    "generic_names": [
      "FLUVOXAMINE MALEATE"
    ],
    "manufacturers": [
      "Ajanta Pharma USA Inc.",
      "Bionpharma Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Drug Interactions (not described in Contraindications or Warnings and Precautions) include the following: Drugs Inhibiting or Metabolized by Cytochrome P450: Fluvoxamine inhibits several cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP3A4, and CYP2C19) ( 7.1 ) ",
      "Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity with coadministration ( 7.2 ) ",
      "Sumatriptan: Rare postmarketing reports of weakness, hyperreflexia, and incoordination following use of an SSRI and sumatriptan",
      "Monitor appropriately if concomitant treatment is clinically warranted ( 7.2 ) ",
      "Tacrine: Coadministration increased tacrine C max and AUC five-and eight-fold and caused nausea, vomiting, sweating, and diarrhea ( 7.2 ) ",
      "Tricyclic Antidepressants (TCAs): Coadministration significantly increased plasma TCA levels",
      "Use caution; monitor plasma TCA levels; reduce TCA dose if indicated ( 7.2 ) ",
      "Tryptophan: Severe vomiting with coadministration ( 7.2 ) ",
      "Diltiazem: Bradycardia with coadministration ( 7.3 ) ",
      "Propranolol or Metoprolol: Reduce dose if coadministered with fluvoxamine and titrate more cautiously ( 7.3 ) "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice",
      "Most common reactions in controlled trials with OCD patients and patients from another studied population (incidence ≥5% and at least twice that for placebo) were abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating and tremor ( 6.2 ) ",
      "The following additional reactions occurred: anxiety, decreased libido, myalgia, pharyngitis, and vomiting in the OCD population; and dyspepsia, dizziness, insomnia, and yawning in another studied population",
      "To report SUSPECTED ADVERSE REACTIONS, contact Ajanta Pharma USA Inc., at 855-664-7744 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Data Sources Fluvoxamine maleate extended-release capsules were studied in one 12-week controlled trial in patients with OCD (N = 124; mean exposure 66.6 days) and in two 12-week controlled trials for another condition (N = 279; mean exposure 59.2 days)",
      "Patients in these trials were initiated on 100 mg/day and were titrated in 50 mg increments over the first 6 weeks to within a range of 100 mg/day to 300 mg/day",
      "The reactions listed in Table 2 show reactions from the two populations separately",
      "Table 3 shows reactions from the three controlled studies combined",
      "6.2 Adverse Reactions Observed in Controlled Trials Adverse Reactions Associated with Discontinuation of Treatment : Of the 124 patients with OCD and 279 patients in other studies treated with fluvoxamine maleate extended-release capsules in controlled clinical trials, 19% and 26% discontinued treat",
      "The most common reactions (≥1%) associated with discontinuation and considered to be drug related (i.e., those reactions associated with dropout at a rate at least"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fluvoxamine maleate extended-release capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD) ( 1 )",
      "Efficacy was demonstrated in: One 12-week study fluvoxamine maleate extended-release capsules in adults ( 14.1 )",
      "Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1 , 14.3 )",
      "One maintenance study with IR fluvoxamine tablets ( 14.2 )",
      "1.1 Obsessive Compulsive Disorder Fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM-IV"
    ]
  },
  "folate": {
    "ingredient": "folate",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "folic": {
    "ingredient": "folic",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "folic a": {
    "ingredient": "folic a",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "folic acid": {
    "ingredient": "folic acid",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "folic acid as dfe": {
    "ingredient": "folic acid as dfe",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "folicacid": {
    "ingredient": "folicacid",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "folinic acid": {
    "ingredient": "folinic acid",
    "is_drug": true,
    "canonical_name": "folinic acid",
    "fda_search_term": "folinic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "follic acid": {
    "ingredient": "follic acid",
    "is_drug": true,
    "canonical_name": "folic acid",
    "fda_search_term": "folic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Folic Acid",
      "Integra F",
      "PNV-DHA"
    ],
    "generic_names": [
      "ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, DL-, PYRIDOXINE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM, FERROUS FUMARATE, MAGNESIUM, DOCONEXENT",
      "FERROUS FUMARATE AND POLYSACCHRIDE IRON COMPLEX AND FOLIC ACID",
      "FOLIC ACID"
    ],
    "manufacturers": [
      "Acella Pharmaceuticals, LLC",
      "Northwind Health Company, LLC",
      "U.S. Pharmaceutical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR)",
      "Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid",
      "Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy",
      "Reducing the dose and administering it with meals will minimize these effects in the sensitive patient",
      "Increasing fiber in the diet can relieve constipation",
      "Iron may turn stools black",
      "This is a harmless effect that is a result of unabsorbed iron",
      "Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I",
      "Integra FTM is best absorbed when taken at bedtime"
    ],
    "indications": [
      "INDICATIONS: Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia",
      "Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid"
    ]
  },
  "follitropin alfa": {
    "ingredient": "follitropin alfa",
    "is_drug": true,
    "canonical_name": "follitropin-alfa",
    "fda_search_term": "follitropin-alfa",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gonal-f"
    ],
    "generic_names": [
      "FOLLITROPIN ALFA"
    ],
    "manufacturers": [
      "EMD Serono, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Reactions and Anaphylaxis [see Warnings and Precautions (5.1) ] Ovarian Hyperstimulation Syndrome [see Warnings and Precautions (5.2) ] Pulmonary and Vascular Complication [see Warni",
      "( 6.1 ) The most common adverse reactions (≥5%) in development of multiple follicles in ART include: headache, nausea, pelvic pain and abdominal pain",
      "( 6.1 ) The most common adverse reactions (>5%) in hypogonadotropic hypogonadal men participating in induction of spermatogenesis include: acne, injection site pain, fatigue, gynecomastia and seborrhea",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono at 1-800-283-8088, Ext 5563 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Study Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice",
      "Women: The safety of GONAL-f was examined in four clinical trials that enrolled 691 women [two trials for ovulation induction (454 women) and two trials for ART (237 women)]",
      "Induction of Ovulation In a randomized, open-labeled, multicenter, active-controlled trial in oligo-anovulatory"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE GONAL-f is indicated for: GONAL-f is a gonadotropin indicated for: Women: Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure",
      "( 1.1 ) Development of multiple follicles in ovulatory infertile women as part of Assisted Reproductive Technology (ART) cycles",
      "( 1.2 ) Men: Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure",
      "( 1.3 ) 1.1 Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure",
      "1.2 Development of multiple follicles in ovulatory infertile women as part of an assisted reproductive technology (ART) cycle"
    ]
  },
  "follitropin beta": {
    "ingredient": "follitropin beta",
    "is_drug": true,
    "canonical_name": "follitropin beta",
    "fda_search_term": "follitropin beta",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine",
      "Naproxen"
    ],
    "generic_names": [
      "NAPROXEN",
      "POVIDONE-IODINE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Atlantis Consumer Healthcare, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "Uses First aid to help prevent infection in minor cuts scrapes burns"
    ]
  },
  "fondaparinux sodiom": {
    "ingredient": "fondaparinux sodiom",
    "is_drug": true,
    "canonical_name": "fondaparinux",
    "fda_search_term": "fondaparinux",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fondaparinux Sodium",
      "fondaparinux sodium"
    ],
    "generic_names": [
      "FONDAPARINUX SODIUM"
    ],
    "manufacturers": [
      "Dr. Reddy's Laboratories Limited",
      "Italfarmaco S.p.A",
      "Mylan Institutional LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS In clinical studies performed with fondaparinux sodium, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium",
      "In addition, fondaparinux sodium neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state",
      "Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of therapy with fondaparinux sodium unless these agents are essential",
      "If co-administration is necessary, monitor patients closely for hemorrhage",
      "[See Warnings and Precautions ( 5.2 ) ] In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 micromolar i.e., 350 mg/L) was 17 to 28%",
      "Inhibition of the other isozymes evaluated (CYPs 1A2, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0 to 16%",
      "Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes",
      "Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected",
      "­ Discontinue agents that may enhance the risk of hemorrhage prior to initiation of therapy with fondaparinux sodium unless essential",
      "If co-administration is necessary,monitor patients closely for hemorrhage"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Spinal or epidural hematomas [see Warnings and Precautions ( 5.1 ) ]",
      "Hemorrhage [see Warnings and Precautions ( 5.2 )]",
      "Renal impairment and bleeding risk [see Warnings and Precautions ( 5.3 ) ]",
      "Body weight <50 kg and bleeding risk [see Warnings and Precautions ( 5.4 ) ]",
      "Thrombocytopenia [see Warnings and Precautions ( 5.5 ) ] The most serious adverse reactions associated with the use of fondaparinux sodium are bleeding complications",
      "( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Dr",
      "Reddy’s Laboratories, Inc",
      "at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of ano",
      "The adverse reaction information below is based on data from 8,877 patients exposed to fondaparinux sodium in controlled trials of hip fracture, hip replacement, major knee, or abdominal surgeries, and DVT and PE treatment",
      "Hemorrhage During administration of fondaparinux sodium, the most common adverse reactions were bleeding complications [see Warnings and Precautions ( 5.2 ) ]",
      "Hip Fracture, Hip Replacement, and Knee Replacement Surgery The rates of major bleeding events reported during 3 active-controlled peri-operative VTE prophylaxis trials with enoxaparin sodium in hip fracture, hip replacement, or knee replacement surgery (N = 3,616) and in an extended VTE prophylaxis",
      "Bleeding Across Randomized, Controlled Hip Fracture, Hip Replacement, and Knee Replacement Surgery Studies Peri-Operative Prophylaxis (Day 1 to Day 7 ± 1 post-surgery) Extended Prophylaxis (Day 8 to Day 28 ± 2 post-surgery"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surger",
      "(1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin",
      "( 1.2 , 1.3 ) 1.1 Prophylaxis of Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing hip fracture surgery, including extended prophylaxis; in patients undergoing hip repla",
      "1.2 Treatment of Acute Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium",
      "1.3 Treatment of Acute Pulmonary Embolism Fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital"
    ]
  },
  "fondaparinux sodium": {
    "ingredient": "fondaparinux sodium",
    "is_drug": true,
    "canonical_name": "fondaparinux",
    "fda_search_term": "fondaparinux",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fondaparinux Sodium",
      "fondaparinux sodium"
    ],
    "generic_names": [
      "FONDAPARINUX SODIUM"
    ],
    "manufacturers": [
      "Dr. Reddy's Laboratories Limited",
      "Italfarmaco S.p.A",
      "Mylan Institutional LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS In clinical studies performed with fondaparinux sodium, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium",
      "In addition, fondaparinux sodium neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state",
      "Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of therapy with fondaparinux sodium unless these agents are essential",
      "If co-administration is necessary, monitor patients closely for hemorrhage",
      "[See Warnings and Precautions ( 5.2 ) ] In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 micromolar i.e., 350 mg/L) was 17 to 28%",
      "Inhibition of the other isozymes evaluated (CYPs 1A2, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0 to 16%",
      "Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes",
      "Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected",
      "­ Discontinue agents that may enhance the risk of hemorrhage prior to initiation of therapy with fondaparinux sodium unless essential",
      "If co-administration is necessary,monitor patients closely for hemorrhage"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Spinal or epidural hematomas [see Warnings and Precautions ( 5.1 ) ]",
      "Hemorrhage [see Warnings and Precautions ( 5.2 )]",
      "Renal impairment and bleeding risk [see Warnings and Precautions ( 5.3 ) ]",
      "Body weight <50 kg and bleeding risk [see Warnings and Precautions ( 5.4 ) ]",
      "Thrombocytopenia [see Warnings and Precautions ( 5.5 ) ] The most serious adverse reactions associated with the use of fondaparinux sodium are bleeding complications",
      "( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Dr",
      "Reddy’s Laboratories, Inc",
      "at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of ano",
      "The adverse reaction information below is based on data from 8,877 patients exposed to fondaparinux sodium in controlled trials of hip fracture, hip replacement, major knee, or abdominal surgeries, and DVT and PE treatment",
      "Hemorrhage During administration of fondaparinux sodium, the most common adverse reactions were bleeding complications [see Warnings and Precautions ( 5.2 ) ]",
      "Hip Fracture, Hip Replacement, and Knee Replacement Surgery The rates of major bleeding events reported during 3 active-controlled peri-operative VTE prophylaxis trials with enoxaparin sodium in hip fracture, hip replacement, or knee replacement surgery (N = 3,616) and in an extended VTE prophylaxis",
      "Bleeding Across Randomized, Controlled Hip Fracture, Hip Replacement, and Knee Replacement Surgery Studies Peri-Operative Prophylaxis (Day 1 to Day 7 ± 1 post-surgery) Extended Prophylaxis (Day 8 to Day 28 ± 2 post-surgery"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surger",
      "(1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin",
      "( 1.2 , 1.3 ) 1.1 Prophylaxis of Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing hip fracture surgery, including extended prophylaxis; in patients undergoing hip repla",
      "1.2 Treatment of Acute Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium",
      "1.3 Treatment of Acute Pulmonary Embolism Fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital"
    ]
  },
  "formamol": {
    "ingredient": "formamol",
    "is_drug": true,
    "canonical_name": "formaldehyde",
    "fda_search_term": "formaldehyde",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Flu-Tone",
      "INFLUENZINUM",
      "Lycopodium Combination 9231"
    ],
    "generic_names": [
      "ANAS BARBARIAE, HEPATIS ET CORDIS EXTRACTUM, AZADIRACHTA INDICA, BAPTISIA TINCTORIA, BRYONIA (ALBA), CROTALUS HORRIDUS, ECHINACEA (ANGUSTIFOLIA), EUPATORIUM PERFOLIATUM, FERRUM PHOSPHORICUM, GELSEMIUM SEMPERVIRENS, GINKGO BILOBA, INFLUENZINUM, MUCOSA NASALIS SUIS, PHYTOLACCA DECANDRA, PINUS SYLVESTRIS, PYROGENIUM, SELENIUM METALLICUM, STILLINGIA SYLVATICA",
      "INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED),INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)",
      "LYCOPODIUM COMBINATION"
    ],
    "manufacturers": [
      "Boiron",
      "Energetix Corporation",
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS If symptoms do not improve or are accompanied by a fever, consult a doctor",
      "Keep out of the reach of children",
      "In case of overdose, get medical help or contact a poison control center right away",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep out of the reach of children",
      "If pregnant or breastfeeding, ask a healthcare professional before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For the temporary relief of loss of appetite, minor abdominal pain, nausea, or vomiting.*"
    ]
  },
  "formoterol": {
    "ingredient": "formoterol",
    "is_drug": true,
    "canonical_name": "formoterol",
    "fda_search_term": "formoterol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Budesonide and Formoterol Fumarate Dihydrate",
      "Formoterol Fumarate",
      "Formoterol fumarate"
    ],
    "generic_names": [
      "BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE",
      "FORMOTEROL FUMARATE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Alembic Pharmaceuticals Inc.",
      "Micro Labs Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Other adrenergic drugs may potentiate effect",
      "Use with caution",
      "( 5.3 , 7.1 ) Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes",
      "Use with caution",
      "( 5.7 , 7.2 , 7.3 ) MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system",
      "Use with extreme caution",
      "( 7.4 ) Beta-blockers may decrease effectiveness",
      "Use with caution and only when medically necessary",
      "( 7.5 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol may be potentiated [see WARNINGS AND PRECAUTIONS ( 5.3 , 5.5 , 5.6 , 5.7 )]",
      "7.2 Xanthine Derivatives, Steroids, or Diuretics Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists [see WARNINGS AND PRECAUTIONS ( 5.7 )]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Long-acting beta 2 -adrenergic agonists, such as formoterol fumarate, as monotherapy (without an inhaled corticosteroid) for asthma increase the risk of asthma-related events",
      "Formoterol fumarate is not indicated for the treatment of asthma [see WARNINGS AND PRECAUTIONS ( 5.1 )]",
      "Most common adverse reactions ( > 2% and more common than placebo) are diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA Inc., at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Beta 2 -Agonist Adverse Reaction Profile Adverse reactions to formoterol fumarate inhalation solution are expected to be similar in nature to other beta 2 -adrenergic receptor agonists including: angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mo",
      "6.2 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults with COPD The data described below reflect exposure to formoterol fumarate inhalation solution 20 mcg twice daily by oral inhalation in 586 patients, including 232 exposed for 6 months and 155 exposed for at least 1 year",
      "Formoterol fumarate inhalation solution was studied in a 12-week, placebo-and active-controlled trial (123 subjects treated with formoterol fumarate inhalation solution) and a 52-week, active-controlled trial (463 subjects treated with formoterol fumarate inhalation solution)",
      "Patients were mostly Caucasians (88%) between 40 to 90 years old (mean, 64 years old) and had COPD, with a mean FEV 1 of 1.33 L",
      "Patients with significant concurrent car"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary ",
      "( 1.1 ) Important limitations of use: Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease",
      "( 1.2 , 5.2 ) Formoterol fumarate inhalation solution is not indicated to treat asthma",
      "( 1.2 ) 1.1 Maintenance Treatment of COPD Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bron",
      "1.2 Important Limitations of Use Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS ( 5.2 )]"
    ]
  },
  "formoterol fumarate": {
    "ingredient": "formoterol fumarate",
    "is_drug": true,
    "canonical_name": "formoterol",
    "fda_search_term": "formoterol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Budesonide and Formoterol Fumarate Dihydrate",
      "Formoterol Fumarate",
      "Formoterol fumarate"
    ],
    "generic_names": [
      "BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE",
      "FORMOTEROL FUMARATE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Alembic Pharmaceuticals Inc.",
      "Micro Labs Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Other adrenergic drugs may potentiate effect",
      "Use with caution",
      "( 5.3 , 7.1 ) Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes",
      "Use with caution",
      "( 5.7 , 7.2 , 7.3 ) MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system",
      "Use with extreme caution",
      "( 7.4 ) Beta-blockers may decrease effectiveness",
      "Use with caution and only when medically necessary",
      "( 7.5 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol may be potentiated [see WARNINGS AND PRECAUTIONS ( 5.3 , 5.5 , 5.6 , 5.7 )]",
      "7.2 Xanthine Derivatives, Steroids, or Diuretics Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists [see WARNINGS AND PRECAUTIONS ( 5.7 )]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Long-acting beta 2 -adrenergic agonists, such as formoterol fumarate, as monotherapy (without an inhaled corticosteroid) for asthma increase the risk of asthma-related events",
      "Formoterol fumarate is not indicated for the treatment of asthma [see WARNINGS AND PRECAUTIONS ( 5.1 )]",
      "Most common adverse reactions ( > 2% and more common than placebo) are diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA Inc., at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Beta 2 -Agonist Adverse Reaction Profile Adverse reactions to formoterol fumarate inhalation solution are expected to be similar in nature to other beta 2 -adrenergic receptor agonists including: angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mo",
      "6.2 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults with COPD The data described below reflect exposure to formoterol fumarate inhalation solution 20 mcg twice daily by oral inhalation in 586 patients, including 232 exposed for 6 months and 155 exposed for at least 1 year",
      "Formoterol fumarate inhalation solution was studied in a 12-week, placebo-and active-controlled trial (123 subjects treated with formoterol fumarate inhalation solution) and a 52-week, active-controlled trial (463 subjects treated with formoterol fumarate inhalation solution)",
      "Patients were mostly Caucasians (88%) between 40 to 90 years old (mean, 64 years old) and had COPD, with a mean FEV 1 of 1.33 L",
      "Patients with significant concurrent car"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary ",
      "( 1.1 ) Important limitations of use: Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease",
      "( 1.2 , 5.2 ) Formoterol fumarate inhalation solution is not indicated to treat asthma",
      "( 1.2 ) 1.1 Maintenance Treatment of COPD Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bron",
      "1.2 Important Limitations of Use Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS ( 5.2 )]"
    ]
  },
  "fosaprepitant": {
    "ingredient": "fosaprepitant",
    "is_drug": true,
    "canonical_name": "fosaprepitant",
    "fda_search_term": "fosaprepitant",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FOCINVEZ",
      "FOSAPREPITANT DIMEGLUMINE"
    ],
    "generic_names": [
      "FOSAPREPITANT DIMEGLUMINE"
    ],
    "manufacturers": [
      "Eugia US LLC",
      "Hikma Pharmaceuticals USA Inc.",
      "Steriscience Specialties Private Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Full Prescribing Information for a list of clinically significant drug interactions",
      "( 4 , 5.1 , 5.4 , 5.5 , 7.1 , 7.2 ) Additional pediatric use information is approved for Merck Sharp & Dohme LLC’s EMEND (fosaprepitant) for injection",
      "However, due to Merck Sharp & Dohme LLC’s marketing exclusivity rights, this drug product is not labeled with that information",
      "7.1 Effect of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs When administered intravenously, fosaprepitant, a prodrug of aprepitant, is converted to aprepitant within 30 minutes",
      "Therefore, drug interactions following administration of FOCINVEZ are likely to occur with drugs that interact with oral aprepitant",
      "Fosaprepitant, given as a single 150-mg dose, is a weak inhibitor of CYP3A4, and the weak inhibition of CYP3A4 continues for 2 days after single dose administration",
      "Single dose fosaprepitant does not induce CYP3A4",
      "Aprepitant is a substrate, an inhibitor, and an inducer of CYP3A4",
      "Aprepitant is also an inducer of CYP2C9 [see Clinical Pharmacology ( 12.3 )] ",
      "Some substrates of CYP3A4 are contraindicated with FOCINVEZ [see Contraindications ( 4 )] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.2 )] Infusion Site Reactions [see Warnings and Precautions ( 5.3 )] Most common adverse reactions in adults (≥2%) are: fati",
      "( 6.1 ) Adverse reactions in pediatric patients are similar to adults",
      "To report SUSPECTED ADVERSE REACTIONS, contact Steriscience at (1-888-278-1784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "The safety of FOCINVEZ has been established from adequate and well-controlled studies of another intravenous formulation of fosaprepitant [see Clinical Studies ( 14 )] ",
      "Below is a display of the adverse reactions of fosaprepitant in these studies",
      "The overall safety of intravenous fosaprepitant was evaluated in approximately 1800 adult and pediatric patients",
      "Adverse Reactions in Adults for the Prevention of Nausea and Vomiting Associated with MEC In an active-controlled clinical trial in patients receiving MEC, safety was evaluated in 504 patients receiving a single dose of intravenous fosaprepitant in combination with ondansetron and dexamethasone (int",
      "The most common adverse reactions are listed in Table 6",
      "Table 6 Most Common Adverse Reactions in Patients Receiving MEC a Intravenous fosaprepitant, ondansetron, and dexamethasone b (N=504) Ondansetron and dexamethasone c (N=497) fatigue 15% 13% diarrhea 13% 11% neutropen"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE FOCINVEZ, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC",
      "delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)",
      "Limitations of Use FOCINVEZ has not been studied for the treatment of established nausea and vomiting",
      "FOCINVEZ is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of (1) : acute and delayed nausea and vomiting associated with initial and repeat courses of highl",
      "delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)"
    ]
  },
  "fosfomycin": {
    "ingredient": "fosfomycin",
    "is_drug": true,
    "canonical_name": "fosfomycin",
    "fda_search_term": "fosfomycin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fosfomycin Tromethamine"
    ],
    "generic_names": [
      "FOSFOMYCIN TROMETHAMINE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Ascend Laboratories, LLC",
      "Kesin Pharma Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including fosfomycin tromethamine, and may range in severity from mild diarrhea to fatal colitis",
      "Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C",
      "difficile produces toxins A and B which contribute to the development of CDAD",
      "Hypertoxin producing strains of C",
      "difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
      "CDAD must be considered in all patients who present with diarrhea following antibiotic use",
      "Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents",
      "If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C",
      "difficile may need to be discontinued",
      "Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C"
    ],
    "drug_interactions": [
      "DRUG INTERACTIONS Metoclopramide: When coadministered with fosfomycin tromethamine, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin",
      "Other drugs that increase gastrointestinal motility may produce similar effects",
      "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with fosfomycin tromethamine"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Clinical Trials: In clinical studies, drug related adverse events which were reported in greater than 1% of the fosfomycin-treated study population are listed below: Drug-Related Adverse Events (%) in Fosfomycin and Comparator Populations Adverse Events Fosfomycin N=1233 Nitrofuran",
      "The following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migrai",
      "One patient developed unilateral optic neuritis, an event considered possibly related to fosfomycin tromethamine therapy",
      "Post-marketing Experience: Serious adverse events from the marketing experience with fosfomycin tromethamine outside of the United States have been rarely reported and include: angioedema, aplastic anemia, asthma (exacerbation), cholestatic jaundice, hepatic necrosis, and toxic megacolon",
      "Although causality has not been established, during post marketing surveillance, the following events have occurred in patients prescribed fosfomycin tromethamine: anaphylaxis and hearing loss",
      "Laboratory Changes: Significant laboratory changes reported in U.S"
    ],
    "indications": [
      "INDICATIONS & USAGE Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis ",
      "Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess",
      "If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected",
      "(See PRECAUTIONS and CLINICAL STUDIES sections.)"
    ]
  },
  "fosinopril": {
    "ingredient": "fosinopril",
    "is_drug": true,
    "canonical_name": "fosinopril",
    "fda_search_term": "fosinopril",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fosinopril Sodium and Hydrochlorothiazide",
      "Fosinopril sodium"
    ],
    "generic_names": [
      "FOSINOPIRL SODIUM",
      "FOSINOPRIL SODIUM",
      "FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE"
    ],
    "manufacturers": [
      "Aurobindo Pharma Limited",
      "Bryant Ranch Prepack",
      "Solco Healthcare LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including fosinopril sodium) may be subject to a variety of adv",
      "Head and Neck Angioedema Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis, or larynx has been reported in patients treated with ACE inhibitors",
      "If angioedema involves the tongue, glottis, or larynx, airway obstruction may occur and be fatal",
      "If laryngeal stridor or angioedema of the face, lips, mucous membranes, tongue, glottis, or extremities occurs, treatment with fosinopril sodium should be discontinued and appropriate therapy instituted immediately",
      "Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) should be promptly administered (see PRECAUTIONS , Information for Patients and ADVERSE REACTIONS )",
      "Patients taking concomitant mTOR inhibitor (e.g",
      "temsirolimus) therapy may be at increased risk for angioedema",
      "Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors",
      "These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal",
      "The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor"
    ],
    "drug_interactions": [
      "Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets",
      "The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium",
      "If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION )",
      "Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia",
      "Monitor serum potassium in such patients",
      "Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium",
      "These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended",
      "If a diuretic is also used, the risk of lithium toxicity may be increased",
      "Antacids In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administrated alone, suggesting that antacids may impair absorpt",
      "Therefore, if concomitant administration of these agents is indicated, dosing should be separated by 2 hours"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Fosinopril sodium tablets have been evaluated for safety in more than 2100 individuals in hypertension and heart failure trials, including approximately 530 patients treated for a year or more",
      "Generally adverse events were mild and transient, and their frequency was not prominently related to dose within the recommended daily dosage range",
      "Hypertension In placebo-controlled clinical trials (688 fosinopril sodium-treated patients), the usual duration of therapy was 2 to 3 months",
      "Discontinuations due to any clinical or laboratory adverse event were 4.1% and 1.1% in fosinopril sodium-treated and placebo-treated patients, respectively",
      "The most frequent reasons (0.4 to 0.9%) were headache, elevated transaminases, fatigue, cough (see PRECAUTIONS , General , Cough ), diarrhea, and nausea and vomiting",
      "During clinical trials with any fosinopril sodium regimen, the incidence of adverse events in the elderly (≥ 65 years old) was similar to that seen in younger patients",
      "Clinical adverse events probably or possibly related or of uncertain relationship to therapy, occurring in at least 1% of patients treated with fosinopril sodium alone and at least as frequent on fosinopril sodium as on placebo in placebo-controlled clinical trials are shown in the table below",
      "Clinical Adverse Events in Placebo-Controlled Trials (Hypertension) Fosinopril Sodium (N = 688) Incidence (Discontinuation) Placebo (N = 184) Incidence (Discontinuation) Cough 2.2 (0.4) 0.0 (0.0) Dizziness 1.6 (0.0) 0.0 (0.0) Nausea/Vomiting 1.2 (0.4) 0.5 (0.0) The following events were also seen at",
      "Other clinical events probably or possibly related, or of uncertain relationship to therapy occurring in 0.2 to 1.0% of patients (except as noted) treated with fosinopril sodium in controlled or uncontrolled clinical trials (N = 1479) and less frequent, clinically significan"
    ],
    "indications": [
      "INDICATIONS AND USAGE Fosinopril sodium tablets are indicated for the treatment of hypertension",
      "They may be used alone or in combination with thiazide diuretics",
      "Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see DOSAGE AND ADMINISTRATION )",
      "In using fosinopril sodium, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease",
      "Available data are insufficient to show that fosinopril sodium does not have a similar risk (see WARNINGS )"
    ]
  },
  "frovatriptan": {
    "ingredient": "frovatriptan",
    "is_drug": true,
    "canonical_name": "frovatriptan",
    "fda_search_term": "frovatriptan",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FROVATRIPTAN",
      "Frovatriptan",
      "frovatriptan succinate"
    ],
    "generic_names": [
      "FROVATRIPTAN SUCCINATE"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals NY LLC",
      "Glenmark Pharmaceuticals Inc., USA",
      "Ingenus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Ergot-containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions",
      "Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and frovatriptan within 24 hours of each other is contraindicated [ see Contraindications ( 4 ) ]",
      "7.2 5-HT 1B/1D Agonists Because their vasospastic effects may be additive, co-administration of frovatriptan and other 5-HT 1 agonists (e.g., triptans) within 24 hours of each other is contraindicated [ see Contraindications ( 4 ) ]",
      "7.3 Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ see Warnings and Precautions ( 5.7 ) ]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in other sections of the labeling:",
      "Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina [see Warnings and Precautions ( 5.1 )]",
      "Arrhythmias [see Warnings and Precautions ( 5.2 )]",
      "Chest, Throat, Neck, and/or Jaw Pain/Tightness/Pressure [see Warnings and Precautions ( 5.3 )]",
      "Cerebrovascular Events [see Warnings and Precautions ( 5.4 )]",
      "Other Vasospasm Reactions [see Warnings and Precautions ( 5.5 )]",
      "Medication Overuse Headache [see Warnings and Precautions ( 5.6 )]",
      "Serotonin Syndrome [see Warnings and Precautions ( 5.7 )]",
      "Increases in Blood Pressure [see Warnings and Precautions ( 5.8 )]",
      "Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.8 )]",
      "Most common adverse reactions (≥2% and >placebo) were dizziness, headache, paresthesia, dry mouth, dyspepsia, fatigue, hot or cold sensation, chest pain, skeletal pain, and flushing ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA a",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Frovatriptan was evaluated in four randomized, double-blind, placebo-controlled, short-term trials",
      "These trials involved 2392 patients (1554 on frovatriptan 2.5 mg and 838 on placebo)",
      "In these short-term trials, patients were predominately female (88%) and Caucasian (94%) with a mean age of 42 years (range 18 to 69).The treatment-emergent adverse events that occurred most frequently following administration of frovatriptan 2.5 mg ( i.e., in at least 2% of patients), and at an inc"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults",
      "Limitations of Use",
      "Use only if a clear diagnosis of migraine has been established",
      "If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks",
      "Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks"
    ]
  },
  "fucidic acid": {
    "ingredient": "fucidic acid",
    "is_drug": true,
    "canonical_name": "fucidic acid",
    "fda_search_term": "fucidic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "fulvestrant": {
    "ingredient": "fulvestrant",
    "is_drug": true,
    "canonical_name": "fulvestrant",
    "fda_search_term": "fulvestrant",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fulvestrant",
      "fulvestrant"
    ],
    "generic_names": [
      "FULVESTRANT"
    ],
    "manufacturers": [
      "Meitheal Pharmaceuticals Inc",
      "Sagent Pharmaceuticals",
      "Sandoz Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS There are no known drug-drug interactions",
      "Although, fulvestrant is metabolized by CYP 3A4 in vitro , drug interactions studies with ketoconazole or rifampin did not alter fulvestrant pharmacokinetics",
      "Dose adjustment is not needed in patients co-prescribed CYP 3A4 inhibitors or inducers [see Clinical Pharmacology ( 12.3 )] ",
      "There are no known drug-drug interactions"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Risk of Bleeding [see Warnings and Precautions ( 5.1 )] Increased Exposure in Patients with Hepatic Impairment [see Warnings and Precautions ( 5.2 )] Injection Site Reaction [see Warni",
      "( 6.1 ) Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of Fulvestrant Injection patients and were not dose-dependent",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc",
      "at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice",
      "Monotherapy Comparison of Fulvestrant Injection 500 mg and Fulvestrant Injection 250 mg (CONFIRM) The following adverse reactions (ARs) were calculated based on the safety analysis of CONFIRM comparing the administration of Fulvestrant Injection 500 mg intramuscularly once a month with Fulvestrant I",
      "The most frequently reported adverse reactions in the Fulvestrant Injection 500 mg group were injection site pain (11.6% of patients), nausea (9.7% of patients), and bone pain (9.4% of patients); the most frequently reported adverse reactions in the Fulvestrant Injection 250 mg group were nausea (13",
      "Table 1 lists adverse reacti"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy",
      "( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy",
      "( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy",
      "( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy",
      "( 1 ) Monotherapy Fulvestrant Injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in p"
    ]
  },
  "furosemide": {
    "ingredient": "furosemide",
    "is_drug": true,
    "canonical_name": "furosemide",
    "fda_search_term": "furosemide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Furosemide"
    ],
    "generic_names": [
      "FUROSEMIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Phlow Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion",
      "Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION )"
    ],
    "drug_interactions": [
      "Drug Interactions Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function",
      "Except in life-threatening situations, avoid this combination",
      "Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity",
      "Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites",
      "There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly",
      "In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment",
      "Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine",
      "Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity",
      "Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure",
      "An interruption or reduction in the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions are categorized below by organ system and listed by decreasing severity",
      "Gastrointestinal System Reactions 1",
      "hepatic encephalopathy in patients with hepatocellular insufficiency 2",
      "jaundice (intrahepatic cholestatic jaundice) 4",
      "increased liver enzymes 5",
      "oral and gastric irritation 7",
      "vomiting Systemic Hypersensitivity Reactions 1",
      "severe anaphylactic or anaphylactoid reactions (e.g., with shock) 2",
      "systemic vasculitis 3",
      "interstitial nephritis 4",
      "necrotizing angiitis Central Nervous System Reactions 1",
      "tinnitus and hearing loss 2",
      "blurred vision 7",
      "xanthopsia Hematologic Reactions 1",
      "aplastic anemia 2"
    ],
    "indications": [
      "INDICATIONS AND USAGE Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome",
      "Furosemide tablets are particularly useful when an agent with greater diuretic potential is desired",
      "Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents",
      "Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone"
    ]
  },
  "fusidic acid": {
    "ingredient": "fusidic acid",
    "is_drug": true,
    "canonical_name": "fusidic acid",
    "fda_search_term": "fusidic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "gaba": {
    "ingredient": "gaba",
    "is_drug": true,
    "canonical_name": "gabapentin",
    "fda_search_term": "gabapentin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gabapentin"
    ],
    "generic_names": [
      "GABAPENTIN"
    ],
    "manufacturers": [
      "Ajenat Pharmaceuticals LLC",
      "AvPAK",
      "Bryant Ranch Prepack"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Concentrations increased by morphine; may need dose adjustment (5.4, 7.1 ) 7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphin",
      "Hydrocodone Coadministration of gabapentin with hydrocodone decreases hydrocodone exposure [ see Clinical Pharmacology (12.3) ]",
      "The potential for alteration in hydrocodone exposure and effect should be considered when gabapentin is started or discontinued in a patient taking hydrocodone",
      "Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression [see Clinical Pharmacology (12.3) ]",
      "7.2 Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs [ see Clinical Pharmacology (12.3) ] ",
      "7.3 Maalox ® (aluminum hydroxide, magnesium hydroxide) The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox ® ) containing magnesium and aluminum hydroxides",
      "It is recommended that gabapentin be taken at least 2 hours following Maalox administration [see Clinical Pharmacology (12.3)] ",
      "7.4 Drug/Laboratory Test Interactions Because false positive readings were reported with the Ames N-Multistix SG ® dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the p"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.1) ] Anaphylaxis and Angioedema [see Warnings and Precautions (5.2",
      "at 1-888-802-1213 or www.acihealthcareusa.com or FDA at1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Postherpetic Neuralgia The most common adverse reactions associated with the use of Gabapentin in adults, not seen at an equivalent frequency among placebo-treated patients, were dizziness, somnolence, and peripheral edema",
      "In the 2 controlled trials in postherpetic neuralgia, 16% of the 336 patients who received Gabapentin and 9% of t"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin Cap"
    ]
  },
  "gabapentin": {
    "ingredient": "gabapentin",
    "is_drug": true,
    "canonical_name": "gabapentin",
    "fda_search_term": "gabapentin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gabapentin"
    ],
    "generic_names": [
      "GABAPENTIN"
    ],
    "manufacturers": [
      "Ajenat Pharmaceuticals LLC",
      "AvPAK",
      "Bryant Ranch Prepack"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Concentrations increased by morphine; may need dose adjustment (5.4, 7.1 ) 7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphin",
      "Hydrocodone Coadministration of gabapentin with hydrocodone decreases hydrocodone exposure [ see Clinical Pharmacology (12.3) ]",
      "The potential for alteration in hydrocodone exposure and effect should be considered when gabapentin is started or discontinued in a patient taking hydrocodone",
      "Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression [see Clinical Pharmacology (12.3) ]",
      "7.2 Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs [ see Clinical Pharmacology (12.3) ] ",
      "7.3 Maalox ® (aluminum hydroxide, magnesium hydroxide) The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox ® ) containing magnesium and aluminum hydroxides",
      "It is recommended that gabapentin be taken at least 2 hours following Maalox administration [see Clinical Pharmacology (12.3)] ",
      "7.4 Drug/Laboratory Test Interactions Because false positive readings were reported with the Ames N-Multistix SG ® dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the p"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.1) ] Anaphylaxis and Angioedema [see Warnings and Precautions (5.2",
      "at 1-888-802-1213 or www.acihealthcareusa.com or FDA at1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Postherpetic Neuralgia The most common adverse reactions associated with the use of Gabapentin in adults, not seen at an equivalent frequency among placebo-treated patients, were dizziness, somnolence, and peripheral edema",
      "In the 2 controlled trials in postherpetic neuralgia, 16% of the 336 patients who received Gabapentin and 9% of t"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin Cap"
    ]
  },
  "gadobutrol": {
    "ingredient": "gadobutrol",
    "is_drug": true,
    "canonical_name": "gadobutrol",
    "fda_search_term": "gadobutrol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gadavist",
      "Gadobutrol",
      "gadobutrol"
    ],
    "generic_names": [
      "GADOBUTROL"
    ],
    "manufacturers": [
      "Bayer HealthCare Pharmaceuticals Inc.",
      "Fresenius Kabi USA, LLC",
      "Slate Run Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in labeling:",
      "Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions ( 5.2 )] ",
      "Hypersensitivity reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )] ",
      "Acute Respiratory Distress Syndrome [see Warnings and Precautions ( 5.4 )] ",
      "Gadolinium Retention [see Warnings and Precautions ( 5.5 )] ",
      "Most common adverse reactions (incidence ≥ 0.5%) are headache, nausea, and dizziness ( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted u",
      "The adverse reactions described in this section reflect gadobutrol injection exposure in 7,713 subjects (including 184 pediatric patients, ages 0 to 17 years) with the majority receiving the recommended dose",
      "Approximately 52% of the subjects were male and the ethnic distribution was 62% Caucasian, 28% Asian, 5% Hispanic, 2.5% Black, and 2.5% patients of other ethnic groups",
      "The average age was 56 years (range from 1 week to 93 years)",
      "Overall, approximately 4% of subjects reported one or more adverse reactions during a follow-up period that ranged from 24 hours to 7 days after gadobutrol injection administration",
      "Adverse reactions associated with the use of gadobutrol injection were usually mild to moderate in severity and transient in nature",
      "Table 2 lists adverse reactions that occurred in ≥ 0.1% subjects who received gadobutrol injection",
      "Table 2: Adverse Reactions Reaction Rate (%) n=7,713 Headache 1.7 Nausea 1.2 Dizziness 0.5 Dysgeusia 0.4 Feeling Hot 0.4 Injection site reactions 0.4 Vomiting 0"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI):",
      "To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 )",
      "To assess the presence and extent of malignant breast disease in adult patients ( 1.2 )",
      "To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 )",
      "To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD)"
    ]
  },
  "gadodiamide": {
    "ingredient": "gadodiamide",
    "is_drug": true,
    "canonical_name": "gadodiamide",
    "fda_search_term": "gadodiamide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "OMNISCAN"
    ],
    "generic_names": [
      "GADODIAMIDE"
    ],
    "manufacturers": [
      "GE Healthcare Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the label: Nephrogenic systemic fibrosis [see Warnings and Precautions (5.2) ] Hypersensitivity reactions [see Warnings and Precautions (5.3) ] Acute Renal Failure [see War",
      "6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse Reactions in Adult Patients In clinical studies 1,160 patients were exposed to OMNISCAN",
      "The most frequent adverse reactions were nausea, headache, and dizziness that occurred in 3% or less of the patients",
      "The majority of these reactions were of mild to moderate intensity",
      "The following adverse reactions occurred in 1% or less of patients: Application Site Disorders: Injection site reaction",
      "Autonomic Nervous System Disorders: Vasodilation",
      "Body as a Whole-General Disorders: Anaphylactoid reactions (characterized by cardiovascular, respiratory, and cutaneous symptoms), fever, hot flushes, rigors, fatigue, malaise, pain, syncope",
      "Cardiovascular Disorders: Cardiac failure, rare arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease, flushing, chest pain, deep thrombophlebitis",
      "Central and Peripheral Nervous System Disorders: Convulsions including grand mal, ataxia, abnormal coordination, paresthesia, tremor, aggravated multiple scle"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE OMNISCAN is a gadolinium-based contrast agent for diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to: Visualize lesions with abnormal vascularity in the brain, spine, and associated tissues ( 1.1 ) Facilitate the visualization of lesions with abnorma",
      "1.2 Body (Intrathoracic [noncardiac], Intra-abdominal, Pelvic and Retroperitoneal Regions) OMNISCAN is a gadolinium-based contrast agent indicated for intravenous use in MRI to facilitate the visualization of lesions with abnormal vascularity within the thoracic (noncardiac), abdominal, pelvic cavit"
    ]
  },
  "gadopentetate dimeglumine": {
    "ingredient": "gadopentetate dimeglumine",
    "is_drug": true,
    "canonical_name": "gadopentetate dimeglumine",
    "fda_search_term": "gadopentetate dimeglumine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gadobutrol"
    ],
    "generic_names": [
      "GADOBUTROL"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Full Prescribing Information for a list of clinically significant drug interactions",
      "( 4 , 5.1 , 5.4 , 5.5 , 7.1 , 7.2 ) Pediatric use information is approved for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.’s EMEND (fosaprepitant) for injection",
      "However, due to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information",
      "7.1 Effect of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs When administered intravenously, fosaprepitant, a prodrug of aprepitant, is converted to aprepitant within 30 minutes",
      "Therefore, drug interactions following administration of fosaprepitant for injection are likely to occur with drugs that interact with oral aprepitant",
      "Fosaprepitant, given as a single 150 mg dose, is a weak inhibitor of CYP3A4, and the weak inhibition of CYP3A4 continues for 2 days after single dose administration",
      "Single dose fosaprepitant does not induce CYP3A4",
      "Aprepitant is a substrate, an inhibitor, and an inducer of CYP3A4",
      "Aprepitant is also an inducer of CYP2C9 [see Clinical Pharmacology (12.3) ]",
      "Some substrates of CYP3A4 are contraindicated with fosaprepitant [see Contraindications (4) ] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in labeling:",
      "Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions ( 5.2 )] ",
      "Hypersensitivity reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )] ",
      "Acute Respiratory Distress Syndrome [see Warnings and Precautions ( 5.4 )] ",
      "Gadolinium Retention [see Warnings and Precautions ( 5.5 )] ",
      "Most common adverse reactions (incidence ≥ 0.5%) are headache, nausea, and dizziness ( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted u",
      "The adverse reactions described in this section reflect gadobutrol injection exposure in 7,713 subjects (including 184 pediatric patients, ages 0 to 17 years) with the majority receiving the recommended dose",
      "Approximately 52% of the subjects were male and the ethnic distribution was 62% Caucasian, 28% Asian, 5% Hispanic, 2.5% Black, and 2.5% patients of other ethnic groups",
      "The average age was 56 years (range from 1 week to 93 years)",
      "Overall, approximately 4% of subjects reported one or more adverse reactions during a follow-up period that ranged from 24 hours to 7 days after gadobutrol injection administration",
      "Adverse reactions associated with the use of gadobutrol injection were usually mild to moderate in severity and transient in nature",
      "Table 2 lists adverse reactions that occurred in ≥ 0.1% subjects who received gadobutrol injection",
      "Table 2: Adverse Reactions Reaction Rate (%) n=7,713 Headache 1.7 Nausea 1.2 Dizziness 0.5 Dysgeusia 0.4 Feeling Hot 0.4 Injection site reactions 0.4 Vomiting 0"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI):",
      "To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 )",
      "To assess the presence and extent of malignant breast disease in adult patients ( 1.2 )",
      "To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 )",
      "To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD)"
    ]
  },
  "gadoteric acid": {
    "ingredient": "gadoteric acid",
    "is_drug": true,
    "canonical_name": "gadoteric acid",
    "fda_search_term": "gadoteric acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "gadoxetic acid": {
    "ingredient": "gadoxetic acid",
    "is_drug": true,
    "canonical_name": "gadoxetic acid",
    "fda_search_term": "gadoxetic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "galantamine": {
    "ingredient": "galantamine",
    "is_drug": true,
    "canonical_name": "galantamine",
    "fda_search_term": "galantamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Galantamine",
      "Galantamine Hydrobromide"
    ],
    "generic_names": [
      "GALANTAMINE",
      "GALANTAMINE HYDROBROMIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Golden State Medical Supply, Inc.",
      "Upsher-Smith Laboratories, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Potential to interfere with the activity of anticholinergic medications ( 7.1 ) Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) 7.1 Use with Anticholi",
      "7.2 Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol [see Clinic"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Serious adverse reactions are discussed in more detail in the following sections of the labeling: Serious Skin Reactions [see Warnings and Precautions ( 5.1 )] Cardiovascular Conditions [see Warnings and Precautions ( 5.3 )] Gastrointestinal Conditions [see Warnings and Precautio",
      "at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The most common adverse reactions (≥5%) in galantamine-treated patients from double-blind clinical trials were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite",
      "The most common adverse reactions associated with discontinuation (≥1%) in galantamine-treated patients from double-blind clinical trials were nausea (6.2%), vomiting (3.3%), decreased appetite (1.5%), and dizziness (1.3%)",
      "The safety of the extended-release capsule and immediate-release tablet formulations of galantamine was evaluated in 3,956 galantamine-treated patients who participated in 8 placebo-controlled clinical studies and 1,454 patients in 5 open-label clinical studies with mild to moderate dementia of the ",
      "In clinical studies, the safety profile of once-daily treatment with extended-release galantamine was simila"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type",
      "Galantamine hydrobromide is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type ( 1 )"
    ]
  },
  "galcanezumab": {
    "ingredient": "galcanezumab",
    "is_drug": true,
    "canonical_name": "galcanezumab",
    "fda_search_term": "galcanezumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMGALITY"
    ],
    "generic_names": [
      "GALCANEZUMAB-GNLM"
    ],
    "manufacturers": [
      "Eli Lilly and Company"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Hypertension [see Warnings and Precautions ( 5.2 )] Raynaud's Phenomenon [see Warnings and",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice",
      "Migraine The safety of EMGALITY has been evaluated in 2586 patients with migraine who received at least one dose of EMGALITY, representing 1487 patient-years of exposure",
      "Of these, 1920 patients were exposed to EMGALITY once monthly for at least 6 months, and 526 patients were exposed for 12 months",
      "In placebo-controlled clinical studies (Studies 1, 2, and 3), 705 patients received at least one dose of EMGALITY 120 mg once monthly, and 1451 patients received placebo, during 3 months or 6 months of double-blind treatment [see Clinical Studies ( 14.1 )] ",
      "Of the EMGALITY-treated patients, approximately 85% were female, 77% were white, and the mean age was 41 years at study entry",
      "The most common adverse reaction was injection site reactions",
      "In Studies 1, 2, and 3, 1.8% of patients discontinued double-blind treatment because of adverse events",
      "Table 1 summarizes the adverse reactions that occurred within up to 6 months of treatment in the migraine studies",
      "Table 1: Adverse Reactions Occurring in Adults with Migraine with an Incidence of at least 2% for E"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine",
      "( 1.1 ) treatment of episodic cluster headache",
      "( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults",
      "1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults"
    ]
  },
  "gama globulin": {
    "ingredient": "gama globulin",
    "is_drug": true,
    "canonical_name": "immunoglobulin",
    "fda_search_term": "immunoglobulin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GUNA-FLAM",
      "GUNA-HEMORRHOIDS",
      "QIVIGY kthm"
    ],
    "generic_names": [
      "ACONITUM NAPELLUS - APIS MELLIFERA - ATROPA BELLADONNA - BASIC CUPRIC CARBONATE - BRYONIA ALBA ROOT - CALCIUM SULFIDE - CITRIC ACID MONOHYDRATE - FERRIC PHOSPHATE - INTERLEUKIN-10 - MELATONIN - METENKEFALIN - PHYTOLACCA AMERICANA ROOT - RANCID BEEF - SODIUM PYRUVATE - SUS SCROFA CONJUNCTIVA - SUS SCROFA PINEAL GLAND - SUS SCROFA PITUITARY GLAND - TRANSFORMING GROWTH FACTOR BETA-1 - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "HUMAN IMMUNOGLOBULIN G"
    ],
    "manufacturers": [
      "Guna spa",
      "Kedrion S.p.A."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Stop use and ask doctor if symptoms persist more than 5 days",
      "If pregnant or breast-feeding ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Contains ethyl alcohol 30%"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTION The passive transfer of antibodies may: Interfere with the response to live virus vaccines, such as measles, rubella, mumps and varicella",
      "( 7 ) Result in misleading positive results in serological testing",
      "( 5.9 , 7 ) 7.1 Effect of QIVIGY on Live attenuated virus vaccines Immune globulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, s and varicella because the continued presence of high levels of passively acquired antibody may in",
      "Inform the immunizing physician of recent therapy with QIVIGY so that appropriate measures may be taken",
      "7.2 Effect of QIVIGY on Serological Testing Passive transmission of antibodies through immune globulin administration may interfere with some serological testing [see Warnings and Precautions (5.10) ]",
      "7.3 Effect of Loop diuretics on QIVIGY The use of loop diuretics should be avoided",
      "Concomitant use of loop diuretics with IGIV may contribute to an increased blood viscosity and subsequently increase the risk of thromboembolic events"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions observed in ≥ 5% of patients were headache, fatigue, nausea, infusion-related reaction, Coombs direct test positive, sinusitis, dizziness and diarrhea",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc",
      "at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in oth",
      "The safety data described in this section reflects exposure to QIVIGY in one clinical study",
      "A total of 47 patients with PI received intravenous infusion of QIVIGY at a dose range of 266 to 826 mg/kg every 3 or 4 weeks for up to 12 months [see Clinical Studies (14) ] ",
      "A total of 643 infusions of QIVIGY were administered, 136 in the every 3-week schedule and 507 in the 4-week schedule",
      "During the study, 4 out of 47 (9%) patients received premedication",
      "The most common product-related adverse events observed in ≥ 5% of clinical study patients with PI were headache, infusion-related reaction, Coombs direct test positive, fatigue, and nausea",
      "Table 2 lists the most common adverse reactions reported in ≥5% of patients",
      "Table 2: Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period",
      "Occurring in ≥ 5% of Patients Adverse Reaction By Patients n (%) [n = 47] By Infusions n (%) [n = 643] Headache 14 (30) 26 (4) Fatigue 7 (15) 10 (2) Nausea 6 (13) 6 (<1) Infusion-related Reaction 5 (11) 7 (1) Coombs Direct Test Positive 5 (11) 8 (1) Sinusitis 3 (6) 3 (<1) Dizziness 3 (6) 3 (<1) Diar"
    ],
    "indications": [
      "Take 15 minutes before meals"
    ]
  },
  "gamma amino butyric acid": {
    "ingredient": "gamma amino butyric acid",
    "is_drug": true,
    "canonical_name": "gamma-aminobutyric acid",
    "fda_search_term": "gamma-aminobutyric acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GABA Phenolic",
      "Gaba",
      "Neuro II"
    ],
    "generic_names": [
      "GABA",
      "GAMMA-AMINOBUTYRIC ACID",
      "TARAXACUM OFFICINALE, HYDRASTIS CANADENSIS, ACETYLCHOLINE CHLORIDE, HISTAMINUM HYDROCHLORICUM, ADRENALINUM, GABA (GAMMA-AMINOBUTYRIC ACID), NOREPINEPHRINE (BITARTRATE), TYRAMINE"
    ],
    "manufacturers": [
      "BioActive Nutritional, Inc.",
      "Deseret Biologicals, Inc.",
      "Energique, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief from symptoms including:",
      "neurological support",
      "appetite control",
      "travel sickness These statements are based upon homeopathic principles",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "gamma aminobutyric acid": {
    "ingredient": "gamma aminobutyric acid",
    "is_drug": true,
    "canonical_name": "gamma-aminobutyric acid",
    "fda_search_term": "gamma-aminobutyric acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GABA Phenolic",
      "Gaba",
      "Neuro II"
    ],
    "generic_names": [
      "GABA",
      "GAMMA-AMINOBUTYRIC ACID",
      "TARAXACUM OFFICINALE, HYDRASTIS CANADENSIS, ACETYLCHOLINE CHLORIDE, HISTAMINUM HYDROCHLORICUM, ADRENALINUM, GABA (GAMMA-AMINOBUTYRIC ACID), NOREPINEPHRINE (BITARTRATE), TYRAMINE"
    ],
    "manufacturers": [
      "BioActive Nutritional, Inc.",
      "Deseret Biologicals, Inc.",
      "Energique, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief from symptoms including:",
      "neurological support",
      "appetite control",
      "travel sickness These statements are based upon homeopathic principles",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "gammaglobulin": {
    "ingredient": "gammaglobulin",
    "is_drug": true,
    "canonical_name": "immunoglobulin",
    "fda_search_term": "immunoglobulin",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GUNA-FLAM",
      "GUNA-HEMORRHOIDS",
      "QIVIGY kthm"
    ],
    "generic_names": [
      "ACONITUM NAPELLUS - APIS MELLIFERA - ATROPA BELLADONNA - BASIC CUPRIC CARBONATE - BRYONIA ALBA ROOT - CALCIUM SULFIDE - CITRIC ACID MONOHYDRATE - FERRIC PHOSPHATE - INTERLEUKIN-10 - MELATONIN - METENKEFALIN - PHYTOLACCA AMERICANA ROOT - RANCID BEEF - SODIUM PYRUVATE - SUS SCROFA CONJUNCTIVA - SUS SCROFA PINEAL GLAND - SUS SCROFA PITUITARY GLAND - TRANSFORMING GROWTH FACTOR BETA-1 - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "HUMAN IMMUNOGLOBULIN G"
    ],
    "manufacturers": [
      "Guna spa",
      "Kedrion S.p.A."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Stop use and ask doctor if symptoms persist more than 5 days",
      "If pregnant or breast-feeding ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Contains ethyl alcohol 30%"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTION The passive transfer of antibodies may: Interfere with the response to live virus vaccines, such as measles, rubella, mumps and varicella",
      "( 7 ) Result in misleading positive results in serological testing",
      "( 5.9 , 7 ) 7.1 Effect of QIVIGY on Live attenuated virus vaccines Immune globulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, s and varicella because the continued presence of high levels of passively acquired antibody may in",
      "Inform the immunizing physician of recent therapy with QIVIGY so that appropriate measures may be taken",
      "7.2 Effect of QIVIGY on Serological Testing Passive transmission of antibodies through immune globulin administration may interfere with some serological testing [see Warnings and Precautions (5.10) ]",
      "7.3 Effect of Loop diuretics on QIVIGY The use of loop diuretics should be avoided",
      "Concomitant use of loop diuretics with IGIV may contribute to an increased blood viscosity and subsequently increase the risk of thromboembolic events"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions observed in ≥ 5% of patients were headache, fatigue, nausea, infusion-related reaction, Coombs direct test positive, sinusitis, dizziness and diarrhea",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc",
      "at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in oth",
      "The safety data described in this section reflects exposure to QIVIGY in one clinical study",
      "A total of 47 patients with PI received intravenous infusion of QIVIGY at a dose range of 266 to 826 mg/kg every 3 or 4 weeks for up to 12 months [see Clinical Studies (14) ] ",
      "A total of 643 infusions of QIVIGY were administered, 136 in the every 3-week schedule and 507 in the 4-week schedule",
      "During the study, 4 out of 47 (9%) patients received premedication",
      "The most common product-related adverse events observed in ≥ 5% of clinical study patients with PI were headache, infusion-related reaction, Coombs direct test positive, fatigue, and nausea",
      "Table 2 lists the most common adverse reactions reported in ≥5% of patients",
      "Table 2: Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period",
      "Occurring in ≥ 5% of Patients Adverse Reaction By Patients n (%) [n = 47] By Infusions n (%) [n = 643] Headache 14 (30) 26 (4) Fatigue 7 (15) 10 (2) Nausea 6 (13) 6 (<1) Infusion-related Reaction 5 (11) 7 (1) Coombs Direct Test Positive 5 (11) 8 (1) Sinusitis 3 (6) 3 (<1) Dizziness 3 (6) 3 (<1) Diar"
    ],
    "indications": [
      "Take 15 minutes before meals"
    ]
  },
  "ganciclovir": {
    "ingredient": "ganciclovir",
    "is_drug": true,
    "canonical_name": "ganciclovir",
    "fda_search_term": "ganciclovir",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ganciclovir"
    ],
    "generic_names": [
      "GANCICLOVIR SODIUM"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Hikma Pharmaceuticals USA Inc.",
      "Pharmascience Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Drug-drug interaction studies were conducted in patients with normal renal function",
      "Patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug following concomitant administration of Ganciclovir Injection Drug-drug interaction studies were conducted in patients with normal renal function",
      "Patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug following concomitant administration of Ganciclovir Injection and drugs excreted by the same pathway as ganciclovir",
      "Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug",
      "Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 6 ",
      "Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 6 [see Clinical Pharmacology (12.3) ] ",
      "Established and Other Potentially Significant Drug Interactions with Ganciclovir Name of the Concomitant Drug Change in the Concentration of Ganciclovir or Concomitant Drug Clinical Comment Imipenem-cilastatin Unknown Coadministration with imipenem-cilastatin is not recommended because generalized s",
      "Cyclosporine or amphotericin B Unknown Monitor renal function when Ganciclovir Injection is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine [see Warnings and Precautions (5.2)]",
      "Mycophenolate mofetil (MMF) ↔ Ganciclovir (in patients with normal renal function) ↔ MMF (in patients with normal renal function) Based on increased risk, patients should be monitored for hematological and renal toxicity",
      "Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Hematologic Toxicity [see Warnings and Precautions (5.1) ] Renal Impairment [see Warnings and Precautions (5.2) ] Impairment of Fertility [see Warnings and Precautions (5.3)",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pharmascience Inc",
      "at 1-888-550-6060 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trial Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in pr",
      "The most common adverse reactions and laboratory abnormalities reported in at least 20% of patients were pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, decreased appetite, dyspnea, abdominal pain, sepsis, hyperhidrosis, and blood creatinine increased",
      "Selected adverse reactions that occurred during clinical trials of Ganciclovir Injection are summarized below, according to the participating study patient population",
      "Three controlled, randomized, phase 3 trials comparing Ganciclovir Injection and ganciclovir capsules for maintenance treatment of CMV retinitis have been completed",
      "During these trials, Ganciclovir Injection or ganciclovir capsules were prematurely discontinued in 9% of subjects because of adverse reactions",
      "Selected adverse reactions and laboratory abnormalities reported during the conduct of the"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ganciclovir Injection Ganciclovir Injection is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for the: treatment of CMV retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS)",
      "( 1.1 ) prevention of CMV disease in adult transplant recipients at risk for CMV disease",
      "( 1.2 ) 1.1 Treatment of CMV Retinitis Ganciclovir Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1 )]",
      "1.2 Prevention of CMV Disease in Transplant Recipients Ganciclovir Injection is indicated for the prevention of CMV disease in adult transplant recipients at risk for CMV disease [see Clinical Studies (14.2) ]"
    ]
  },
  "ganirelix": {
    "ingredient": "ganirelix",
    "is_drug": true,
    "canonical_name": "ganirelix",
    "fda_search_term": "ganirelix",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ganirelix Acetate"
    ],
    "generic_names": [
      "GANIRELIX ACETATE"
    ],
    "manufacturers": [
      "Meitheal Pharmaceuticals Inc.",
      "Mullan Pharmaceutical Inc.",
      "Organon LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Ganirelix acetate injection should be prescribed by physicians who are experienced in infertility treatment",
      "Before starting treatment with ganirelix acetate, pregnancy must be excluded",
      "Safe use of ganirelix acetate during pregnancy has not been established (see CONTRAINDICATIONS and PRECAUTIONS )"
    ],
    "drug_interactions": [
      "Drug Interactions No formal drug-drug interaction studies have been performed"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The safety of ganirelix acetate was evaluated in two randomized, parallel-group, multicenter controlled clinical studies",
      "Treatment duration for ganirelix acetate ranged from 1 to 14 days",
      "Table IV represents adverse events (AEs) from first day of ganirelix acetate administration until confirmation of pregnancy by ultrasound at an incidence of ≥ 1% in ganirelix acetate-treated subjects without regard to causality",
      "TABLE IV: Incidence of common adverse events (Incidence ≥ 1% in ganirelix acetate-treated subjects)",
      "Completed controlled clinical studies (All-subjects-treated group)",
      "Adverse Events Occurring in ≥ 1% Ganirelix Acetate N=794 % (n) Abdominal Pain (gynecological) 4.8 (38) Death Fetal 3.7 (29) Headache 3.0 (24) Ovarian Hyperstimulation Syndrome 2.4 (19) Vaginal Bleeding 1.8 (14) Injection Site Reaction 1.1 (9) Nausea 1.1 (9) Abdominal Pain (gastrointestinal) 1.0 (8) ",
      "Congenital Anomalies An observational study in more than 1,000 newborns compared the incidence of congenital anomalies in newborns of women administered ganirelix acetate to historical controls of a GnRH agonist",
      "This study demonstrated that the incidence of congenital anomalies in children born after COH treatment in women using ganirelix acetate was comparable with that reported after a COH treatment cycle using a GnRH agonist",
      "The incidence of congenital malformations after some Assisted Reproductive Technologies (ART) [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception",
      "This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm ch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation"
    ]
  },
  "garamycin": {
    "ingredient": "garamycin",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gastroprazole": {
    "ingredient": "gastroprazole",
    "is_drug": true,
    "canonical_name": "lansoprazole",
    "fda_search_term": "lansoprazole",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Lansoprazole"
    ],
    "generic_names": [
      "LANSOPRAZOLE"
    ],
    "manufacturers": [
      "Camber Pharmaceuticals, Inc.",
      "NuCare Pharmaceuticals,Inc.",
      "Xiromed LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Tables 2 and 3 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with lansoprazole delayed release capsules and instructions for preventing or managing them",
      "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs",
      "Clinically Relevant Interactions Affecting Drugs Co-Administered with Lansoprazole Delayed Release Capsules and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable",
      "The clinical importance and the mechanisms behind these interactions are not always known",
      "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance",
      "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with lansoprazole may increase toxicity of the antiretroviral drugs",
      "There are other antiretroviral drugs which do not result in clinically relevant interactions with lansoprazole",
      "Intervention : Rilpivirine-containing products : Concomitant use with Lansoprazole delayed release capsules is contraindicated [ see Contraindications ( 4 ) ]",
      "See prescribing information",
      "Atazanavir : See prescribing information for atazanavir for dosing information"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions ( 5.2 )] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions ( 5.3 )] Bone Fracture [see Warnings and Preca",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Xiromed LLC at 844-XIROMED (844-947-6633) or FDA at 1-800-FDA-1088 o r www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "Worldwide, over 10,000 patients have been treated with lansoprazole in Phase 2 or Phase 3 clinical trials involving various dosages and durations of treatment",
      "In general, lansoprazole treatment has been well-tolerated in both short-term and long-term trials",
      "The following adverse reactions were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of lansoprazole delayed-release capsule-treated patients and occurred at a greater rate in lansoprazole delayed-release capsule-treated patients than placebo-trea",
      "Incidence of Possibly or Probably Treatment-Related Adverse Reactions in Short-Term, Placebo-Controlled Lansoprazole Studies Body System/Adverse Event Lansoprazole (N="
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of H",
      "pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Maintenance of healed duodenal ulcers in adults ( 1.3 ) Treatment of active benign gastric ulcer in adults ( 1.4 ) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults ( 1.5 ) Risk reductio",
      "( 1.7 ) Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older",
      "( 1.8 ) Maintenance of healing of EE in adults ( 1.9 ) Pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (ZES) in adults ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healin",
      "1.2 Eradication of H"
    ]
  },
  "gatifloxacin": {
    "ingredient": "gatifloxacin",
    "is_drug": true,
    "canonical_name": "gatifloxacin",
    "fda_search_term": "gatifloxacin",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GATIFLOXACIN",
      "Gatifloxacin Ophthalmic Solution 0.5%",
      "ZYMAXID"
    ],
    "generic_names": [
      "GATIFLOXACIN",
      "GATIFLOXACIN OPHTHALMIC SOLUTION 0.5%"
    ],
    "manufacturers": [
      "Allergan, Inc.",
      "Caplin Steriles Limited",
      "Leading Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ] Growth of Resistant Organisms With Prolonged Use [ see Warnings and Precautions ( 5.2 ) ] Corneal Endothelial Cel",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "In clinical studies of patients with bacterial conjunctivitis treated with ZYMAXID ® (N=717), the most frequently reported adverse reactions occurring in ≥ 1 % of patients were: worsening of the conjunctivitis, eye irritation, dysgeusia, and eye pain",
      "Additional adverse reactions reported with other formulations of gatifloxacin ophthalmic solution in other clinical studies included chemosis, conjunctival hemorrhage, dry eye, eye discharge, eyelid edema, headache, increased lacrimation, keratitis, red eye, papillary conjunctivitis, and reduced vis",
      "6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ZYMAXID ® or with other formulations of gatifloxacin ophthalmic solution",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "These reactions included anaphylactic reactions and angioedema (including pharyngeal, oral or facial edema), blepharitis, dyspnea,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pne",
      "ZYMAXID ® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoni"
    ]
  },
  "gatifloxacine": {
    "ingredient": "gatifloxacine",
    "is_drug": true,
    "canonical_name": "gatifloxacin",
    "fda_search_term": "gatifloxacin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GATIFLOXACIN",
      "Gatifloxacin Ophthalmic Solution 0.5%",
      "ZYMAXID"
    ],
    "generic_names": [
      "GATIFLOXACIN",
      "GATIFLOXACIN OPHTHALMIC SOLUTION 0.5%"
    ],
    "manufacturers": [
      "Allergan, Inc.",
      "Caplin Steriles Limited",
      "Leading Pharma, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ] Growth of Resistant Organisms With Prolonged Use [ see Warnings and Precautions ( 5.2 ) ] Corneal Endothelial Cel",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "In clinical studies of patients with bacterial conjunctivitis treated with ZYMAXID ® (N=717), the most frequently reported adverse reactions occurring in ≥ 1 % of patients were: worsening of the conjunctivitis, eye irritation, dysgeusia, and eye pain",
      "Additional adverse reactions reported with other formulations of gatifloxacin ophthalmic solution in other clinical studies included chemosis, conjunctival hemorrhage, dry eye, eye discharge, eyelid edema, headache, increased lacrimation, keratitis, red eye, papillary conjunctivitis, and reduced vis",
      "6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ZYMAXID ® or with other formulations of gatifloxacin ophthalmic solution",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "These reactions included anaphylactic reactions and angioedema (including pharyngeal, oral or facial edema), blepharitis, dyspnea,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pne",
      "ZYMAXID ® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoni"
    ]
  },
  "gefitinib": {
    "ingredient": "gefitinib",
    "is_drug": true,
    "canonical_name": "gefitinib",
    "fda_search_term": "gefitinib",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gefitinib"
    ],
    "generic_names": [
      "GEFITINIB"
    ],
    "manufacturers": [
      "Natco Pharma USA LLC",
      "Qilu Pharmaceutical Co., Ltd.",
      "Teva Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "CYP3A4 Inducer: Increase gefitinib tablets to 500 mg daily in patients receiving a strong CYP3A4 inducer",
      "CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with gefitinib tablets",
      "Drugs Affecting Gastric pH: Avoid concomitant use of gefitinib tablets with proton pump inhibitors, if possible",
      "Hemorrhage in patients taking warfarin: Monitor changes in prothrombin time or INR",
      "( 7.2 ) 7.1 Drugs Affecting Gefitinib Exposure CYP3A4 Inducer Drugs that are strong inducers of CYP3A4 increase the metabolism of gefitinib and decrease gefitinib plasma concentrations",
      "Increase gefitinib tablets to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume gefitinib tablets at 250 mg 7 days after discontinuation of the strong inducer [ see Dosage and Administration (2.4) , Clinical Pharmacology ",
      "CYP3A4 Inhibitor Drugs that are strong inhibitors of CYP3A4 (e.g., ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations",
      "Monitor adverse reactions when administering strong CYP3A4 inhibitors with gefitinib tablets",
      "Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse drug reactions are discussed in more detail in other sections of the labeling:",
      "Interstitial Lung Disease [ see Warnings and Precautions (5.1) ]",
      "Hepatotoxicity [ see Warnings and Precautions (5.2) ]",
      "Gastrointestinal Perforation [ see Warnings and Precautions (5.3) ]",
      "Severe or Persistent Diarrhea [ see Warnings and Precautions (5.4) ]",
      "Ocular Disorders including Keratitis [ see Warnings and Precautions (5.5) ]",
      "Bullous and Exfoliative Skin Disorders [ see Warning and Precautions (5.6) ] The most commonly reported adverse drug reactions (ADRs), reported in more than 20% of the patients and greater than placebo were skin reactions and diarrhea",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact QILU PHARMA, INC",
      "at 484-838-0633 / 484-875-3013 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of gefitinib tablets is based on the data from 2462 patients with NSCLC who received gefitinib tablets 250 mg daily monotherapy in three randomized clinical studies (Study 2, Study 3 and Study 4)",
      "Patients with a history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis that required steroid treatment or any evidence of clinically active interstitial lung disease were excluded from these studies",
      "Controlled Studies: Study 2 was a randomized, multicenter, open-label trial in which 1217 patients were randomized to receive first-line treatment for metastatic NSCLC; 607 patients received gefitinib tablets 250 mg daily and 589 patients received carboplatin/paclitaxel",
      "The median duration of treatment with gefitinib tablets was 5.9 months",
      "The study population characteristics were: median age 57 y"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved tes",
      "Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [ see Clinical Studies (14) ]",
      "Gefitinib tablets are a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved",
      "(1) Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations"
    ]
  },
  "gemcitabine": {
    "ingredient": "gemcitabine",
    "is_drug": true,
    "canonical_name": "gemcitabine",
    "fda_search_term": "gemcitabine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gemcitabine",
      "INLEXZO"
    ],
    "generic_names": [
      "GEMCITABINE",
      "GEMCITABINE HYDROCHLORIDE",
      "GEMCITABINE INTRAVESICAL"
    ],
    "manufacturers": [
      "Janssen Biotech, Inc",
      "Mylan Institutional LLC",
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Hypersensitivity [see Contraindications (4) ]",
      "Schedule-Dependent Toxicity [see Warnings and Precautions (5.1) ]",
      "Myelosuppression [see Warnings and Precautions (5.2) ]",
      "Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.3) ]",
      "Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.4) ]",
      "Hemolytic Uremic Syndrome [see Warnings and Precautions (5.5) ]",
      "Hepatic Toxicity [see Warnings and Precautions (5.6) ]",
      "Exacerbation of Radiation Therapy Toxicity [see Warnings and Precautions (5.8) ]",
      "Capillary Leak Syndrome [see Warnings and Precautions (5.9) ]",
      "Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.10) ] The most common adverse reactions for the single agent (≥20%) are nausea/vomiting, anemia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), neutropenia, increased alkaline phospha",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Single Agent The data described below reflect exposure to gemcitabine as a single agent administered at doses between 800 mg/m 2 to 1250 mg/m 2 intravenously over 30 minutes once weekly, in 979 patients with various malignancies",
      "The most common (≥20%) adverse reactions of single agent gemcitabine are nausea/vomiting, anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), neutropenia, increased alkaline phosphatase,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated:",
      "in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy",
      "in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated",
      "in combination with cisplatin for the treatment of non-small cell lung cancer",
      "as a single agent for the treatment of pancreatic cancer"
    ]
  },
  "gemfibrozil": {
    "ingredient": "gemfibrozil",
    "is_drug": true,
    "canonical_name": "gemfibrozil",
    "fda_search_term": "gemfibrozil",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gemfibrozil"
    ],
    "generic_names": [
      "GEMFIBROZIL"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Cadila Pharmaceuticals Limited",
      "Cipla USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Because of chemical, pharmacological, and clinical similarities between gemfibrozil and clofibrate, the adverse findings with clofibrate in two large clinical studies may also apply to gemfibrozil",
      "In the first of those studies, the Coronary Drug Project, 1,000 subjects with previous myocardial infarction were treated for five years with clofibrate",
      "There was no difference in mortality between the clofibrate-treated subjects and 3,000 placebo-treated subjects, but twice as many clofibrate-treated subjects developed cholelithiasis and cholecystitis requiring surgery",
      "In the other study, conducted by the World Health Organization (WHO), 5,000 subjects without known coronary heart disease were treated with clofibrate for five years and followed one year beyond",
      "There was a statistically significant (44%) higher age-adjusted total mortality in the clofibrate-treated group than in a comparable placebo-treated control group during the trial period",
      "The excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis",
      "The higher risk of clofibrate-treated subjects for gallbladder disease was confirmed",
      "Because of the more limited size of the Helsinki Heart Study, the observed difference in mortality from any cause between the gemfibrozil and placebo groups is not statistically significantly different from the 29% excess mortality reported in the clofibrate group in the separate WHO study at the ni",
      "Noncoronary heart disease related mortality showed an excess in the group originally randomized to gemfibrozil primarily due to cancer deaths observed during the open-label extension",
      "During the five year primary prevention component of the Helsinki Heart Study, mortality from any cause was 44 (2.2%) in the gemfibrozil group and 43 (2.1%) in the placebo group; including the 3.5 year follow-up period since the trial was completed, cumulative"
    ],
    "drug_interactions": [
      "Drug Interactions ( A) HMG-CoA Reductase Inhibitors: The concomitant administration of gemfibrozil with simvastatin is contraindicated (see CONTRAINDICATIONS and WARNINGS )",
      "Avoid concomitant use of gemfibrozil with rosuvastatin",
      "If concomitant use cannot be avoided, initiate rosuvastatin at 5 mg once daily",
      "The dose of rosuvastatin should not exceed 10 mg once daily",
      "The risk of myopathy and rhabdomyolysis is increased with combined gemfibrozil and HMG-CoA reductase inhibitor therapy",
      "Myopathy or rhabdomyolysis with or without acute renal failure have been reported as early as three weeks after initiation of combined therapy or after several months (see WARNINGS )",
      "There is no assurance that periodic monitoring of creatine kinase will prevent the occurrence of severe myopathy and kidney damage",
      "(B) Anticoagulants: CAUTION SHOULD BE EXERCISED WHEN WARFARIN IS GIVEN IN CONJUNCTION WITH GEMFIBROZIL",
      "THE DOSAGE OF WARFARIN SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS",
      "FREQUENT PROTHROMBIN DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN LEVEL HAS STABILIZED"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS In the double-blind controlled phase of the primary prevention component of the Helsinki Heart Study, 2,046 patients received gemfibrozil for up to five years",
      "In that study, the following adverse reactions were statistically more frequent in subjects in the gemfibrozil group: GEMFIBROZIL ( N = 2,046 ) PLACEBO ( N = 2,035 ) Frequency in percent of subjects Gastrointestinal reactions 34.2 23.8 Dyspepsia 19.6 11.9 Abdominal pain 9.8 5.6 Acute appendicitis 1.",
      "Gallbladder surgery was also performed more frequently in the gemfibrozil group compared to the placebo group (1.9% versus 0.3%, p=0.07) in the secondary prevention component",
      "A statistically significant increase in appendectomy in the gemfibrozil group was seen also in the secondary prevention component (6 on gemfibrozil versus 0 on placebo, p=0.014)",
      "Nervous system and special senses adverse reactions were more common in the gemfibrozil group",
      "These included hypesthesia, paresthesias, and taste perversion",
      "Other adverse reactions that were more common among gemfibrozil treatment group subjects but where a causal relationship was not established include cataracts, peripheral vascular disease, and intracerebral hemorrhage",
      "From other studies it seems probable that gemfibrozil is causally related to the occurrence of MUSCULOSKELETAL SYMPTOMS (see WARNINGS ), and to ABNOR"
    ],
    "indications": [
      "INDICATIONS AND USAGE Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1",
      "Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them",
      "Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia)",
      "Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis",
      "Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis"
    ]
  },
  "gentamici": {
    "ingredient": "gentamici",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gentamicin": {
    "ingredient": "gentamicin",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gentamicin 3": {
    "ingredient": "gentamicin 3",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gentamycin": {
    "ingredient": "gentamycin",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gentamycin sulph": {
    "ingredient": "gentamycin sulph",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gentamycin sulphate": {
    "ingredient": "gentamycin sulphate",
    "is_drug": true,
    "canonical_name": "gentamicin",
    "fda_search_term": "gentamicin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Gentamicin",
      "Gentamicin Sulfate"
    ],
    "generic_names": [
      "GENTAMICIN SULFATE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people",
      "Aminoglycosides can cause fetal harm when administered to a pregnant woman",
      "Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
      "Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides",
      "Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate",
      "It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
      "If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported",
      "They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended",
      "Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy",
      "Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible",
      "Hearing loss is usually manifested initially by diminution of high-tone acuity",
      "Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs",
      "Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported",
      "NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended",
      "Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid react"
    ],
    "indications": [
      "INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by su",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species ",
      "Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissu"
    ]
  },
  "gentian violet": {
    "ingredient": "gentian violet",
    "is_drug": true,
    "canonical_name": "gentian violet",
    "fda_search_term": "gentian violet",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GNP Gentian Violet 1%",
      "Gentian Violet",
      "Sanar Naturals Gentian Violet"
    ],
    "generic_names": [
      "GENTIAN VIOLET",
      "GENTIAN VIOLET 1%"
    ],
    "manufacturers": [
      "Amerrisource Bergen",
      "Sanvall Enterprises, Inc",
      "World Perfumes Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external treatment of abrasions and minor cuts Do not Do not apply to an ulcerative lesions as this may cause tattooing of the skin",
      "Do not use in eyes Stop use and ask a doctor if redness, irritation, swelling, or pain persists or increases or if infection occurs",
      "Keep out of reach of children",
      "In case of ingestion, seek medical help or contact Poison Control Center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses For external treatment of abrasions and minor cuts"
    ]
  }
}